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ABSTRACT
A Patient-Focused Psychotherapy Quality Assurance System:
Meta-Analytic and Multilevel Analytic Review

Kenichi Shimokawa
Department of Psychology
Doctor of Philosophy

Outcome research has documented worsening among a minority of the patient population (5 to
10%). In this study a psychotherapy quality assurance system intended to enhance outcomes in
patients at risk of treatment failure was reviewed through the use of meta-analytic, megaanalytic, and multilevel analytic techniques. A pooled dataset from six major studies conducted
at a large university counseling center and a hospital outpatient setting (N = 6151, mean age =
23.3 years, female = 63.2%, Caucasian = 85%) were re-analyzed to examine the effects of
progress feedback on patient outcome. In this quality assurance system, the Outcome
Questionnaire-45 was routinely administered to patients to monitor their therapeutic progress and
was utilized as part of an early alert system to identify patients at risk of treatment failure.
Patient progress feedback based on this alert system was provided to clinicians to help them
intervene before treatment failure occurred. Intent-to-treat and efficacy analyses of the effects of
feedback interventions were conducted to obtain the estimates of effects expected from
implementation of this quality assurance system as a policy as well as in clinical trials. Three
forms of feedback interventions—integral elements of this quality assurance system—were
effective in enhancing treatment outcome, especially for signal alarm patients. Two of the three
feedback interventions were also effective in preventing treatment failure (Clinical Support
Tools and the provision of patient progress feedback to therapists). The Clinical Support Tool
intervention was effective not only in terms of the amount of outcome enhancing effect, but also
in the rate of patient recovery. The current state of evidence appears to support the efficacy and
effectiveness of feedback interventions in enhancing treatment outcome.

Keywords: treatment outcomes, treatment failure, patient deterioration, feedback, psychotherapy
quality assurance
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1
A Patient-Focused Psychotherapy Quality Assurance System:
Meta-Analytic and Multilevel Analytic Review
In this era of accountability, healthcare systems, including mental healthcare systems,
have been placed under a tremendous pressure to demonstrate the effectiveness of their service in
bringing about improved patient outcome (Lambert, Bergin, & Garfield, 2004; Reed & Eisman,
2006). Within this context, psychology as a discipline has increased its emphasis on what is
commonly referred to as evidence-based practice in psychology (EBPP; APA, 2006). However,
the notion of EBPP has been conceptualized and practiced in various ways. For example, the
past decade saw enthusiasm for identifying particular treatments that work more or less
effectively in specific contexts (e.g., disorders) and populations (Chambless et al., 1996, 1998).
This emphasis on identifying what has been termed as empirically supported treatments (ESTs),
is often referred to as the EST movement; however, this movement has raised concerns from
many psychologists about the exclusive efforts to develop brief, manualized treatments (APA,
2006). Various groups of psychologists, including those representing several divisions of APA,
National Institute of Mental Health, and the Department of Health and Human Service’s
Substance Abuse and Mental Health Services Administration, embarked on developing
frameworks to conceptualize and examine scientifically based practice at both the state and
federal levels (e.g., National Institutes of Health, 2002). Within this context, concerns had
steadily increased regarding the use and misuse of evidence from psychotherapy research
findings, such as insurance companies placing restrictions on both the amount of care and the
choice of treatments.
These concerns led to the appointment of the APA Presidential Task Force on EvidenceBased Practice (Task Force) in 2005 to make explicit psychology’s stance to consider the “full
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range of evidence that policymakers must consider” and its “fundamental commitment to
sophisticated evidence-based psychological practice” (APA, 2006, p. 273). In this Task Force’s
recent report (APA, 2006), the following definition for EBPP was set forth: “Evidence-based
practice in psychology (EBPP) is the integration of the best available research with clinical
expertise in the context of patient characteristics, culture, and preferences” (p. 273; emphasis
included in the original text). Although varying views about the conceptualization and practice
of EBPP have been raised, including criticisms about the lack of inclusiveness of the APA
Presidential Task Force’s philosophical stance (e.g., Wendt & Slife, 2006), the Task Force’s
attempt to recognize a broader range of evidence is to be congratulated.
Regarding the phrase “clinical expertise” in this definition, the Task Force expounded the
following (APA, 2006; p. 276-277):
Clinical expertise also entails the monitoring of patient progress (and of changes in the
patient’s circumstances—e.g., job loss, major illness) that may suggest the need to adjust
the treatment (Lambert, Bergin, & Garfield, 2004). If progress is not proceeding
adequately, the psychologist alters or addresses problematic aspects of the treatment (e.g.,
problems in the therapeutic relationship or in the implementation of the goals of the
treatment) as appropriate.
Such practice of monitoring and modifying treatment response has been an important aspect of
ensuring quality care for clients, and thus has been a central element of patient-focused research
(Howard, Moras, Brill, Martinovich, & Lutz, 1996; Lambert et al., 2003).
The paradigm of patient-focused research advocates systematic evaluation of a patient’s
response to treatment throughout the course of therapy (Howard, et al. 1996). In this paradigm,
the patient is considered the most critical informant of distress and thus the outcome. The
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advocates of this approach recommend providing clinicians with the feedback of their client’s
progress. Such feedback allows the therapist to make treatment decisions based on client distress
rather than on fixed treatment protocols and mandated policies regarding treatment length.
Based on the patient-focused research paradigm, several quality assurance systems have been
developed (Beutler, 2001; Kordy, Hannöver, & Richard, 2001; Lambert, Hansen, & Finch, 2001;
Lueger et al., 2001).
An important area of psychotherapy research literature from an EBPP perspective and a
serious concern for patient-focused research paradigm is the consistent findings that not all
clients derive benefit from psychotherapy, and that some actually get worse in treatment,
experiencing an increase of distress (Hansen, Lambert, & Forman, 2002). These patients are
often referred to as treatment failures or non-responders (Mash & Hunsley, 1993). Although a
causal relationship cannot be easily drawn between psychotherapy and the failing outcome, it
should be alarming to a profession that seeks to be of help to its consumers that their
“customers” leave their service worse off than when they first came for help (Finch, Lambert, &
Schaalje, 2001). While these cases of treatment worsening may comprise only about 10% of
total cases, failing cases also impose serious economic implications to persons who did not get
the benefit they sought and to the third party payers who endorsed the ineffective treatments. In
addition to the economic implications of treatment failures, the sheer number of patients whose
quality of life worsens despite receiving psychotherapy places prevention of treatment failure as
an important goal of outcome research and practice.
To help prevent treatment failures, Lambert and colleagues (Lambert, Hansen, et al.,
2001) developed a quality assurance system to enhance the treatment outcome of the individual
patient. This system is established on three major principles: (1) developing a reasonable
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estimate of the expected progress of the average patient based on the patient scores on the
Outcome Questionnaire-45.2 (OQ; description of this instrument provided below); (2) a data
driven process of comparing the actual progress of a patient of interest to expected progress, and
(3) the provision of treatment progress information (feedback) to the therapist and case
managers. Six major studies have been conducted to evaluate the effects of providing feedback
about patient progress and the expected progress trajectory of the patient. These studies have
been published elsewhere (Harmon, Lambert, Slade, Smart, & Lutz, 2007; Hawkins, Lambert,
Vermeersch, Slade, & Tuttle, 2004; Lambert, Whipple, et al., 2001; Lambert, Whipple,
Vermeersch, et al., 2002; Slade, Lambert, Harmon, Smart, & Bailey, 2008; Whipple et al., 2003).
The basic rationale behind the concept of providing feedback to clinicians is
straightforward. Therapist can be more responsive to patient needs if they know that the patient
is not succeeding as intended. As has been repeatedly demonstrated in clinical research, any
prediction relying on statistical or actuarial methods tend to fare better than clinical judgment
alone (see Ægisdóttir et al., 2006 for a recent major meta-analytic review on this subject). Such
actuarial/clinical prediction research can be traced back to the work of Paul Meehl, who reached
the same conclusion in 1954 (see Grove, 2005, for an in-depth discussion). This notion is
especially salient when clinicians are making predictions about treatment failures. For instance,
more recently, Hannan and colleagues (Hannan et al., 2005) have demonstrated how clinicians
fare poorly in predicting deteriorated cases in psychotherapy. Hatfield, McCullough, Frantz, and
Krieger (2009) found only 32% of therapists recorded patient worsening in their case notes,
despite dramatic escalation in their symptoms in the week prior to meeting with their therapist.
The psychological community has increasingly recognized the importance of providing
feedback to clinicians regarding their patients’ progress. For instance, APA Task Force (2006)
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noted that one of the “most pressing research needs” in EBPP includes this particular type of
research, which they recapitulated as “providing clinicians with real-time patient feedback to
benchmark progress in treatment and clinical support tools to adjust treatment as needed
(p.278).”
In the following sections, a brief description of the feedback system developed by
Lambert’s team, including the overview of the designs of the past major studies, a brief summary
of the past developments in Lambert and his colleague’s feedback studies, and the rationale,
purposes, methodology, and limitations of the present study are described.
Feedback System
Defining outcome. In each of the six studies examined in this study, patients’
psychological dysfunction was measured by the Outcome Questionnaire-45.2 (OQ; Lambert,
Morton, et al., 2004). This 45-item self-report scale was designed to be administered during the
course of therapy on a weekly basis as well as at termination. The OQ is comprised of three
subscales: Symptom Distress (SD; measures symptoms of psychological disturbance, mainly
depression and anxiety related), Interpersonal Relations (IR; measures satisfaction and problems
in interpersonal relationships), and Social Role (SR; measures the patient’s level of social role
performance, such as problems at work). The OQ provides the total score, based on all 45 items
and the subscale scores. The total OQ score represents the current level of distress of a given
person, high scores indicating high level of distress. The OQ total scores were the only measure
of treatment outcome in the aforementioned major six studies (brief explanation of these studies
are provided below). Thus, stated in another way, the treatment outcome was operationally
defined in the previous major studies as the level of distress measured by the total OQ scores.
Normative data of the OQ were obtained from several samples across various locations in
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the United States. The details of the normative data are provided in the OQ manual (Lambert,
Morton, et al., 2004). The total score has adequate three-week test-retest reliability (r = .84) and
high internal consistency reliability (Cronbach’s alpha = .93). The OQ has been shown to have
strong concurrent validity, with validity coefficients ranging from .55 to .88 on SCL-90R, Beck
Depression Inventory, Zung Self Rating Depression Scale, Zung Self Rating Anxiety Scale,
Taylor Manifest Anxiety Scale, State Trait Anxiety Inventory, Inventory of Interpersonal
Problems, Social Adjustment Scale, and the SF 36 Medical Outcome Questionnaire (Lambert,
Morton, et al., 2004; Umphress, Lambert, Smart, & Barlow, 1997). The OQ has also been found
to be sensitive to change over short periods of time when taken by patients in treatment
(Vermeersch, Lambert, & Burlingame, 2000; Vermeersch et al., 2004) while untreated
individuals’ scores remained stable (Durham, 1999), thus demonstrating that this instrument is
suitable for tracking change in patient disturbance.
Defining negative outcome and positive outcome. One of the key features of patientfocused methodologies involves the establishment of cutoff scores on outcome measures to
determine if a given patient’s change should be considered reliable or clinically significant.
Using the formulas developed by Jacobson and Truax (1991), the OQ scores of both clinical and
non-clinical samples were analyzed to provide cutoff scores for a Reliable Change Index (RCI)
for the total and subscale scores (Lambert et al. 2004). The RCI of the total OQ score was 14.
This means that a patient who makes a change equal to or greater than this value is considered to
have reliably improved or reliably deteriorated, depending on the direction of the change. In
addition to calculating the RCI value for the clinical significance cutoff score for the OQ total
scores, a score demarcating the clinical population from the non-clinical population was
calculated to be 63/64. This means that a person with an OQ total score of 63 or less is more
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likely to come from the non-clinical population whereas an individual with a total OQ score of
64 or above indicates that the individual is more likely from the clinical population. These two
criteria (RCI and clinical significance cutoff score of the OQ total scores) are used to determine
negative and positive outcomes.
Defining identification of potential treatment failures. Various methods have been
tried to determine the best way to accurately identify treatment failures (Lambert et al., 2003).
Two methods (rational and empirical) have been demonstrated to be particularly effective in
predicting the final treatment outcomes (OQ total scores at termination). The rational method is
based on the algorithms that use information regarding the patient’s early response to treatment,
the dose response relationship, and the reliability of the OQ-45 (Lambert, Morton, et al., 2004;
The details of the rational methods are provided in Lambert, Whipple, Bishop, et al., 2002). The
empirical method utilized expected recovery curves for making predictions about final treatment
outcomes. Standard recovery curves were developed based on the OQ total scores of 11,492
individuals with two or more OQ administrations from various clinical settings across the US
(see Finch, Lambert, & Schaalje 2001). Based on the severity of distress, the full range of OQ
total scores (0 to 180) were divided into 50 distinct groups.
These groups were created by first rank ordering all of the initial OQ total scores.
Hierarchical linear modeling techniques were used to estimate the recovery curve for each of the
OQ score groups. In addition to the calculation of the estimated recovery curves, tolerance
intervals were calculated to allow for the identification of OQ total scores that are outside of the
upper and lower limits of tolerance intervals for each given session. Sets of two tolerance
intervals were established for the mean OQ scores at each session to identify unexpected change
in progress in both positive and negative directions. These two-tailed intervals were set at 68%
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and 80%. These intervals provided cutoff scores at each session for identifying 16% and 10% of
the patients who were likely to fail in therapy or drop out prematurely. The details of the
establishment of the expected recovery curves are described in the article by Finch, Lambert, &
Schaalje (2001). As already mentioned above, the accuracy and clinical utility of the OQ
algorithms for identifying at risk individuals for treatment failure have been demonstrated by
Hannan and colleagues (2005), Lambert, Whipple, Bishop, et al. (2002), and Spielmans, Lambert
and Masters (2006).
Patient progress feedback. As Lambert, Harmon, Slade, Whipple, and Hawkins (2005)
stated, “the essence of improving outcomes for poorly responding patients is the development of
a signal-alarm system that attempts to identify the failing patient before termination occurs” (p.
168). In the OQ feedback system, patients are administered the OQ at each session, beginning at
the intake until termination. Based on the patients’ session-by-session OQ data, feedback
regarding each patient’s predicted functioning at termination was provided to the clinicians in a
form of a progress graph with the patient’s past OQ scores up to the most recent OQ
administration, color-coded message (green, white, yellow, and red) to catch the clinician’s
attention and to quickly convey the patient’s progress status, and the feedback message
corresponding to the color-coded message (The details of the messages are found elsewhere; e.g.,
Lambert et al., 2003; Lambert et al., 2005). The form of feedback has evolved as
methodological improvements were made to the feedback studies. The first five feedback
studies (studies 1, 2, 3, 4, and 5) used this form of feedback to clinicians. Most recently, the
entire feedback system has been computerized by the use of the “OQ-Analyst” to allow for
generation of immediate feedback at the beginning of each therapy session as patients fill out the
OQ before meeting with their therapist. The feedback given to the clinicians essentially includes
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all of the elements of feedback from the earlier methodology with the addition of the patient’s
responses on several critical items (e.g., suicide potentiality item), the patient’s subscale scores,
and the patient’s current OQ total score in relation to various norm scores (i.e., community norm,
outpatient norm, and inpatient norm).
Summary of Past Developments
To summarize the past six feedback studies, several acronyms are used to identify the
experimental conditions. As patients entered treatment and subsequently participated in the past
studies, they were assigned to one of the following conditions (see Figure 1 for detailed
representation of all conditions used in the past studies): therapists of patients received OQ-based
feedback (Fb); both therapists and patients received feedback (P/T Fb); and therapists of patients
did not receive feedback or TAU (No-Fb). As treatment continued, patients divided themselves
into two groups based on their treatment progress as measured by the OQ. Patients not
progressing as expected (signal alarm cases; either red or yellow signal) were classified as “noton-track” (NOT). Patients who progressed as expected (i.e., white or green signals) were termed
“on-track” (OT). In recent studies, of those patients who were in the Fb and T/P Fb conditions
and later identified as NOT, half the patients were given an additional intervention—“Clinical
Support Tools” or CST. Accordingly, these groups of patients were termed NOT-Fb+CST or
NOT-T/P Fb+CST.
In the first in a series of similar studies, Lambert, Whipple, et al. (2001) studied the
effects of delivering feedback to therapists in a university counseling setting. This study
included 609 participants, randomly assigned either to the experimental (Fb) condition (n = 307)
or to the control (No-Fb) condition (n = 302). A main effect was found of keeping patients in
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treatment longer, as well as improving outcome of the participants in the Fb condition relative to
the clients in the control group (No-Fb) who were predicted to be treatment failures (NOT).
A replication study (study 2; Lambert, Whipple, Vermeersch, et al., 2002) was conducted
on 1020 participants in the same university counseling center setting. In this study, participants
were assigned to the experimental (Fb) group or the control (No-Fb) group depending on the
semester in which they sought services. Thus, random assignment was not used. However, the
authors reported that the groups were demographically equivalent. This study used 49 therapists
(22 doctoral level psychologists and 27 doctoral students in training, including interns).
Therapist assignment effect was demonstrated to be controlled by having approximately the
same number of clients in both experimental and control groups and all therapists participating in
both conditions. The results showed increased duration of treatment and improved outcome for
NOT cases, thus replicating the findings of study 1. Nearly twice as many clients in the Fb
condition reached clinically significant or reliable improvement and fewer actually deteriorated
at termination.
In study 3, Whipple et al. (2003) hypothesized that strengthening the effects of feedback
might improve the treatment outcome as well as the number of sessions attended by the
individuals who were predicted to be treatment failures. To bolster the feedback effects, the
researchers introduced the notion of Clinical Support Tools (CST) as a problem solving strategy
to inform the therapists of factors that may be obstructing treatment. Their CST consisted of
self-report measures of therapeutic alliance, client perceived social support, and readiness to
change, and a decision tree to help clinicians examine these factors in a hierarchical fashion. The
decision tree also advised for possible diagnostic reformulation and/or medication referral to a
medical professional as appropriate. Whipple et al. (2003) found that clients in the CST
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condition, who were identified as signal cases (NOT-Fb+CST), had better outcome than the
signal cases whose clinicians either received feedback on their treatment response (NOT-Fb) or
did not receive feedback (NOT-No-Fb). However, a methodological limitation was the failure to
randomly assign participants to the CST experimental conditions.
In study 4, Hawkins et al. (2004) applied OQ feedback in a hospital-based outpatient
setting, further hypothesizing that providing outcome feedback to patients themselves in addition
to clinicians may have incremental value in enhancing outcome. Participants were 201 patients
and five therapists (out of 715 patients invited to participate, 313 consented, 112 were excluded
for not meeting the inclusion criteria of having at least two therapy sessions or by therapists’
discretion for the possible iatrogenic effects of giving feedback to patients in four cases).
Participants were randomly assigned to various treatment groups, using a randomized block
design, with therapists serving as the blocking variable. The researchers found an effect for the
clinician feedback condition as well as the clinician and patient feedback condition, and that the
clinician and patient feedback condition demonstrated an incremental treatment effect. It should
be noted that the NOT-Fb condition in this study did not include a CST feedback condition.
In study 5, Harmon et al. (2007) conducted a replication study, combining the
experimental conditions used in studies 3 and 4 in a counseling center setting. This study used
more than 1,374 participants. This study included random assignment to the CST condition, thus
making an improvement over the Whipple methodology (study 3). The findings replicated the
feedback effects on improved outcome in NOT groups. However, the effects of giving feedback
to clients did not replicate the findings of study 4 (Hawkins, et al., 2004). In this study, the
outcome of the patients in the Fb condition and that of the T/P Fb condition did not show a
statistically significant difference in both OT and NOT groups. One methodological limitation
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should be mentioned regarding this and the subsequent study. Based on the consistent findings
indicating the benefits of providing OQ-based feedback to clinicians, the counseling center
where the series of studies were conducted adopted routine provision of OQ-45 feedback to
clinicians as part of their standard of care at the same time the Harmon study (study 5)
commenced. This change in the center’s policy prevented implementation of the treatment as
usual (TAU) condition (i.e., No-Fb condition) in this and the subsequent study, thus making
direct comparisons between the No-Fb condition and various experimental conditions no longer
available.
In the most recent study (study 6), Slade et al., (2008) made improvements in the CST
measures and added computer-generated real-time feedback via the OQ-Analyst. Accordingly,
this study addressed the question of whether immediate, computer-generated feedback is superior
to time-delayed feedback in improving outcome for NOT clients. This study also employed an
alternative self-report scale for measuring client motivation for therapy and incorporated an
additional self-report scale of client’s level of perfectionism. Furthermore, this study
incorporated the therapist-patient feedback condition as Studies 4 and 5 did. Results from the
Slade study suggest that the use of the revised CST improved outcome, again replicating the
work of Harmon and Whipple, but failed to find an effect for combined therapist and client
progress feedback.
After the completion of study 3, Lambert and his colleagues conducted a small metaanalysis of the first three studies (Lambert et al., 2003). In this study, the researchers found that
overall the Fb conditions had a deterioration rate of 5% whereas the No-Fb condition resulted in
9% deterioration rate. They also found that, although the overall improvement rates of the
feedback and no-feedback conditions did not differ greatly, of those who were identified as NOT
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cases, the No-Fb group had a 21% deterioration rate while the Fb group showed a deterioration
rate of 13%. Furthermore, of the individuals identified as NOT cases, those in the Fb condition
had greater reliable and clinically significant change rates (35%) than the signal cases in the
TAU condition (21%). These results suggested substantial beneficial effects of progress
feedback especially on those clients who were at risk of failing treatment.
Now that three more major studies have been completed with further developments in the
feedback system, and that the effects of the CST have not been summarized across studies,
conducting another review appeared appropriate. Furthermore, the 2003 meta-analysis focused
mainly on the evaluation of the effect sizes associated with Fb and No-Fb conditions thereby
essentially addressing questions regarding the amount of effects without addressing questions
about the patterns of change in patient outcome across sessions, such as the rate of recovery.
The overall purpose of the current study was to conduct a quantitative summary of the past
studies on the OQ-45 based quality assurance system. Before describing the research questions,
however, a few notes on the methodology of this study should be made.
Methodological Considerations
Meta-analysis has become a popular method of reviewing research results over the last
two decades in various scientific disciplines (Rosenthal & DiMatteo, 2001). Although metaanalytic methods have become more sophisticated over the years, there is no consensus on a
single method (Rosenthal & DiMatteo, 2001). Meta-analysis is a quantitative method for
combining numerical results from multiple studies and allows researchers to arrive at more
precise and replicable conclusions than those derived from any single study or a nonquantitative, narrative account (Rosenthal & DiMatteo, 2001). The scope of the present study is
limited to the quality assurance system developed by Lambert and his colleagues. At least two
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primary reasons exist for this limited scope. The primary reason is that, to our knowledge, no
other published studies have incorporated the methodology used by Lambert’s team for the same
purpose, which is to enhance the treatment outcome of signal-alarm clients through the use of
feedback interventions. Thus, broadening the scope of the present study (e.g., investigating the
effects of feedback interventions in general) cannot address the questions of our interest.
Another reason is that a recent meta-analysis of feedback interventions in health services,
including studies that examined the effects of providing feedback to mental health professionals
of their clients’ status, has already been conducted. Sapyta, Riemer, and Bickman (2005),
referring to their recent meta-analysis, reported the average effect size of feedback interventions
was 0.21. When the effect of feedback on “flagged” clients (our signal-alarm cases) was
compared to feedback on not flagged clients (our on-track cases), feedback interventions to
flagged samples had an effect size of 0.31.
A meta-analysis takes either fixed- or random-effects models, depending on the nature of
inferences the researcher wish to make (Hedges & Vevea, 1998). Fixed models are appropriate
in the following circumstances:
If the analyst wishes to make inferences only about the effect-size parameters in the set of
studies that are observed (or to a set of studies identical to the observed studies except for
uncertainty associated with the sampling of participants into those studies) . . . [fixed]effects analysis procedures are appropriate for making conditional inferences (Hedges &
Vevea, 1998, p. 487).
Thus, as Hedges and Vevea (1998) further explained, meta-analysis based on fixed-models
cannot make any inference about any other studies that “may be done later, could have been
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done earlier, or may have already been done but are not included among the observed studies (p.
487).” Thus, the inferential ability of fixed-effects models is very limited.
Random-effects models are utilized when the researcher “wishes to make inferences
about the parameters of a population of studies that is larger than the set of observed studies and
that may not be strictly identical to them” (Hedges & Vevea, 1998). Regarding the use of
random-effects models, Overton (1998) recommended the following:
When the contextual conditions are ill defined (e.g., a relatively new research area or one
in which previously ignored contextual factors are being discovered to be important), a
mixed model is advised to account for the uncertainty in the critical contextual
determinants of the effect under study. Or if the sample domain notably underrepresents
the population domain, again a mixed model is preferred because of the uncertainty
expressed by the relatively limited sampling of conditions in the meta-analysis studies (p.
376).
Given that research on providing feedback for the purpose of enhancing treatment outcome is
relatively new and under-explored in psychotherapy literatures and generalization is desirable, a
random-effects model was employed in the present study.
The notion of non-independence of effects (Rosenthal & DiMatteo, 2001) should also be
addressed in the present study because of the homogeneous characteristics of the studies
included in the present analysis (i.e., Five of the six studies were conducted at the same
university counseling center setting, conducted by the same research team, and all studies were
conducted by the same research team.).
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Study 1: Meta- and Mega-Analyses of OQ Total Scale Score-Based Outcome
Now that three more major studies have been completed after the first small metaanalysis by Lambert et al. (2003a) with further developments in the feedback system, and that
the effects of the P/T Fb and CST Fb interventions have not been summarized across studies,
conducting another research synthesis study appeared appropriate. As repeatedly demonstrated
in the previous feedback studies, OQ feedback interventions appear to be effective in enhancing
outcome for NOT patients, while having little impact on OT cases. Thus, the primary purpose of
this meta-analysis was to investigate the effects of various OQ feedback interventions on patient
outcome whose progress was identified as NOT. Although subtle differences existed in the
operationalization of feedback interventions across studies, given similarities in methodologies,
all of the feedback interventions were grouped in one of the following:
•

NOT Feedback (NOT Fb): 1 NOT patients whose OQ progress feedback was provided to
their therapists only.

•

NOT Patient/Therapist Feedback (NOT P/T Fb): 2 NOT patients whose OQ progress
feedback was provided directly to both patients and therapists.

•

CST Feedback (CST Fb): 3 NOT patients whose OQ progress feedback and Clinical
Support Tools were provided to their therapists.

•

NOT Treatment As Usual (TAU): 4 NOT patients whose therapists received no feedback
intervention.

1

Studies 1, 2, 3, and 4 included the NOT Fb condition.
Studies 4, 5, and 6 included NOT P/T Fb condition.
3
Studies 3, 5, and 6 utilized Clinical Support Tools Feedback interventions. Due to study designs, studies 5 and 6
employed variations of CST Feedback groups: CST Feedback group, Patient/Therapist CST Feedback group, a week
delayed CST Feedback group, and two weeks delayed CST Feedback group. Due to statistically non-significant
findings between the CST groups, we combined them as CST Feedback group in this meta-analysis.
4
Studies 1, 2, 3, and 4 included the NOT TAU condition.
2
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•

OT Feedback (OT Fb): 5 OT patients whose OQ progress feedback was provided to their
therapists only.

•

OT Patient/Therapist Feedback (OT P/T Fb): 6 OT patients whose OQ progress feedback
was provided directly to both patients and therapists.

•

OT Treatment As Usual (OT TAU): 7 OT patients whose therapists received no feedback
intervention.

Selection Criteria and Participants
All of the six OQ feedback studies published to date were included in this analysis. Each
study’s demographic variables, mean OQ total score at pre-treatment, and n and percentage of
patients identified as NOT cases are reported in Table 1 in Appendix A (All tables are presented
in Appendix A). Of the 6,151 cases included in this study, 355 patients were included multiple
times either in different studies or within the same study. Inclusion of data from multiple
episodes of care for the same individuals violates the statistical assumption of independence of
observation. In routine clinical practice, however, patients frequently return to treatments for
various reasons. Thus, inclusion of all data was deemed to yield results that are more
representative of naturalistic treatment settings. Analyses were conducted both with and without
the patients who appeared multiple times. Because results were nearly identical, only the results
from analyses with patients of multiple appearances are reported unless indicated otherwise.
The statistical methods used in the previous feedback studies reflect two distinct
approaches: effectiveness analysis based on the intent-to-treat (ITT) principle and efficacy
analysis (Lachin, 2000; Atkins, 2009). These approaches reflect two distinct philosophies in
terms of the interpretation of their results. The former addresses the overall effect of a treatment
5

All six studies included the OT Fb condition.
Studies 4, 5, and 6 included the OT P/T Fb condition.
7
Studies 1, 2, 3, and 4 included the OT TAU condition.
6
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at the population level, regardless of various treatment compliance issues that may arise in
naturalistic clinical settings. This method essentially includes the data of all patients solely on
the basis of the initial assignment to treatment conditions. The latter approach addresses the
effect of a given treatment on a subset of patients who met certain compliance criteria to be
considered “completers” of the treatment regimen. The studies, which examined the effects of the
Fb intervention against the TAU employed the effectiveness analyses. Alternatively, two of the
three studies that employed the CST Fb condition applied post-hoc screening criteria to analyze
a subset of patients who completed the prescribed feedback interventions. Given these
differences in analytical approaches, each feedback treatment under both approaches was
evaluated using the original datasets of all six studies included in this study.
In the ITT analyses, all participants in the CST Fb, NOT P/T Fb, NOT Fb, NOT TAU,
OT P/T Fb, OT Fb, and OT TAU groups were included. These analyses provide the most
conservative estimates of the treatment effects, as they even incorporate the data of individuals
whose post-treatment scores are missing, including the data of those with only the intake and
warning OQ scores. Patients with only one data point were grouped within the OT groups. To
obtain conservative estimates of these patients’ post-test scores, their last observed data point (or
their only data point) was carried forward and treated as their post test score, utilizing the last
observation carried forward method. The breakdown of the number of participants in each
treatment condition across all six studies was as follows: NOT Fb (n = 427), NOT P/T Fb (n =
222), CST Fb (n = 415), NOT TAU (n = 318), OT Fb (n = 2390), OT P/T Fb (n = 935), and OT
TAU (n = 1445).
In the efficacy analyses, the inclusion criteria were retrospectively defined to represent
the least necessary condition in which the effects of the OQ feedback interventions (i.e., Fb, P/T
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Fb, and CST Fb) could be measured. 8 For the analyses of CST Fb interventions, the exclusion
criteria as defined in the original articles in studies 5 and 6 (Harmon et al., 2007; Slade et al.,
2008) were used. Study 3 was the first study to implement the CST intervention; however, this
study did not employ exclusion criteria similar to those applied in studies 5 and 6. Thus, the
minimum inclusion criteria 9 required for a given patient to be considered a completer of the CST
intervention in study 3 were retrospectively defined and applied. Through the application of the
aforementioned inclusion criteria, the following number and percentage of participants were
included in each treatment condition when aggregated across studies: NOT Fb, n = 263 (61.6%);
NOT P/T Fb, n = 177 (79.7%); CST Fb, n = 217 (52.2%); OT Fb, n = 1651 (69.0%); OT P/T Fb,
n = 777 (83.1%).
Dependent Measures and Computation of Effect Sizes
The effects of OQ feedback interventions were compared on the following dependent
measures: Mean post-treatment OQ total score, the odds of patients achieving clinically
significant improvement at post-treatment, the odds of the occurrence of clinically significant
worsening (or deterioration) at post-treatment, mean pre-post change scores, and between group
differences in pre-post change scores. Mean number of sessions attended by patients in each

8

The efficacy sample inclusion criteria for the NOT Fb and NOT P/T Fb groups were defined as follows: attended
at least five sessions (for studies 1, 2, 3, 4, and 5) or four sessions (for study 6 due to electronic immediate progress
feedback), completed the OQ in at least three sessions, and the last recorded OQ score came from at least two
sessions (for studies 1, 2, 3, 4, and 5) or one session (for study 6) after the patient was identified as a NOT case. The
efficacy sample inclusion criteria for the OT Fb and OT P/T Fb groups were set more loosely than their NOT
counterparts, given that a majority of OT patients left treatment before the effects of feedback treatments could be
measured (i.e., nearly 70% attended four or less sessions). Accordingly, the OT Fb and P/T Fb criteria were defined
as the following: attended at least two sessions and filled out the OQ in at least two of the sessions attended.
9
To identify a given patient as a NOT case, administer the CST intervention, and measure the effects of the CST
intervention in study 3, the patient needed to have attended at least six sessions (three of which occurred after the
patient was identified as a NOT case) and filled out the OQ in at least three of the sessions. Application of these
inclusion criteria, nonetheless, does not guarantee the inclusion of only those who completed the CST intervention.
For instance, NOT patients who attended more than required number of sessions, but failed to complete the OQ after
the administration of the CST intervention would still be included in the analysis despite lacking the post-treatment
score.
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condition was also compared for the ITT analyses, but not for the efficacy analyses, as different
numbers of sessions attended by patients were part of the inclusion criteria.
Following recommendations by Overton (1998) and Hedges and Vevea (1998), given that
the research on providing feedback for the purpose of enhancing treatment outcome is relatively
new in psychotherapy outcome literature; that studies included in this meta-analysis contained
slight variations in research designs; and that the purpose of the present study was to investigate
the applicability of our findings to a broader clinical contexts, a random-effects model was
employed. Hedges’s standardized mean difference g (Hedges, 1981) was used as the unit of
effect size for mean post-treatment OQ total score comparisons and mean number of sessions
attended by patients between feedback groups and control groups. Formulae for obtaining
Hedges’s g are provided in Appendix B. Random weights were then assigned to individual
standardized mean differences to obtain the estimated weighted mean effect size per comparison.
Formulae for calculating random weights and estimated weighted mean effect sizes (or combined
effect sizes) are presented in Appendix C. As lower OQ scores indicate lower levels of distress,
negative effect sizes in post-treatment OQ total scores comparisons signify superior outcome of
the treatment condition in question. Although the P/T Fb and CST Fb groups were not directly
compared against the TAU condition in some of the studies, such comparisons were considered
to provide more intuitive interpretation regarding the effects of feedback interventions in relation
to the TAU condition. Thus, mega-analyses on the pooled dataset from all of the six feedback
studies were conducted to calculate the effect sizes of feedback interventions (i.e., P/T Fb and
CST Fb) in relation to TAU. Such an approach with large n provides an alternative method to
traditional meta-analysis in research synthesis (e.g., DeRubeis, Gelfand, Tang, & Simons, 1999;
Serretti, Cusin, Rausch, Bondy, & Smeraldi, 2006).
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Possible heterogeneity of effect sizes and publication biases were tested. Given the small
number of studies included in this study, mega-analytic approaches were used to test for the
homogeneity of effect sizes. To test for heterogeneity of effect sizes in mean post-treatment OQ
score differences, separate analyses of covariance were performed for each pooled treatment
group, with study as the factor, post-treatment OQ total score as the dependent variable, and pretreatment OQ total score as the covariate. To test for equivalence in pre-treatment distress level
across groups, independent samples t-test for each between-group comparison was conducted.
To test for heterogeneity of effect sizes in mean number of session attendance, one-way analyses
of variance for each pooled treatment group were conducted, with number of session attendance
as the dependent variable and study as the factor. Classic fail-safe N test (Rosenthal, 1979),
Orwin’s (1983) fail-safe N test, and Duval and Tweedie's (2000) trim and fill were performed to
address possible publication biases.
Another set of treatment outcomes investigated in this study was differences in
proportions and odds of patient outcome classification based on clinical significance indices.
The use of clinical significance indices based on a clinical cutoff score and reliable change index
methods proposed by Jacobson and Truax (1991) is one of the hallmarks of the OQ-45-based
quality assurance system. As demonstrated by Beckstead et al. (2003) and Lunnen and Ogles
(1998), the OQ-45-based clinical significance classification of patient outcome appears to reflect
meaningful change as well as the functional/dysfunctional state of patients. In this quantitative
review, the clinical significance status for each patient at termination was classified in one of the
three categories: deterioration/reliable worsening, no change, or clinically significant
improvement. When examining the differences in the proportion of patients who experienced
deterioration among two groups in comparison (e.g., feedback versus TAU), patients in each
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group were first dichotomized into either deterioration cases or non-deterioration cases. Odds of
patients experiencing deterioration were calculated for each group in comparison. The odds of
deterioration among the treatment group were divided by the odds of deterioration among the
control group to yield the odds ratio (OR). When the odds of deterioration are identical for both
groups, the resulting OR is 1. If the odds of deterioration among the treatment group are lower
than those in the control group, the resulting OR is less than 1. Accordingly, if the odds of
deterioration among the treatment group are higher than the control group, the resulting OR is
higher than 1. To examine the difference in the odds of deterioration, statistical significant test
were conducted with the alpha of .05. Similar procedures were followed when the odds of
clinically significant improvement were examined.
The results are presented in three ways. First, n and percentage of patients in each of the
three clinical significance categories for each feedback intervention group across all six studies
were aggregated and reported. Second, the odds of the occurrence of deteriorated/reliably
worsened cases were compared for each feedback intervention group against its control group
(i.e., TAU or Fb groups, depending on the comparisons being made) in the unit of odds ratio.
Third, the odds of the occurrences of clinically significant improvement were similarly compared
for each feedback intervention against its control. To expedite the statistical calculations,
Comprehensive Meta-Analysis, Version 2 was utilized in the calculation of effect sizes.
Analyses of Effect Sizes
Effects of Feedback Interventions on Post-treatment OQ Total Score in NOT
Patients. The combined effect size and the results of tests of publication bias for each of the
comparisons presented below are summarized in Table 2.
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Feedback (Fb) effect. The results of one-way ANCOVA, testing for heterogeneity of
effects across studies, with study as the factor, post-treatment OQ total score as the dependent
variable, and pre-treatment OQ total score as the covariate, indicated no significant study effect
among the Fb group in ITT analysis, F(5, 420) = 0.221, p = 0.951, or efficacy analysis, F(5, 250)
= 1.49, p = 0.192. However, statistically significant study effect was found for the TAU group,
F(3, 313) = 2.79, p = 0.041. The result of the independent samples t-test of pre-treatment mean
OQ scores between pooled Fb and TAU groups was not significant in ITT analysis, t(743) = -.28,
p = .778, or efficacy analysis, t(579) = -0.48, p = 0.631, indicating Fb and TAU were comparable
at pre-test distress level. Thus, despite the heterogeneity among the TAU groups in mean posttest scores, given equivalent pre-treatment OQ scores across groups, proceeding with
aggregating the TAU data was deemed appropriate in favor of ecological validity. ITT metaanalysis indicated that effect sizes of individual studies comparing the NOT Fb and NOT TAU
groups ranged from g = -0.42, p < 0.001, 95% CI [-0.68, -0.17] to g = 0.08, p = 0.742, 95% CI [0.41, 0.58] (See Table 1 in Appendix D for complete list of individual effect sizes and the forest
plot). The aggregate effect size was statistically significant at the .05 level, g = -0.28, p = 0.003,
95% CI [-0.47, -0.10]—equivalent of 6.4 OQ total score difference on average. When the
efficacy sample inclusion criteria were applied to the same comparison groups, the results
showed greater treatment effect favoring the Fb intervention. As shown in Table 2 in Appendix
D, effect sizes for individual studies ranged from g = -0.78, p < 0.001, 95% CI [-1.11, -0.45] to g
= -0.18, p = 0.523, 95% CI [-0.73, 0.37]. The aggregate effect size was significant at the .05
level, g = -0.53, p <0.001, 95% CI [-0.78, -0.28], which equates to 12.0 OQ total points
difference on average.
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Patient/therapist feedback (P/T Fb) effect. Although the ideal evaluation would have
been to compare all of the feedback interventions against the TAU group, the last two feedback
studies (studies 5 and 6) containing the P/T Fb groups did not have TAU groups, as explained
earlier. Thus, P/T Fb groups were compared against Fb groups, where Fb groups were used as
the benchmark to evaluate incremental benefits of the P/T Fb intervention. The results of oneway ANCOVA to test the heterogeneity of effects showed that study effect did not reach
statistical significance for the P/T Fb groups in ITT analysis, F(2, 218) = 1.58, p = 0.208, or
efficacy analysis, F(2, 173) = 1.62, p = 0.201. As presented in Table 3 in Appendix D, ITT
analyses of NOT P/T Fb vs. NOT Fb indicated none of the individual effect sizes were
significant at the .05 level, with individual effect sizes ranging from g = -0.44, p = 0.071, 95% CI
[-0.92, 0.04] to g = -0.10, p = 0.526, 95% CI [-0.39, 0.20]. The aggregate effect size also did not
reach statistical significance at the .05 level, g = -0.16, p = 0.099, 95% CI [-0.36, 0.03]. As
presented in Table 4 in Appendix D, when the efficacy criteria were applied, individual effect
sizes ranged from g = -0.39, p = 0.177, 95% CI [-0.96, 0.18] to g = -0.06, p = 0.734, 95% CI
[-0.40, 0.28]. The aggregated effect size was similar to that of the ITT analysis, g = 0.16, p =
0.163, 95% CI [-0.37, 0.06]. These results suggest that, in terms of treatment outcome at
termination, providing progress feedback to both clinicians and patients adds no significant
incremental benefit to providing progress feedback only to clinicians (who may or may not share
it with patients).
Pre-treatment mean OQ total score comparison between the pooled P/T Fb and pooled
TAU groups did not reach statistical significance for either ITT analysis, t(538) = 0.65, p =
0.518, or efficacy analysis, t(493) = .24, p = 0.810, indicating that the two groups did not differ
significantly in their initial level of disturbance. ITT post-treatment score difference was

25
significant at the .05 level, g = -0.36, p <0.001, 95% CI [-0.54, -0.19], equivalent of 7.9 points
difference in mean OQ total scores. Efficacy post-treatment score difference was also
significant, g = -.55, p <0.001, 95% CI [-0.73, -0.36], equivalent of mean OQ total score
difference of 11.7 points. These results suggest that NOT patients in the P/T Fb condition
experience greater therapeutic gain as measured by the OQ-45 at termination than those in TAU.
Such therapeutic benefits are more pronounced among those who stayed in treatment long
enough to experience the benefits of P/T Fb intervention.
Clinical support tools feedback (CST Fb) effect. As in the case of P/T Fb analyses, two
of the three studies that tested the effects of the CST interventions (studies 5 and 6) did not
employ the TAU condition. Thus, the CST Fb groups were also compared to the Fb groups to
estimate their incremental clinical benefits over the Fb condition. The results of one-way
ANCOVAs to test for heterogeneity of effects for the CST Fb group did not reach statistical
significance in ITT analysis, F(2, 411) = 2.00, p = 0.137 or efficacy analysis, F(2, 213) = 0.48, p
= 0.617. As presented in Table 5 in Appendix D, the ITT analysis indicated that individual
effect sizes ranged from g = -0.23, p = 0.094, 95% CI [-0.49, 0.04] to g = -0.11, p = 0.415, 95%
CI [-0.38, 0.16]. The combined effect size was significant at the .05 level, g = -0.16, p = 0.048,
95% CI [-0.33, -0.002], indicating approximately 3.6 OQ total points difference on average,
favoring the CST Fb group. When the efficacy criteria were applied to both the CST Fb and Fb
groups, the combined effect size was g = -0.19, p = 0.113, 95% CI [-0.43, 0.05], equivalent of
approximately 4.2 OQ total points difference on average. Individual effect sizes ranged from g
= -0.32, p = 0.053, 95% CI [-0.65, 0.01] to g = -0.11, p = 0.606, 95% CI [-0.32, 0.55] (Table 6 in
Appendix D). It should be pointed out that, contrary to the outcome comparison between the
CST Fb group and the Fb group reported in study 3 (Whipple, et al., 2003), which reported
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results favoring the CST Fb group, application of the efficacy criteria in this study yielded a
result favoring the Fb group. Although the two groups appeared demographically similar at pretreatment, given that random assignment of NOT patients to CST Fb and Fb groups was not
employed in this study, such contradictory findings may have been due to unknown artifacts
resulting from therapists’ selection of patients into treatment conditions. When study 3 was
removed from the efficacy analysis, the aggregate effect size of the CST Fb group over Fb group
improved to g = -0.29, p = 0.013, 95% CI [-0.52, -0.06], equivalent of approximately 6.2 OQ
point difference on average. These results suggest that, on average, those NOT patients who
receive the CST intervention in routine care in addition to the Fb intervention experience small
additional therapeutic gains represented in about 3 to 4 OQ points reduction over those who
receive only progress feedback intervention alone. Those who stay in treatment long enough to
experience the benefit of the CST intervention, on average, experience further distress reduction
over those who experience the benefit of the Fb intervention alone. More studies employing
random assignment-based comparison between the CST Fb and Fb conditions may help us better
estimate the effect of the CST Fb intervention.
Pre-treatment mean OQ total score comparison between the pooled CST Fb and pooled
TAU groups did not reach statistical significance for either ITT analysis, t(731) = -0.34, p =
0.732, or efficacy analysis, t(533) = 0.73, p = 0.468, indicating the two groups were comparable
at pre-treatment. ITT analysis indicated that post-treatment score difference between CST Fb
group and NOT TAU was significant at the .05 level, g = -0.44, p < 0.001, 95% CI
[-0.59, -0.30], equivalent of 9.5 points difference in mean OQ total scores. Efficacy posttreatment score difference was also significant, g = -.70, p < 0.001, 95% CI [-0.88, -0.52],
equivalent of mean OQ total score difference of 14.6 points. These results suggest NOT patients
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who receive the CST Fb intervention, on average, experience significantly more therapeutic gain
than those in the TAU condition. Such therapeutic gain is more pronounced among who stay in
treatment long enough to see the benefit of the CST Fb intervention.
Effects of feedback interventions on clinical significance. The n and percentage of the
clinical significance classification of patient outcome at termination were aggregated by each
treatment condition and are presented in Table 3. The summary of combined effects for the odds
of deterioration/reliable worsening and the results of tests of publication bias are presented in
Table 4. The summary of combined effects for the odds of clinically significant improvement
and the results of tests of publication bias are presented in Table 5.
Feedback (Fb) effect. When the odds of patient deterioration/reliable worsening at
termination of the NOT Fb group were compared against NOT TAU, the results of ITT analyses
indicated that the combined effect was significant at the .05 level, OR = 0.62, p = 0.040, 95% CI
[0.40, 0.98], with effect sizes of individual studies ranging from OR = 0.21, p = 0.063, 95% CI
[0.04, 1.09] to OR = 0.72, p = 0.315, 95% CI [0.39, 1.32] (Table 7 in Appendix D). When the
efficacy criteria were applied to the Fb group, the combined odds of deterioration for the Fb
group decreased to OR = 0.44, p = 0.015, 95% CI [0.23, 0.85], with odds ratios of individual
studies ranging from OR = 0.21, p = 0.041, 95% CI [0.05, 0.94] to OR = 0.60, p = 0.238, 95% CI
[0.25, 1.41] (Table 8 in Appendix D). These results suggest that the odds of deterioration among
NOT patients in TAU are approximately 1.5 times higher than those who received the Fb
intervention in routine practice. The results further suggest that the odds of deterioration among
TAU are about 2.3 times higher than those who had stayed in treatment long enough to receive
the benefit of the Fb intervention. When the odds of patients achieving clinically significant
improvement at termination were compared between the NOT Fb group and NOT TAU, the
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results indicated a significantly increased odds at the .05 level favoring the Fb group, OR = 1.70,
p = 0.005, 95% CI [1.17, 2.46], with individual effect sizes ranging from OR = 1.44, p = 0.539,
95% CI [0.45, 4.65] to OR = 2.17, p = 0.012, 95% CI [1.19, 3.97] (Table 9 in Appendix D).
When the efficacy criteria were applied, the combined odds ratio of the occurrence of clinically
significant improvement among the NOT Fb group against the NOT TAU group was OR = 2.55,
p < 0.001, 95% CI [1.64, 3.98], with odds ratios of individual studies ranging from OR = 1.23, p
= 0.766, 95% CI [0.32, 4.67] to OR = 2.97, p = 0.003, 95% CI [1.44, 6,11] (Table 10 in
Appendix D). These results suggest clinical benefit of the Fb intervention in reducing the
occurrence of treatment failure while increasing the odds of patients experiencing clinically
significant improvement.
Patient/therapist feedback (P/T Fb) effect. When the odds of the occurrence of
deterioration/reliable worsening were compared between the NOT P/T Fb and NOT Fb groups,
the results of ITT analyses indicated that effect sizes of individual studies ranged from OR =
1.00, p = 1.000, 95% CI [0.42, 2.38] to OR = 1.74, p = 0.184, 95% CI [0.77, 3.95] (Table 11 in
Appendix D). The combined effect size was not statistically significant, OR = 1.35, p = 0.306,
95% CI [0.758, 2.413]. When the efficacy criteria were applied, the combined odds ratio of
deterioration cases increased for the P/T Fb condition, although the results did not reach the .05
significance level, OR = 1.89, p = 0.094, 95% CI [0.90, 3.96]. Individual effect sizes ranged
from OR = 0.68, p = 0.788, 95% CI [0.04, 11.53] to OR = 2.95, p = 0.047, 95% CI [1.02, 8.54]
(Table 12 in Appendix D). Although statistical significance was not achieved, the results suggest
a higher rate of deterioration among NOT patients in the P/T Fb condition than those in the Fb
condition.
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ITT comparisons of the odds of clinically significant improvement yielded the combined
effect of OR = 1.44, p = 0.086, 95% CI [0.95, 2.19], with individual effect sizes ranging from OR
= 1.26, p = 0.495, 95% CI [0.65, 2.47] to OR = 1.94, p = 0.179, 95% CI [0.74, 5.10] (Table 13 in
Appendix D). The efficacy analyses indicated that the combined effect size was similar to that
obtained from the ITT sample, OR = 1.38, p = 0.164, 95% CI [0.88, 2.18] with a similar range of
individual study effect sizes, OR = 1.25, p = 0.521, 95% CI [0.63, 2.50] to OR = 1.56, p =
0.459, 95% CI [0.48, 5.00] (Table 14 in Appendix D). Although statistical significance was not
reached, the results suggest higher odds of clinically significant improvement among NOT
patients in the P/T Fb condition than those in the Fb condition. These results suggest that
provision of direct progress feedback to NOT patients has potential clinical effects that may
enhance outcome in some patients even beyond what can be achieved by provision of progress
feedback to clinicians alone, while having possible iatrogenic effect in some.
The odds of deterioration/reliable worsening between the pooled NOT P/T Fb group and
pooled NOT TAU group did not reach statistical significance in ITT analysis, OR = 0.74, p =
0.199, 95% CI [0.47, 1.17], or efficacy analysis, OR = 0.68, p = 0.134, 95% CI [0.42, 1.13].
The odds of clinically significant improvement between the pooled NOT P/T Fb group and
pooled NOT TAU was significant in both ITT analysis, OR = 2.20, p < 0.001, 95% CI[1.51,
3.21] and efficacy analysis, OR = 2.87, p < 0.001, 95% CI [1.93, 4.27]. These results suggest
that the P/T Fb intervention, in comparison to TAU, does not decrease the odds of deterioration,
but increases the odds of improvement among NOT patients.
Clinical support tools feedback (CST Fb) effect. ITT Comparisons between the CST Fb
groups against the NOT Fb groups indicated that individual effect sizes of deterioration/reliable
worsening ranged from OR = 0.59, p = 0.342, 95% CI [0.20, 1.76] to OR = 1.043, p = 0.916,
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95% CI [0.48, 2.29] (Table 15 in Appendix D) with the combined effect size of OR = 0.76, p =
0.288, 95% CI [0.46, 1.26]. The results of efficacy analyses indicated the combined effect was
OR = 0.66, p = 0.329, 95% CI [0.29, 1.52] with individual effect sizes ranging from OR = 0.54,
p = 0.356, 95% CI [0.15, 2.0] to OR = 0.83, p = 0.756, 95% CI [0.25, 2.74] (Table 16 in
Appendix D). When the odds of patients achieving clinically significant improvement were
compared in the ITT analyses, the combined effect size was OR = 1.53, p = 0.016, 95% CI [1.08,
2.18] favoring the CST Fb, with individual study effect sizes ranging from OR = 1.22, p = 0.467,
95% CI [0.69, 2.184] to OR = 1.97, p = 0.050, 95% CI [1.00, 3.87] (Table 17 in Appendix D).
The results of the efficacy analyses of comparing the odds of patients achieving clinically
significant improvement yielded the combined effect size of OR = 1.83, p = 0.098, 95% CI
[0.89, 3.76], with individual effect sizes ranging from OR = 1.167, p = 0.729, 95% CI [0.487,
2.729] to OR = 3.610, p < 0.001, 95% CI [1.847, 7.057] (Table 18 in Appendix D). These results
suggest that the CST Fb, in comparison to the NOT Fb increases the odds of patients achieving
clinically significant improvement, but the odds of deterioration/reliable worsening does not
seem to decrease, at least at a statistically significant level.
The odds of deterioration/reliable worsening between the pooled CST Fb group and the
pooled NOT TAU group reached statistical significance in both ITT analysis, OR = 0.51, p =
0.001, 95% CI [0.34, 0.76] and efficacy analysis, OR = 0.23, p < 0.001, 95% CI [0.12, 0.44].
The odds of clinically significant improvement between the pooled CST Fb group and the pooled
TAU was significant in both ITT analysis, OR = 2.20, p < 0.001, 95% CI [1.51, 3.21] and
efficacy analysis, OR = 2.87, p < 0.001, 95% CI [1.93, 4.27]. The odds of clinically significant
improvement between the same groups reached statistical significance in ITT analysis, OR =
2.01, p < 0.001, 95% CI [1.51, 2.92] and efficacy analysis, OR = 3.85, p < 0.001, 95% CI [2.65,
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5.60]. These results indicate that the odds of patients in TAU experiencing deterioration are
approximately 2.0 times higher than those receiving the CST Fb in routine care settings (ITT).
When comparing against those who complete the CST intervention, the odds of
deterioration/reliable worsening among the TAU patients is approximately 4.3 times higher than
those in the CST group. The results further indicate that the odds of patients in the CST Fb
group achieving clinically significant improvement in routine care settings (ITT) is
approximately 2.0 times higher than those in TAU. The odds of clinically significant
improvement among those who complete the CST Fb intervention are about 3.9 times higher
than those in the TAU.
Pre-post change in OQ total scores. Prior to calculating combined pre-post effect sizes,
series of one-way ANCOVAs were conducted to test the presence of heterogeneity among mean
pre-post change scores across studies, using pre-post change score as the dependent variable,
study as the factor, and pre-treatment OQ score as a covariate. The results of ANCOVA for
NOT TAU was significant at .05 level, F(3, 313) = 2.788, p = 0.041. The cause of the
heterogeneity among NOT TAU, which ranged from M = -8.41 (SD = 18.32) in study 4 to M =
4.81 (SD = 21.23) in study 1, is not known at this time. The results of ANCOVAs for NOT Fb
was not significant in ITT analysis, F(5, 420) = 0.223, p = 0.953 or efficacy analysis, F(5, 256) =
1.428, p = 0.214. Similarly, heterogeneity was not observed among NOT P/T Fb group in either
ITT analysis, F(2, 218) = 1.583, p = 0.208 or efficacy analysis, F(2, 173) = 1.618, p = 0.201.
CST Fb groups also did not yield significant results in ITT analysis, F(2, 411) = 1.995, p =
0.137, or efficacy analysis, F(2, 213) = 0.484, p = 0.617. Given the heterogeneity among the
NOT TAU groups, the consequences of the effect size calculation method (i.e., meta-analysis
versus mega-analysis) were considered. To investigate such consequences of using one method

32
over the other, effect sizes were calculated and compared in both ways. The results showed that
the smaller the between-study heterogeneity were (i.e., smaller F ratio found in the ANCOVAs
reported earlier), the more similar the results between the mega-analysis and the meta-analysis.
For instance, NOT Fb, which had the smallest F ratio of all treatment conditions, yielded the
effect sizes and 95% CIs that were essentially identical. The results from the meta-analysis and
mega-analysis were also similar in other treatment groups, although the results from the megaanalysis tended to yield somewhat smaller effect sizes and/or 95% CIs. Given the preference for
generalizability of the results, the results from the meta-analysis seemed more appropriate. Thus,
only the meta-analytic results are reported where both methods were utilized.
Pre-post change effect size was obtained for each treatment group and presented in Table
6. Effect sizes for between-group difference in the pre-post change effect size were then
calculated for each between-group comparison of interest. In the ITT analysis, the pre-post
effect size of the TAU was g = -0.04, p = 0.706, 95% CI [-0.23, 0.15]. The effect size for the
NOT Fb group was g = -0.25, p < 0.001, 95% CI [-0.33, -0.16]. The effect size for NOT P/T Fb
was g = -0.49, p < 0.001, 95% CI [-0.75, -0.22]. The effect size for the CST Fb group was g
= -0.45, p < 0.001, 95% CI [-0.59, -0.31]. In the efficacy analysis, the pre-post effect size of the
NOT Fb group was g = -0.42, p < 0.001, 95% CI [-0.58, -0.26]. The effect size for the NOT P/T
Fb was g = -0.68, p < 0.001, 95% CI [-1.04, -0.32]. The effect size for the CST Fb group was g
= -0.82, p < 0.001, 95% CI [-0.98, -0.314]. The summary of effect sizes from both the ITT and
efficacy analyses are presented in Table 7.
Effect sizes for the between-group difference in pre-post change scores on OQ total scale
scores in the ITT analyses were as follows. The combined effect size for NOT Fb versus NOT
TAU was g = -0.28, p < 0.001, 95% CI [-0.44, -0.11]. The combined effect size for NOT P/T Fb
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versus NOT Fb was g = -0.17, p =0.096, 95% CI [-.37, 0.03]. The combined effect size for CST
Fb versus NOT Fb was g = -0.21, p = 0.013, 95% CI [-0.38, -0.04]. As in the case with betweengroup comparisons of mean post-treatment OQ total scores, a mega-analytic approach was
utilized to calculate the effect sizes of the CST Fb and the NOT P/T Fb groups in relation to
NOT TAU. The effect size for the pooled CST Fb versus pooled NOT TAU was g = -0.43, p <
0.001, 95% CI [-0.58, 0.32]. The effect size for the pooled NOT P/T Fb versus NOT TAU was g
= -0.44, p < 0.001, 95% CI [-0.62, -0.27].
In the efficacy analyses, the combined effect size for NOT Fb versus NOT TAU was g =
-0.60, p < 0.001, 95% CI [-0.81, -0.40]. When the NOT P/T Fb group was compared to NOT Fb
in the efficacy analysis, the combined effect size was g = -0.15, p =0.173, 95% CI [-0.37, 0.07].
The comparison between the CST and NOT Fb groups yielded a combined effect size of g
= -0.29, p < 0.062, 95% CI [-0.60, 0.02]. When study 3 was removed from the analysis, the
combined effect size was g = -0.40, p = 0.020, 95% CI [-0.74, -0.06]. Utilizing a mega-analytic
approach, the effect size between the pooled NOT P/T Fb versus pooled NOT TAU was g
= -0.56, p < 0.001, 95% CI [-0.74, -0.37]. The combined effect size between the pooled CST Fb
group versus the pooled NOT TAU group was g = -0.78, p < 0.001, 95% CI [-0.96, -0.60].
Effects of feedback interventions on session attendance. The number of therapy
sessions utilized by patients was thought of as an effect of feedback interventions in previous
studies. Because the number of sessions attended by patients was part of the efficacy criteria,
between-group comparisons of the mean number of session attendance were appropriate only for
the ITT analyses. The summary of effect sizes and the results of tests of publication bias are
presented in Table 6.
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Feedback (Fb) effect. A one-way ANOVA was conducted on the NOT Fb groups to test
for heterogeneity of effect sizes, which resulted in significant study effect, F(5, 421) = 2.78, p =
0.017. Although speculations could be made about the presence of possible moderators (e.g.,
treatment settings in which original studies took place), the data was pooled across studies, given
that the difference between the highest mean attendance (M = 10.8) and lowest mean attendance
(M = 8.44), as tested by independent samples t-test, was not significant, t(116) = 1.93, p = 0.056.
The one-way ANOVA on the NOT TAU group yielded significant study effect, F(3, 314) = 6.55,
p < 0.001, with a significant difference between the highest mean attendance (M = 11.22; study
4) and the lowest mean attendance (M = 6.03; study 1), t(61) = -2.563, p = 0.013. In this case,
given such a large discrepancy in mean session attendance, the presence of moderator(s) might
have contributed to the heterogeneity. Study 1, in particular, was the only study resulting in a
very large effect size, while other studies yielded small effect sizes. The causes for such wide
dispersion are not known at this time. Thus, although the data was pooled in favor of ecological
validity in this study, future investigation of moderators appears warranted. The combined effect
of the differences in mean session attendance between the NOT Fb and NOT TAU groups was g
= 0.27, p = 0.217, 95% CI [-0.16, 0.69] with individual effect sizes ranging from –0.10, p =
0.459, 95% CI [-0.37, 0.17] to g = 1.09, p < 0.001, 95% CI [0.58, 1.60] (Table 19 in Appendix
D). The results did not show statistically significant difference in the mean number of sessions
utilized between the Fb and TAU groups.
Patient/therapist feedback (P/T Fb) effect. The results of one-way ANOVA on the NOT
P/T Fb groups did not support the presence of heterogeneity among mean session attendance
across studies, F(2, 219) = 2.67, p = 0.071. The combined effect size of differences in mean
session attendance between the NOT P/T Fb and NOT Fb groups was g = 0.12, p = 0.311, 95%
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CI [0.11, 0.35] with individual effect sizes ranging from g = –0.22, p = 0.356, 95% CI [-0.69,
0.25] to g = 0.23, p = 0.145, 95% CI [-0.08, 0.54] (Table 20 in Appendix D). The results did not
support the presence of increase in mean number of sessions in P/T Fb groups. The effect size of
the pooled NOT P/T Fb group in relation to the pooled NOT TAU group was g = 0.40, p <
0.0001, 95% CI [0.23, 0.58], indicating the attendance of 2.6 more sessions by those in the P/T
Fb group (of which 2.5 sessions occurred after the signal alarm event).
Clinical support tools feedback (CST Fb) effect. One-way ANOVA on the CST Fb
groups resulted in significant study effect, F(2, 412) = 4.50, p = 0.012. The combined effect of
the difference in mean session attendance between the CST Fb and NOT Fb groups was g =
0.41, p = 0.024, 95% CI [0.05, 0.76] with individual effect sizes ranging from g = 0.22, p =
0.106, 95% CI [-0.05, 0.48] to g = 0.816, p < 0.001, 95% CI [0.48, 1.16] (Table 21 in Appendix
D). Study 3 resulted in significantly larger number of session attendance (mean difference of 4.6
sessions). Given the possible bias reflected in the assignment process in study 3, another
weighted mean effect size was calculated after removing the data from study 3. The result was
significant at the .05 level, g = 0.22, p = 0.020, 95% CI [0.035, 0.410], suggesting significantly
more average session attendance (1.8 more sessions) by NOT patients in the CST Fb groups than
those in the Fb groups on average in routine care. The effect size of the pooled CST group in
relation to the pooled TAU group was g = 0.48, p < 0.001, 95% CI [0.33, 0.63], indicating the
attendance of 3.4 more sessions 10 by those in the CST group (of which 2.7 sessions occurred
after the signal alarm event).
Feedback effects on on-track patients. The effects of P/T Fb and Fb interventions on
on-track (OT) patients were tested, using mega-analytic approaches. Prior to comparing
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The results were equivalent when the data of patients in study 3 were removed from the analysis, g = 0.45, p <
0.001, 95% CI [0.29, 0.60], or 3.2 more sessions attended by CST Fb group.
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feedback intervention groups against TAU, heterogeneity of effects was tested in the same
manner as the NOT samples. Statistically significant heterogeneity was detected at the .05 level
in both (1) ANCOVAs of mean post-test OQ scores by study with pre-test OQ score as a
covariate and (2) ANOVAs of mean pre-test scores by study. The primary reason for this
heterogeneity was the significantly higher mean post-test and pre-test scores of patients in study
4 (Hawkins, et al., 2004). When the data of patients from study 4 was removed from the
analyses, study effects no longer reached statistical significance. When the data was pooled by
treatment conditions across studies and tested for equivalence in mean pre-test scores by
independent samples t-tests, no significant differences were found. Considering the fact that
patients from study 4 were found in all three of the OT treatment conditions (i.e., OT Fb, OT P/T
Fb, and OT TAU groups), and based on the equivalent mean pre-test scores by treatment
conditions, the data was pooled by OT treatment conditions in favor of ecological validity.
Feedback effects (Fb). Contrary to the findings in a previous meta-analysis (Lambert, et
al. 2003), when the mean numbers of sessions attended by patients in OT Fb and OT TAU were
compared in ITT analysis, no statistically significant difference was found, g = 0.01, p = 0.792,
95% CI [-0.06, 0.07]. Although the overall decrease in session attendance was not observed,
patients in the OT Fb group, on average, experienced greater therapeutic gains. In terms of mean
post-test OQ score difference, ITT analysis was significant at .05 level, g = -0.12, p < 0.001,
95% CI [-0.19, -0.06], equivalent of approximately 2.8 OQ point reduction, while efficacy
analysis was also significant at .05 level, g = -0.30, p < 0.001, 95% CI [-0.37, -0.23], equivalent
of 6.5 OQ point reduction.
When the odds of patient deterioration/reliable worsening at termination of the OT Fb
group were compared against OT TAU, the results of ITT mega-analyses indicated that the effect
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size was significant at the .05 level, OR = 0.63, p = 0.030, 95% CI [0.41, 0.95]. Efficacy
analysis was not significant at the .05 level, OR = 0.81, p = 0.341, 95% CI [0.52, 1.25]. When
the odds of the occurrence of patient reliable/clinically significant improvement at termination
were compared, both ITT and efficacy analyses were significant at the .05 level with respective
odds ratios of OR = 1.20, p = 0.010, 95% CI [1.04, 1.38] and OR = 2.09, p < 0.001, 95% CI
[1.80, 2.42]. These results suggest that, while the amount of utilization of sessions essentially
remains the same, OT patients in Fb condition on average experience superior treatment outcome
and may have decreased odds of experiencing deterioration than those in TAU.
Patient/therapist feedback effects (P/T Fb). When the mean number of session
attendance was compared between the OT P/T Fb and OT TAU groups in ITT analysis, the
results were significant at .05 level, g = 0.10, p < 0.02, 95% CI [0.01, 0.18], equivalent of
approximately 0.4 more sessions attendance by the OT P/T Fb. In terms of mean post-test OQ
score differences, both ITT and efficacy analyses respectively yielded significant results at the
.05 level, g = -0.18, p < 0.001, 95% CI [-0.26, -0.96], equivalent of approximately 4.1 OQ point
reduction on average, and g = -0.32, p < 0.001, 95% CI [-0.40, -0.23], equivalent of
approximately 7.1 OQ score point reduction on average.
When the odds of the occurrence of patient reliable worsening/deterioration at
termination were compared, both ITT and efficacy analyses were not significant at the .05 level
with respective odds ratios of OR = 0.71, p = 0.215, 95% CI [0.42, 1.22] and OR = 0.86, p =
0.585, 95% CI [0.55, 1.47]. When the odds of the occurrence of reliable/clinically significant
improvement were compared, ITT and efficacy analyses respectively yielded significant results
at the .05 level, OR = 1.65, p < 0.001, 95% CI [1.39, 1.96] and OR = 2.36, p < 0.001, 95% CI
[1.97, 2.82]. These results suggest that, in comparison to TAU, patients who receive P/T Fb
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intervention on average experience superior treatment outcome in terms of distress reduction and
improved odds of achieving reliably positive change, while the odds of reliable
worsening/deterioration remain the same as those for patients in TAU.
Discussion on Study 1
This meta- and mega-analytic study evaluated the effects of three types of patient
progress feedback interventions used in the OQ-based quality assurance system: progress
feedback to therapists, progress feedback to both patients and therapists, and Clinical Support
Tools in addition to progress feedback. These interventions were aimed at monitoring individual
patient progress in treatment, identifying patients at risk of treatment failure, and intervening
before termination occurs. The effects of these interventions were evaluated with patients whose
progress in treatment was identified as not-on-track (NOT), i.e., at risk of leaving treatment
worse off than when entering the treatment as well as those identified as on-track (OT). Two
sets of analyses were conducted to estimate the effects of feedback interventions that can be
expected in routine practice (intent-to-treat analyses; ITT) and among patients who stay in
treatment until the effects of feedback interventions could be measured (efficacy analyses). The
effects of the feedback interventions were evaluated on the basis of between group differences in
mean OQ total scores at termination of treatment, rate and odds of clinically significant change
status at termination, and mean number of sessions attended.
Overall, the effects of feedback interventions on patients who were identified as being at
risk of treatment failure (NOT) were more substantial than those identified as being on-track.
When compared to the NOT TAU in ITT analyses, the combined effects (Hedges’s g) of mean
post-treatment OQ total scores for the NOT Fb, NOT P/T Fb, and the CST Fb groups were -0.28,
-0.36, and -0.44, respectively. The overall percentages of reliable worsening/deterioration
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(clinically significant improvement) among the NOT TAU, NOT Fb, NOT P/T Fb, and CST Fb
groups were 20.1% (22.3%), 13.6% (30.9%), 15.8% (38.7%), and 11.3% (37.6%), respectively.
The odds ratio of reliable worsening/deterioration (clinically significant improvement) for the
NOT Fb, NOT P/T Fb, and CST Fb groups in relation to NOT TAU were 0.62 (1.70), 0.74
(2.20), and 0.51 (2.01), respectively. These results indicate that all forms of feedback
interventions were effective in enhancing outcome while reducing treatment failures among
NOT patients, with an exception of the P/T Fb intervention in its effects in preventing treatment
failure. These results also show that, when the treatment impact is evaluated on the level of
routine care (ITT analysis), the three types of feedback interventions are similar in their effects
on treatment outcomes.
The effects of feedback interventions on those who satisfied the least necessary
conditions to likely have been the actual recipients of the feedback interventions were also
estimated (efficacy analyses). Such criteria comprised of minimum numbers of session
attendance (i.e., at least four to six sessions, depending on feedback conditions) and minimum
numbers of completion of the OQ (i.e., at least three to four administrations, depending on
conditions). The effect sizes (Hedges’s g) for the mean post-treatment OQ total score
differences between the NOTFb, NOT P/T Fb, and CST Fb groups in comparison to NOT TAU
were -0.53, -0.55, -0.70, respectively. Furthermore, the percentages of patients experiencing
reliable worsening/deterioration (clinically significant improvement) for the NOT TAU, NOT
Fb, NOT P/T Fb, and CST Fb groups were 20.1% (22.3%), 9.1% (37.6%), 14.7% (45.2%), and
5.5% (52.5%), respectively. The combined odds ratio of reliable worsening/deterioration
(clinically significant improvement) for the NOT Fb, NOT P/T Fb, and CST Fb groups were 0.44
(2.55), 0.68 (2.97), and 0.23 (3.85), respectively. These results indicate greater treatment effects

40
in all of the outcome criteria evaluated in this study, except for the NOT P/T Fb condition in its
effect to reduce reliable worsening/deterioration.
Contrary to the previous meta-analysis (Lambert, et al., 2003), this study highlighted
effects of feedback interventions on OT patients. Although not to the magnitude experienced by
the NOT counterparts, patients in OT P/T Fb and OT Fb appear to experience more distress
reduction and increased odds of experiencing reliable/clinically significant improvements than
those in OT TAU.
It is interesting to note the pattern of outcomes seen in the P/T Fb patients. Specifically,
this intervention yielded increased treatment enhancing effects while yielding similar rate of
reliable worsening/deterioration when compared with that of the TAU group. These results
suggest the possibility of a mechanism that interacts with provision of direct progress feedback
to patients in such a way that enhances outcome for some, while inhibiting outcome
enhancement for others.
Another aim of this meta-analysis was to investigate the incremental benefit of the NOT
P/T Fb and CST Fb interventions in comparison to the NOT Fb intervention. Because previous
reports (Harmon, et al., 2007; Slade, et al., 2008) provided only the results of efficacy analyses
for the CST Fb intervention, I compared this intervention against the NOT Fb intervention under
equivalent inclusion criteria. Although the comparative magnitude of the effects of the CST Fb
over the Fb were smaller than previously reported (primarily due to comparing the efficacy CST
Fb samples against the ITT NOT Fb samples in previous studies), results of ITT analyses
produced statistically significant effects in terms of superior distress reduction at post-treatment
(g = -0.16, p < 0.05) and increased odds of clinically significant improvement (OR = 1.53, p <
0.05). Although statistical significance was observed in comparisons between the CST Fb and
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NOT Fb groups, there were overlaps in 95% confidence intervals between the CST Fb versus
NOT TAU comparisons and the NOT Fb versus NOT TAU comparisons. Efficacy analyses,
however, did not yield statistically significantly greater additive treatment effects for the CST Fb
group over the NOT Fb group. These statistically non-significant results, however, should not be
automatically assumed to be indications of no additive effect, as reflected in greater effect sizes
yielded in the efficacy analyses. Statistically non-significant results may be due to the lack of
statistical power because of the reduction of sample sizes by applying exclusion criteria. Future
trials featuring the CST Fb and P/T Fb interventions may further our understanding of the
magnitude of these interventions.
Comparison of ITT analyses and efficacy analyses opens questions about possible
mechanisms of change. Because the primary element of the exclusion criteria used in efficacy
analyses was the number of sessions attended by patients, a question arises as to how much of
the improvements in the results of efficacy analyses were function of the dose-response effect
(Hansen, Lambert, & Forman, 2002). Improvements in treatment outcome among the efficacy
samples also suggest a higher proportion of poorer outcomes among patients who left treatment
before the feedback interventions could have taken the effect. If so, it appears important that
proactive effort be given to retain at risk patients in treatment, even more so for those
experiencing worsening at early stages of therapy.
As a supplemental analysis, to test the possibility of disproportional occurrences of
reliable worsening/deterioration and clinically significant improvement based on the length of
treatment, the percentages and odds of such outcomes on the pooled dataset of all NOT cases (N
= 1382) were calculated. Of those NOT patients who left treatment after five sessions or less
(early terminators; n = 381), 22.8% deteriorated, while 12.1% clinically significantly improved.
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In contrast, of those NOT patients who stayed in treatment six sessions or more (late terminators;
n = 1001), 11.7% later reliably worsened/deteriorated, while 39.9% clinically significantly
improved. When early terminators and late terminators were compared, the odds ratio of reliable
worsening/deterioration for the early terminator was 2.24, while the odds ratio of clinically
significant improvement was 0.21. These findings underline the need to retain NOT patients in
treatment longer. Future research effort to uncover the therapeutic and counter-therapeutic
processes of engaging NOT patients in treatment is recommended. Future research concerning
the process of deterioration also appears to be an important area to be explored further.
Limitations of study 1. While research synthesis, such as this quantitative review,
provides various statistical advantages in data analyses, this study has limitations, many of which
were inherent in the original studies. Reliability of treatment implementation may have been an
issue in individual studies as the use of feedback interventions by therapists were not closely
controlled or monitored. While statistical power increased owning to data synthesis/pooling, the
magnitude of true effects may have been underestimated. Because random assignment to
conditions was not incorporated in two of the studies (Lambert, Whipple, Vermeersch et al.,
2002; Whipple, et al., 2003), selection bias may have occurred, resulting in heterogeneous
samples of patients. Similarly, an argument can be made against causal statements based on the
data of studies not directly compared in the same randomized trials, such as in the case of
comparing the CST Fb group and the pooled TAU group in the Harmon and Slade studies.
However, pooled TAU data from multiple studies may provide the most reliable benchmark for
comparing alternative treatment strategies.
Although this issue was not detected in original studies, application of uniform
inclusion/exclusion criteria in this study revealed some heterogeneity of effects across studies.
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However, examination of evidence based on different inclusion criteria shed some light on the
consequences of applying such criteria. Through the use of intent-to-treat and efficacy analyses,
this study provided better understanding about the effects that can be expected when the
feedback interventions are implemented as a policy, as well as the effects expected from
controlled trials. Nonetheless, further replications across different patient populations by
different research groups are needed before the boundary conditions of effectiveness will be
known.
Another criticism may be made regarding the possibility of mono-method bias because
this line of research used only the OQ-45 as the outcome measure as well as the method for
identifying NOT cases. An argument can be made of using multi-method, multi-perspective
outcome assessment to capture more breadth of information related to patient treatment progress
and outcome. Such methods may be valuable in enhancing more comprehensive understanding
of the impact of feedback interventions than the methodology utilized in the line of research
reviewed. However, routine assessment and monitoring of outcome requires an instrument that
is time- and cost-efficient. In routine care where treatment termination is determined largely by
patients and treatment length is unknown at the outset, the use of multiple outcome measures is
not feasible. Given the established reliability and validity of the OQ-45 as a sensitive measure of
treatment outcome (Vermeersch, et al., 2004) and that its’ classification of patient change is
concordant with other frequently used measures, the use of the OQ-45 as the sole assessment tool
seems well suited for the purpose of quality assurance in routine clinical practice.
Another limitation of this line of research is the exclusive use of OQ total score in
outcome monitoring and feedback provision. Although extensive examination of OQ subscales
was performed in this study, the original feedback studies did not utilize subscale information in
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progress feedback. Thus, the treatment effects reflected at the subscale level were still effects
based on the OQ total score system. As already discussed in the meta-and mega-analytic
investigations of the OQ subscale, subscale based information could provide unique clinical
information that cannot be captured by the total scale score alone. Development and
implementation of OQ subscale score based progress feedback, in addition to the well
established total scale score based system may further enhance the clinical utility of this quality
assurance system. One practical advantage of subscale-based feedback system is that it requires
no more burden on patients other than filling out the OQ as they normally do.
Although I do not considered the following as a limitation to this line of research, it is
important to point out that the feedback procedures in the OQ quality assurance system appear to
be more appropriate for cases that are predicted to deteriorate, not all patients. To better
understand the effects of feedback interventions in a broad context of routine clinical practice,
the overall effects of feedback interventions on all patients included in original studies (both ontrack and not-on-track patients) by pooling the entire datasets of the six studies (N = 6151; ITT
analyses). Of those who received any form of feedback interventions, 4.7 % of patients
experienced reliable worsening or deterioration, while 37.4% of patients experienced clinically
significant improvement. Of those patients in routine care (i.e., no feedback; treatment-asusual), 6.1% reliably worsened/deteriorated while 30.2% achieved clinically significant
improvement. Accordingly, overall odds of deterioration among the pooled feedback
interventions group in relation to patients receiving treatment-as-usual were statistically
significant (OR = 0.76, p = 0.024). The overall odds of clinically significant improvement
among those in the pooled feedback group was also statistically significant (OR = 1.38, p <
0.001). The overall effects in terms of post-treatment mean OQ total scores showed significantly
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less disturbance (g = -0.12, SE = 0.03, p < 0.001). This effect size translates to 2.9 OQ total
points reduction on average. The overall reduction of deteriorated cases, increase in clinically
significant improvement, and decrease in distress level at termination occurred within a context
of utilizing an average of 0.9 more session of care. Although the value judgment regarding the
average increase of 0.9 more sessions of care may vary, the benefit of the feedback interventions,
especially for patients who are at risk of treatment failure, appears worthy of a serious
consideration for routine implementation of outcome monitoring and provision of feedback.
Study 2: Meta-analysis of Outcome Questionnaire-45 Subscale Scores
Selection Criteria and Participants
Retrieval of OQ subscale scores. The effects of feedback interventions on OQ subscale
scores were investigated, employing the same statistical methodologies used in the meta-analysis
and mega-analysis of the feedback effects on the OQ total scale scores. Prior to conducting
statistical analyses, however, significant effort was expended on retrieving the OQ subscale
scores for each of the datasets of the original feedback studies because OQ subscale scores were
not included in the original datasets. Brigham Young University Counseling and Career Center,
where five of the six studies in this review were conducted, maintained a separate dataset of OQ
scores for research purposes. The person ID number, date of OQ administration, and OQ total
scores were used to retrieve the OQ subscale scores for each data point for each participant. The
original dataset of study 4 (Hawkins et al., 2004) no longer contained the participants’ original
ID numbers, thus, the matching procedure became difficult. To make the procedure further
complicated, study 4 had no backup dataset with original OQ subscale scores, thus, the hard copy
of the administered OQ protocols were re-scanned, cleaned, and scored prior to commencing the
matching procedure. Due to various human errors inherent in filling out paper forms, complete
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replication of the original dataset based on the re-scanned data was not achieved. In study 4,
each individual data point was matched on the basis of the combinations of demographic
variables that were common to both the original dataset and the re-scanned dataset, such as
therapist ID, date of OQ administration, OQ total score, patient gender, marital status, and
employment status, in so far as they were available.
Inclusion and exclusion criteria. 6,151 patients included in the meta-analysis of OQ
total scale scores utilized a total of 33,558 sessions. Of these sessions recorded in the original
feedback study datasets, patients as a whole completed the OQ-45 in 91.4% of the sessions,
which resulted in 30,660 data points with OQ administrations. Of these, 29,437 observations
were matched with subscale scores, using series of syntaxes that outlined variables to link
between each observation in the datasets from the original studies to corresponding subscale
scores. Some subscale scores could not be matched by the use of syntaxes alone because of
some presumed human errors at the time of data entry, such as dates of the OQ administration
entered incorrectly in either the original dataset or the subscale score database. Judging the
relations to other variables, however, an additional 709 observations were matched manually. In
sum, 30,146 sessions out of 30,660 sessions (98.3%) succeeded in retrieval of the OQ subscale
scores (N = 6044).
The accuracy of the data match was assessed in two ways. First, for each case, the total
scale scores from the original studies and those derived from the matched datasets were
compared at pre-treatment, the time of signal warning (for not-on-track cases), and posttreatment. The following number of cases had discrepancies by greater or smaller than four OQ
points between the total scale scores from the original studies and those derived from the merged
datasets at pre-treatment (n1), the time of warning (n2), post-treatment (n3), and both pre-
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treatment and post-treatment (n4), respectively: n1 = 261, n2 = 45, n3 = 206, and n4 = 25. In some
cases, discrepancies in scores seemed so large that the two scores being matched seemed to come
from different data points. However, given that the reasons for such discrepancies were
unknown, all merged data was included in this study. This decision to include all of the merged
data has some possible consequences. For instance, discrepancies in pre- or post-treatment total
scores could alter such relationships in the data as the correlations between the pre-post change
scores in the total scale and subscales. Clinical significance classifications, which also rely on
the pre-post change scores as well as the pre- and post-treatment scores, may not match
depending on the degree of discrepancies. In the second approach to assessing the accuracy of
the data match, the mean, standard deviation and n of OQ total scale scores from the original
study datasets and merged datasets were calculated and compared at pre-treatment, time of signal
warning, and post-treatment (Table2.1). As can be seen on Table 9, the merged data appears to
have accurately reproduced the original data structures.
Assessment of relations between OQ total scale and subscales. As discussed earlier,
OQ subscale scores have not been studied in previous feedback studies. Thus, to interpret the
results of analyses based on OQ subscale scores, gaining rudimentary understanding about the
relations between the OQ total scale scores and subscale scores in the feedback studies was
deemed necessary. Several approaches were utilized to explore such relations. First, the
correlations between the total scale score and each of the subscale scores at three time points
were calculated: pre-treatment, time of signal warning, and post-treatment. These correlations
were thought of as initial estimates of similarities between the effect sizes obtained from group
differences in mean post-treatment OQ total scale scores and effect sizes obtained from
corresponding subscale scores. Second, the correlations between the pre-post change scores
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between the total scale and subscales were calculated to obtain the estimates of associations
between the total scale and subscale pre-post change effect sizes. Third, to investigate the
relations between the clinical significance status of the outcome at termination based on the total
scale scores and those based on subscale scores, flow charts were created to show the breakdown
of the n and percentage of matched/non-matched cases.
Correlation between OQ total scale scores and subscale scores. The Pearson’s
correlation coefficients between the total scale and subscale scores at pre-treatment, signal
warning, and post-treatment as well as pre-post change scores are reported in Table 10. High
correlations were found between the OQ total scale scores and the SD scale scores. The IR and
SR subscales presented lower, but still moderate correlations. Correlation coefficients of the IR
and SR subscales were very similar to each other. These results suggested that the meta- and
mega-analytic results in this study on the SD subscale would be similar to those found in the
total scale analyses.
Match in clinical significance status between OQ total scale scores and subscale
scores. To investigate the matches between clinical significance status between the outcome
classification system based on the total scale and those based on the subscales, patient outcome
status at termination were broken down to the following categories. To facilitate ease in
understanding various classifications, a flowchart of patient classification is provided in Figure 1.
It should be noted, however, that these categorizations are not exhaustive as to including
all possible combinations between the classifications based on the total scale scores and those
based on the subscale scores.
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•

Deterioration cases—(a) patient was classified as a deterioration case based only on
the total scale, but not on any of the subscales; (b) patient was classified as a
deterioration case based on both the total scale and at least one subscale;

•

No change cases—(c) patient was classified as achieving no significant change on
both the total scale and all of the subscales, (d) patient was classified as achieving no
significant change on the total scale, but was identified as a deterioration case on at
least one subscale, (e) patient was classified as achieving no significant change on the
total scale, but was identified as a reliable improvement/clinically significant
improvement case on at least one subscale, (f) patient was classified as a no change
case on the total scale, but had mixture of both deterioration and improvement on
subscales.

•

Reliable improvement/clinically significant improvement—(g) patient was classified
as a reliable improvement/clinically significant improvement case on the total scale
only, and (h) patient was classified as a reliable improvement/clinically significant
improvement case on both the total scale and at least one subscale.

In a small minority of cases, outcome classifications in the total scale and subscales were
contradictory (e.g., clinically significant improvement on the total scale, but one of the subscales
indicated deterioration). In approximately half of these cases, the cause of such discrepancy
seemed to have resulted from discrepancies in the data match as described earlier. In other cases,
the discrepancy in outcome classification seemed to have resulted from large changes on the SD
subscale “masking” the changes of other subscales that went in the opposite direction. As
presented in Figure 1, cases where both the total scale score-based clinical significance
classification and those based on the subscales matched, n and percentage of the given clinical

50
significance (i.e., deterioration, no change, or reliable improvement/clinically significant
improvement) on each subscale and combinations of subscales are reported. The results show
about 79% of deterioration cases based on the total scale classification were also identified as
deterioration cases in at least one of the subscales. Nearly 79% of those subscale-based
deterioration cases involved either deterioration in the SD subscale alone (43%) or combinations
of the SD scale and other subscales. Interestingly, deterioration on the IR and SR subscales were
identified mostly when they were the sole subscale classified as deterioration (10% each) or
when combined with the SD scale. Only in rare instances (1.6%) did deterioration occur on the
combination of the IR and SR scales, but not the SD scale, when deterioration was also observed
on the total scale.
The matching results further showed that when patients were classified as reliable
improvement/clinically significant improvement cases, in approximately 90% of the time
patients were also classified as achieving the same outcome on at least one subscale or
combinations of subscales. In nearly 95% of those matched cases involved clinically significant
improvement in the SD subscale, either as the SD scale alone (48%) or the SD subscale in
combination with other subscales (47%). The occurrences of clinically significant improvement
on the IR and SR subscales seemed underrepresented, especially when they were the sole
subscale being identified as meeting the criteria for achieving reliable improvement/clinically
significant improvement (2 to 3%).
These results initially seemed to suggest close overlaps between the total scale-based
outcome classification and the SD subscale-based classification. However, a closer look at the
data of “no change” cases on the total scale revealed that the IR and SR subscale-based
classifications provided unique outcome information that was not detected by the total scale-
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based system. For instance, 166 patients in the no-change category based on the total scale
outcome classification (equivalent of more than a half the number of those who were identified
as deterioration cases based on the total scale system, n = 309) experienced deterioration on at
least one subscale. Combining all deterioration cases based on the IR subscale, 37% (n = 59)
were classified as no-change cases on the total scale outcome classification. Similarly, of all the
SR subscale-based deterioration cases, 33% (n = 46) of them were identified as no-change cases
on the total scale classification. 25% of the deterioration cases on the SD subscale were
classified as no-changers on the total scale.
These results suggest that a sizable portion of deterioration at the subscale level was not
detected by the total scale score classification. In contrast, relatively smaller percentage of
improvement cases based on the subscale classification systems were identified as no change
cases on the total scale system. Of all the improvement cases on the subscales, 12% from the SD
subscale, 6% from the IR subscale, and 7% from the SR subscale (including combinations of
clinically significant improvement status attained on multiple subscales) were classified as no
change cases on the total scale. These results suggest that when clinically significant
improvement occurred at the subscale level, such outcome was likely reflected in the total scale
score based outcome classification. These results appeared to support the possible unique
contributions the OQ subscale analyses might add to our understanding of the effects of feedback
interventions on patient outcome. It is important to note that in the original feedback studies, the
feedback provided to clinicians regarding their patients’ progress was based on the OQ total
scale scores alone. It is thus possible that the provision of OQ subscale based feedback might
have resulted in greater change on the outcome at the subscale level. The analyses reported in
this review, however, examined the effects of the OQ total scale scores-based feedback
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interventions as measured at the OQ subscale level, not the effects of providing feedback based
on the OQ subscale scores.
Dependent Measures and Computation of Effect Sizes
To be consistent with the methodologies utilized in the OQ total scale analyses, the
following dependent measures were used to assess the effects of feedback treatments: Mean
post-treatment OQ subscale scores, mean pre-treatment to post-treatment change scores, the odds
of patients achieving clinically significant improvement at post-treatment based on the subscalelevel outcome classification, and the odds of the occurrence of clinically significant worsening
(or deterioration) at post-treatment based on the subscale-level outcome classification. Effect
sizes were calculated based on the methodologies utilized for the OQ total scale analyses, except
as noted in specific sections below.
Analysis of OQ Subscale Effect Sizes
Post-treatment between-group difference. In the sections below, the meta-analytic and
mega-analytic results of post-treatment between-group differences in each of the OQ subscales
are discussed in turn. The results of each subscale analysis, including the results of tests of
publication bias, are presented in Tables 11, 12, and 13. To facilitate ease in comparing effect
sizes between groups and across different subscales, effect sizes and corresponding 95% CIs are
summarized in Table 14.
Symptom distress (SD) scale.
Feedback effect. The results of one-way ANCOVA, testing for heterogeneity of effects
across studies, with study as the factor, post-treatment SD subscale score as the dependent
variable, and pre-treatment SD subscale score as the covariate, indicated no significant study
effect among the Fb group in ITT analysis, F(3, 261) = 0.88, p = 0.883, or efficacy analysis F(3,

53
130) = 1.43, p = 0.237. Similarly, no statistically significant study effect was found among the
NOT TAU, F(3, 307) = 1.88, p =0.133. These results do not support the presence of
heterogeneity of effect sizes. The results of independent samples t test, comparing the pretreatment symptom distress level as measured by the SD subscale between the pooled NOT Fb
and the NOT TAU groups showed no between treatment group difference in either ITT analysis,
t(576) = -0.55, p = 0.586, or efficacy analysis, t(445) = -0.33, p = 0.740.
The combined effect size for the mean difference in post-treatment SD subscale scores
between the NOT Fb group and the NOT TAU group was significant in ITT analysis, g = -0.26,
p = 0.002, 95% CI [-0.42, -0.09], equivalent of 3.7 OQ points difference in mean post-treatment
SD scores, with individual effect sizes ranging from g = -0.38, p = 0.137, 95% CI [-0.88, 0.12] to
g = -0.04, p = 0.878, 95% CI [-0.53, 0.46]. The combined effect size for the efficacy analysis
was also significant, g = -0.52, p < 0.001, 95% CI [-0.73, -0.32], equivalent of 7.4 OQ points
difference, with individual effect sizes ranging from g = -0.69, p < 0.001, 95% CI [-1.02, -0.36]
to g = -0.27, p = 0.337, 95% CI [-0.82, 0.28].
Patient/therapist feedback (P/T Fb) effect. As with the meta-analyses of the OQ total
scale scores, incremental effects of the NOT P/T Fb and CST Fb interventions were tested
against the NOT Fb group. The results of ANCOVAs, testing the heterogeneity of effects by
study with pre-treatment SD subscale scores as a covariate did not reach statistical significance at
the .05 level in ITT analysis, F(2, 217) = 1.46, p = 0.234, or efficacy analysis, F(2, 172) = 1.56, p
= 0.212. Mean pre-treatment SD subscale scores were near identical between the NOT P/T Fb
group and NOT Fb group in both ITT analysis, t(405) = -0.11, p = 0.912 and efficacy analyses,
t(321) = -0.17, p = 0.865. The combined effect size for the comparison between NOT P/T Fb
and NOT Fb was not significant in either ITT analysis, g = -0.11, p = 0.272, 95% CI [-0.30,
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0.09], or efficacy analyses g = -0.09, p = 0.403, 95% CI [-0.31, 0.13]. These results suggest that
provision of progress feedback to both patients and therapists adds little benefit to provision of
feedback to therapists alone in reducing symptom distress.
The NOT P/T Fb group was also compared to the NOT TAU group. The results for
independent samples t-test of pre-treatment SD subscale scores between pooled NOT P/T Fb and
pooled NOT TAU groups was not significant in either ITT analysis, t(531) = 0.483, p = 0.629, or
efficacy analysis, t(486) = 0.21, p = 0.838. These results indicate equivalence of pre-treatment
distress level between the two groups. The effect size in ITT analysis was g = -0.24, p = 0.008,
95% CI [-0.41, -0.06], an equivalent of 3.3 OQ point difference on average, favoring the NOT
P/T Fb group over the NOT TAU group. The effect size in efficacy analysis was g = -0.39, p <
0.001, 95% CI [-0.57, -0.20], equivalent of 5.4 OQ point difference on average, favoring NOT
P/T Fb group. These results show that the effect sizes of post-treatment comparisons between
the NOT P/T Fb group and the NOT group are smaller than those between the NOT Fb group
and the NOT TAU. Yet, the effect sizes between the NOT P/T Fb and NOT Fb were in favor of
the NOT P/T Fb albeit the results did not reach statistical significance.
These seemingly inconsistent findings were the results of having two different NOT Fb
groups in the above comparisons. In the case of comparisons between the NOT Fb and NOT
TAU, studies 1, 2, 3, and 4 (i.e., Lambert, et al., 2001; Lambert, et al., 2002; Whipple, et al.,
2003; and Hawkins, et al., 2005) were used. The comparisons between the NOT P/T Fb and
NOT Fb groups were based on studies 4, 5, and 6 (i.e., Hawkins, et al., 2005, Harmon, et al.,
2007, and Slade, et al., 2008). The NOT Fb groups from the latter studies had a higher mean
post-treatment scores (i.e., higher distress) than those from the earlier studies.
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Clinical Support Tools feedback (CST Fb) effects. The results of one-way ANCOVA to
test for the presence of heterogeneity of effects resulted in a statistically significant result among
the CST group in ITT analysis, F(2, 408) = 4.97, p = 0.007, but not in efficacy analysis, F(2,
210) = 0.264, p = 0.768. The significant results seen in the ITT analysis appears mainly due to
study 3 (Whipple, et al., 2003), where the mean pre-treatment SD subscale score was higher and
post-treatment SD subscale score was lower than other studies. Controlling for the pre-treatment
score appears to have contributed to a significant discrepancy on the mean post-treatment SD
subscale scores. The combined effect size for the group difference between the CST Fb and
NOT Fb groups at post-treatment was not significant for the ITT analysis, g = -0.15, p = 0.066,
95% CI [-0.32, 0.01], with individual effect sizes ranging from g = -0.07, p = 0.623, 95% CI
[-0.33, 0.20] to g = -0.24, p = 0.082, 95% CI [-0.50, 0.03]. The combined effect size was also
not significant in efficacy analysis g = -0.18, p = 0.086, 95% CI [-0.38, 0.03], with individual
effect sizes ranging from g = -0.29, p = 0.085, 95% CI [-0.62, 0.04] to g = 0.08, p = 0.736, 95%
CI [-0.37, 0.52].
Although statistical significance was not achieved, both the ITT and efficacy effect sizes
resembled those found in the OQ total scale scores analyses, including the unique behaviors of
the CST Fb group in study3. The lack of statistical power may have been an issue. The CST Fb
group was also mega-analytically compared with NOT TAU, comparing the pooled datasets of
the two groups. The results of independent samples t-test of difference in mean pre-treatment
SD subscale scores between the pooled CST Fb and the pooled NOT TAU did not reach
statistical significance in ITT analysis, t(722) = -0.416, p = 0.678 or efficacy analysis, t(524) =
0.517, p = 0.606, indicating that both groups were comparable in pre-treatment symptom distress
level as measured by the SD subscale. The effect size in ITT analysis was g = -0.33, p < 0.001,
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95% CI [-0.47, -0.18], equivalent of 4.5 OQ point difference on average, favoring the CST Fb
group. The effect size in efficacy analysis was g = -0.55, p < 0.001, 95% CI [-0.73, -0.38],
equivalent of 7.5 OQ point difference on average, favoring the CST Fb group.
Interpersonal relations (IR) subscale.
Feedback (Fb) effects. One-way ANCOVAs were performed to test for the heterogeneity
of effects, using post-treatment IR subscale score as the dependent variable, study as a factor,
and pre-treatment IR subscale score as a covariate. The NOT Fb group did not result in
significant study effects at the .05 level for either ITT analysis, F(3, 261) = 1.12, p = 0.342, or
efficacy analysis, F(3, 130) = 1.72, p = 0.165. The NOT TAU group resulted in significant
heterogeneity, F(3, 307) = 3.18, p = 0.024. The cause of this heterogeneity appears multifaceted,
including varying levels of pre-treatment and post-test IR scores across studies as well as
directions of pre-treatment to post-treatment change on this subscale. Due to this heterogeneity,
the effect sizes were calculated both meta-analytically and mega-analytically, where patients
were grouped into pooled NOT Fb or NOT TAU groups. The effect sizes were essentially
identical, thus only the meta-analytic results are presented here. There was no significant
difference in the mean pre-treatment IR score between NOT Fb and NOT TAU in ITT analysis,
t(576) = -0.92, p = 0.357, or efficacy analysis, t(445) = -0.72, p = 0.473, indicating that the two
groups were comparable in the average level of disturbance in interpersonal relations at pretreatment.
In ITT analysis, individual effect sizes ranged from g = -0.40, p = 0.002, 95% CI
[-0.65, -0.14] to g = -0.12, p = 0.638, 95% CI [-0.38, 0.62]. The combined effect size for the
mean post-treatment difference in mean IR subscale scores between NOT Fb and NOT TAU was
g = -0.24, p = 0.013, 95% CI [-0.43, -0.05], representing the average of 1.5 IR subscale score
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difference on average, favoring the NOT Fb group. In efficacy analysis, individual effect sizes
ranged from -0.72, p < 0.001, 95% CI [-1.05, -0.38] to g = -0.03, p = 0.926, 95% CI [-0.58,
0.52]. The combined effect was g = -0.37, p = 0.016, 95% CI [-0.67, -0.07], indicating an
average of 2.4 difference in IR subscale scores at post-treatment, favoring the NOT Fb group. It
should be noted that, because the IR and SR subscales have far fewer number of items than the
SD subscale, effect sizes of similar magnitude on the IR and SR subscales do not translate to
similar mean differences in the raw score unit (i.e., OQ points).
Patient/therapist feedback (P/T Fb) effect. The results of one-way ANCOVA to test for
the potential study effects did not support the presence of heterogeneity in either ITT analysis,
F(2, 217) = 0.05, p = 0.952 or efficacy analysis, F(2, 172) = 0.251, p = 0.778. Mean pretreatment IR subscale scores were near identical between the NOT P/T Fb group and NOT Fb
group in both ITT analysis, t(405) = -0.07, p = 0.944 and efficacy analyses, t(321) = -0.10, p =
0.924. In ITT analysis, individual effect sizes in the mean post-treatment IR subscale scores
between NOT P/T Fb and NOT Fb ranged from g = -0.38, p = 0.121, 95% CI [-0.86, 0.10] to g =
0.06, p = 0.671, 95% CI [-0.23, 0.36]. The combined effect size was g = -0.06, p = 0.569, 95%
CI [-0.28, 0.15]. In efficacy analysis, individual effect sizes ranged from g = -0.48, p = 0.103,
95% CI [-1.05, 0.10] to g = -0.01, p = 0.958, 95% CI [-0.35, 0.33] with the combined effect size
of g = -0.12, p = 0.274, 95% CI [-0.34, 0.10]. These results suggest that provision of progress
feedback to patients and therapists to NOT patients does not appear to provide unique advantage
over provision of progress feedback to therapists alone in improving interpersonally oriented
outcome. The NOT P/T Fb group was also compared to NOT TAU, using a mega-analytic
approach. The results of independent samples t-test did not yield group difference in mean pretreatment IR scores in either ITT analysis, t(531) = -0.247, p = 0.805 or efficacy analysis, t(486)
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= -0.497, p = 0.620, indicating the two groups were comparable at pre-treatment in distress
related to interpersonal relations. The effect size in ITT analysis was g = -0.29, p = 0.001, 95%
CI [-0.46, -0.12], equivalent of 1.9 OQ points, favoring the NOT P/T Fb. The effect size in
efficacy analysis was g = -0.43, p < 0.001, 95% CI [-0.61, -0.24], equivalent of 2.8 OQ points
difference on average, favoring the NOT P/T Fb.
Clinical support tools feedback (CST Fb) effects. The results of ANCOVAs did not
support the presence of heterogeneity of effects in terms of study effects in either ITT analysis,
F(2, 408) = 2.18, p = 0.115, or efficacy analysis, F(2, 210) = 1.04, p = 0.357. Pre-treatment
mean IR subscale scores of CST Fb and NOT Fb were comparable in both ITT sample, t(654) =
0.63, p = 0.512, and efficacy sample, t(380) = 1.58, p = 0.116. In ITT analysis, individual effect
sizes ranged from g = -0.13, p = 0.459, 95% CI [-0.46, 0.21] to g = -0.05, p = 0.736, 95% CI
[-0.31, 0.22], with the combined effect size of g = -0.08, p = 0.357, 95% CI [-0.24, 0.09]. In
efficacy analysis, the combined effect size was also statistically non-significant, g = -0.12, p =
0.247, 95% CI [-0.32, 0.08] with individual effect sizes ranging from g = -0.24, p = 0.152, 95%
CI [-0.57, 0.09] to g = -0.01, p = 0.952, 95% CI [-0.46, 0.43]. These results suggest that CST Fb
intervention has little advantage over NOT Fb in improving interpersonal aspects of outcome in
terms of the post-treatment IR scores.
The CST Fb group was also compared to NOT TAU. Pre-treatment mean IR subscale
scores did not differ in either ITT analysis, t(722) = -1.17, p = 0.242 or efficacy analysis, t(524)
= 0.15, p = 0.882, indicating that patients in CST Fb and NOT TAU on average began treatment
with equivalent level of interpersonal disturbance. In ITT analysis, the effect size in terms of
mean post-treatment IR subscale scores difference was g = -0.42, p < 0.001, 95% CI
[-0.51, -0.27], equivalent of 2.7 OQ points difference on average, favoring the CST Fb group.
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The effect size in efficacy analysis was g = -0.54, p < 0.001, 95% CI [-0.71, -0.36], equivalent of
3.5 OQ point difference on average, favoring the CST Fb group. These results suggest CST Fb
group had a moderate effect in improving interpersonally oriented outcome.
Social role (SR) subscale.
Feedback (Fb) effects. The results of one-way ANCOVAs, testing for heterogeneity of
effects across studies, with study as the factor, post-treatment SR subscale score as the dependent
variable, and pre-treatment SR subscale score as the covariate, indicated no significant study
effect among the Fb group in ITT analysis, F(3, 261) = 0.72, p = 0.542, or efficacy analysis, F(3,
130) = 1.96, p = 0.124. The results showed a significant heterogeneity for the NOT TAU group,
F(3, 307) = 3.73, p = 0.012. Effect sizes were calculated using both meta-analytic and megaanalytic approaches. Meta-analytic results yielded slightly smaller effect sizes than megaanalytic approach, but the differences were .02 and .04 for the ITT and efficacy analyses,
respectively. Thus, only the mega-analytic results are presented. Mean pre-treatment SR
subscale scores between NOT Fb and NOT TAU were equivalent in both ITT analysis, t(576) =
0.74, p = 0.463, and efficacy analysis, t(445) = -0.25, p = 0.805.
The combined effect size between the NOT Fb and NOT TAU was g = -0.24, p = 0.005,
95% CI [-0.40, -0.07], equivalent of 1.1 OQ point difference on average, favoring the NOT Fb
group. Individual effect sizes ranged from g = -0.37, p = 0.005, 95% CI [-0.62, -0.11] to g =
0.08, p = 0.754, 95% CI [-0.42, 0.57]. In efficacy analysis the effect size was g = -0.48, p
<0.001, 95% CI [-0.69, -0.28], equivalent of 2.3 OQ points difference, favoring the NOT Fb
group. Individual effect sizes ranged from g = -0.65, p < 0.001, 95% CI [-0.98, -0.32] to g
= -0.07, p = 0.801, 95% CI [-0.62, 0.48]. These results suggest that Fb has a small to moderate
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advantage over TAU in improving outcome related to the social role performance of NOT
patients.
Patient/therapist feedback effect. The results of ANCOVAs, testing the possible
heterogeneity of effects did not reach statistical significance in either ITT analysis, F(2, 217) =
2.42, p = 0.092, or efficacy analysis, F(2, 172) = 2.54, p = 0.082. The between-group difference
on pre-treatment SR subscale scores did not reach statistical significance in either ITT analysis,
t(405) = 0.97, p = 0.334, or efficacy analysis, t(321) = 0.26, p = 0.792, indicating that the two
groups were comparable in the level of disturbance at pre-treatment as measured by the SR
subscale. The combined effect size for the difference in mean post-treatment SR subscale scores
in ITT analysis was g = -0.22, p = 0.137, 95% CI [-0.52, 0.07], equivalent of 1.0 OQ point
difference on average, favoring the NOT P/T Fb; however, this difference is not statistically
significant. Individual effect sizes ranged from g = -0.42, p = 0.008, 95% CI [-0.73, -0.11] to g =
0.02, p = 0.907, 95% CI [-0.28, 0.31]. In efficacy analysis, the combined effect size was g
= -0.24, p = 0.193, 95% CI [-0.61, 0.12] with individual effect sizes ranging from g = -0.53, p =
0.002, 95% CI [-0.86, -0.20] to g = 0.01, p = 0.934, 95% CI [-0.33, 0.35]. These results suggest
that P/T Fb intervention adds little incremental benefit to the Fb. The ranges of effect sizes,
however, suggest that some studies demonstrated more incremental benefits than others.
Prior to comparing the NOT P/T Fb group with NOT TAU using a mega-analytic
approach, independent samples t-tests were conducted to compare the mean pre-treatment SR
subscale scores to test for equivalence of the two groups at pre-treatment. The results did not
reach significance in either ITT analysis, t(531) = 0.583, p = 0.560, or efficacy analysis, t(486) =
0.002, p = 0.998, indicating that both groups were equivalent at pre-treatment. The effect size
for ITT analysis was g = -0.40, p < 0.001, 95% CI [-0.57, -0.23], equivalent of 1.9 OQ point
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difference on average at post-treatment, favoring the NOT P/T Fb group. The effect size for
efficacy analysis was g = -0.56, p < 0.001, 95% CI [-0.75, -0.37], equivalent of 2.5 OQ point
difference on average at post-treatment.
Clinical Support Tools feedback (CST Fb) effects. Similar to the results of other subscale
score analyses, the results of ANCOVAs testing for heterogeneity among the CST Fb group
showed significant study effect in ITT analysis, F(2, 408) = 4.09, p = 0.017, but not in efficacy
analysis, F(2, 210) = 0.69, p = 0.504. As in the case with other subscale analyses, the primary
cause of heterogeneity in ITT analysis appears to be the greater degree of difference in pre-post
change scores observed among patients in study 3. There was no significant difference in mean
pre-treatment SR subscale scores between CST Fb and NOT Fb in either ITT analysis, t(654) =
0.42, p = 0.677, or efficacy analysis, t(380) = 0.29, p = 0.776, indicating that these groups were
equivalent at pre-treatment in terms of social role performance as measured by the SR subscale
scores.
The combined effect size, comparing the mean post-treatment SR scores between CST Fb
and NOT Fb, was significant at .05 level in ITT analysis, g = -0.20, p = 0.018, 95% CI
[-0.36, -0.03], equivalent of 0.9 OQ point difference on average, favoring the CST Fb group.
Individual effect sizes ranged from g = -0.36, p = 0.036, 95% CI [-0.70, -0.02] to g = -0.08, p =
0.548, 95% CI [-0.35, 0.18]. The combined effect size in efficacy analysis was also significant,
g = -0.28, p = 0.006, 95% CI [-0.49, -0.08], equivalent of 1.2 OQ point difference on average,
with individual effect sizes ranging from g = -0.36, p = 0.027, 95% CI [-0.68, -0.04] to g = -0.15,
p = 0.509, 95% CI [-0.59, 0.29]. These results suggest that CST Fb may add small incremental
benefits over the Fb intervention in terms of social role performance at post-treatment.
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The pooled data of the CST Fb was also compared with the pooled NOT TAU. No
significant pre-treatment mean SR score differences was found in either ITT analysis, t(722)
= -0.26, p = 0.796 or efficacy analysis, t(524) = -0.49, p = 0.625, indicating that both groups
were equivalent in social role performance at pre-treatment as measured by the SR subscale. The
effect size for ITT analysis was g = -0.38, p < 0.001, 95% CI [-0.53, -0.23], equivalent of 1.7 OQ
point difference on average, favoring the CST Fb group. In efficacy analysis, g = -0.64, p <
0.001, 95% CI [-0.81, -0.46], equivalent of 2.9 OQ point difference on average.
Pre-post change in OQ subscale scores. The effect sizes for pre-treatment to posttreatment change scores in OQ subscales were calculated for each feedback condition, using
mega-analytic approaches. Two types of effect sizes were calculated for pre-post change
subscale scores. First pre-post change effect size was obtained and reported on the pooled
dataset for each treatment group (See Table 15). The formulae for calculating pre-post change
effect size (in Hedges’s g) are presented in Appendix B. A mega-analytic approach was used to
calculate the effect sizes in terms of between-group difference in the amount of mean pre-post
change scores on the OQ subscales. The formulae for calculating the standardized difference in
mean pre-post change scores are also presented in Appendix B.
Pre-post change in OQ subscale scores by feedback condition.
Treatment as usual (TAU). The pre-post change effect sizes of the NOT TAU group for
the SD scale, IR scale, and SR scale were g = -0.14, p = 0.019, 95% CI [-0.25, -0.02]; g = 0.12, p
= 0.018, 95% CI [0.02, 0.22]; and g = 0.09, p = 0.128, 95% CI [-0.03, 0.21], respectively. These
results suggest that NOT TAU group as a whole experienced a small degree of, but statistically
significant, improvement in symptom distress, while experiencing a statistically significant
worsening in disturbances related to interpersonal relations and no change in the social role
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performance. The summary of pre-post effect sizes for NOT TAU group and other NOT groups
are presented in Table 16.
Feedback (Fb) effect. In ITT analysis, the respective pre-post change effect sizes of the
NOT Fb group for the SD scale, IR scale, and SR scale were g = -0.30, p < 0.001, 95% CI [-0.39,
-0.21]; g = -0.06, p = 0.163, 95% CI [-0.15, 0.03]; and g = -0.13, p = 0.008, 95% CI
[-0.23, -0.03]. In efficacy analysis, the respective effect sizes for the SD, IR, and SR subscales
were g = -0.49, p < 0.001, 95% CI [-0.61, -0.37]; g = -0.17, p = 0.003, 95% CI [-0.29, -0.06]; and
g = -0.25, p < 0.001, 95% CI [-0.39, -0.12]. The effect sizes for the NOT Fb are summarized in
Table 17. These results indicate that the greatest reduction of distress in the NOT Fb group
occurred in symptom distress. The IR subscale had the smallest effect sizes, suggesting the least
change from pre-treatment to post-treatment among patients receiving the Fb intervention.
When the pre-post change effect sizes of the NOT Fb group were compared with those of
NOT TAU, between-group effect sizes (Hedges’s g) in ITT analysis for the SD, IR, and SR
subscales were -0.20 (p = 0.015), -0.18 (p = 0.029), and -0.28 (p < 0.001), respectively.
Although these group differences were statistically significant, the average amount of change
that occurred in the IR and SR subscales was quite small for the NOT Fb patients, with pre-post
change effect sizes of -0.06 and -0.13, respectively, in the intent-to-treat (ITT) analysis. The
between group differences were significant because the NOT TAU patients on average
experienced increase in the disturbances measured by the IR and SR subscales, g = 0.12 and g =
0.09, respectively, suggesting worsening of the outcome on these dimensions.
Symptom distress as measured by the SD subscale showed the most positive change in
both the NOT Fb group (g = -0.30) and the NOT TAU (g = -0.14). In efficacy analyses, the
effect sizes for the SD, IR, and SR subscales were -0.47, -0.36, and -0.41, respectively (all p <
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0.001). Details of the results are presented on Table 18. These results suggest that patients in
the NOT Fb on average experienced a greater degree of improvement in all three major domains
of outcome as measured by the OQ. The results further suggest that between-group differences
in the pre-treatment to post-treatment change are unitary across the SD, IR, and SR subscales.
Patient/therapist feedback (P/T Fb) effects. In ITT analysis, the pre-post effect sizes of
the NOT P/T group for the SD, IR, and SR subscales were g = -0.42, p < 0.001, 95% CI
[-0.56, -0.27]; g = -0.16, p = 0.025, 95% CI [-0.30, -0.02]; and g = -0.37, p < 0.001, 95% CI
[-0.51, -0.23], respectively. In efficacy analysis, the effect sizes for the SD, IR, and SR subscales
were g = -0.56, p < 0.001, 95% CI [-0.74, -0.37]; g = -0.28, p = 0.001, 95% CI [-0.44, -0.11]; and
g = -0.50, p < 0.001, 95% CI [-0.68, -0.32], respectively. These results suggest that pretreatment to post-treatment change in the SR subscale among the NOT P/T Fb patients showed a
similar degree of change in the positive direction as the SD subscale.
As in other meta- and mega-analytic results presented in this study, the NOT P/T Fb
group was compared to the NOT Fb group and NOT TAU. In ITT analysis, between-group
difference effect sizes (Hedges’s g) in pre-post change for the SD, IR, and SR subscales
were -0.10 (p = 0.317), -0.07 (p = 0.509), -0.29 (p = 0.004), respectively. In efficacy analysis,
effect sizes for the SD, IR, and SR subscales were -0.08 (p = 0.494), -0.13 (p = 0.237), and -0.24
(p = 0.029). These results suggest that the P/T Fb intervention has a small effect on improving
social role performance-related outcome measured by the SR subscale in comparison to
provision of progress feedback to therapists alone in NOT patients.
When comparing the NOT P/T Fb group with NOT TAU, the effect sizes from ITT
analysis for the SD, IR, and SR subscales were -0.27 (p = 0.002), -0.29 (p < 0.001), and -0.44 (p
< 0.001), respectively. In efficacy analysis, effect sizes for the SD, IR, and SR subscale scores
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were -0.39, -0.41 and -0.53 (all p < 0.001), respectively. It is interesting to note that the patients
in the NOT P/T Fb group on average endorsed the most change in the social role performance
aspect of outcome in comparison to both NOT Fb and NOT TAU. The possible meanings of
these findings, although reliable, are unknown at this time.
Clinical support tools (CST) effects. Pre-post change effect sizes for the SD, IR, and SR
subscale scores in ITT analysis were g = -0.43, p < 0.001, 95% CI [-0.53, -0.33]; g = -0.23, p <
0.001, 95% CI [-0.33, -0.13]; and g = -0.29, p < 0.001, 95% CI [-0.29, -0.40], respectively. In
efficacy analyses, the respective subscale pre-post change effect sizes were g = -0.76, p < 0.001,
95% CI [-0.91, -0.60]; g = -0.46, p < 0.001, 95% CI [-0.61, -0.32]; and g = -0.54, p < 0.001, 95%
CI [-0.70, -0.38], respectively. These results suggest that, consistent with other feedback
interventions, patients in the CST Fb condition experienced the most change in their symptom
distress. Interestingly, contrary to other subscales, there was a greater degree of change on the
interpersonally oriented outcome measured by the IR subscale. This may be due to the fact that
the CST intervention calls clinician’s attention toward intervening in the patient’s life outside of
the therapeutic hour.
When the pre-post change scores in subscales were compared to the NOT Fb group, the
effect sizes (Hedges’s g) for the SD, IR, and SR subscale scores in ITT analysis were -0.13 (p =
0.107), -0.12 (p = 0.137), and -0.18 (p = 0.026), respectively. In efficacy analysis, the effect
sizes for SD, IR, and SR subscales in comparison to NOT Fb were -0.23 (p = 0.024), -0.29 (p =
0.005), and -0.27 (p = 0.009), respectively. These results suggest that, in comparison to NOT Fb
patients in the efficacy sample, the CST Fb group, who stayed in treatment long enough to reap
the benefit of this treatment, experienced statistically significant pre-post improvement in all
dimensions of outcome measured by the OQ.
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When the subscale pre-post change scores of the CST Fb group were compared to those
of the NOT TAU group, the effect sizes (Hedges’s g) for the SD, IR, and SR subscale scores in
ITT analysis were -0.30, -0.36, and -0.34 (all p < 0.001), respectively. In efficacy analysis, the
effect sizes for SD, IR, and SR subscales in comparison to NOT TAU were -0.60, -0.60
and -0.57 (all p < 0.001), respectively. These results indicate that the CST Fb group as a whole
experienced moderate pre-treatment to post-treatment change in all dimensions measured by the
OQ.
Differences in clinical significance. As in the case with evaluating the OQ total scale
scores based treatment outcome, treatment outcome at the subscale level was evaluated on the
basis of the rates and odds of clinically significant change status at termination. The n and
percentage of clinical significance classification of patient outcome at termination for each
subscale were aggregated by treatment condition and presented in Tables 17 (SD scale), 18 (IR
scale), and 19 (SR scale). These results indicate that the percentages of clinical significance
classification for the SD subscale closely resembled those observed for the OQ total scale
classification, with an exception of a lower rate of deterioration and an increased rate of
clinically significant improvement among the NOT TAU group. Conversely, the rates of reliable
deterioration and clinically significant improvement in all treatment conditions for the IR and SR
subscales were considerably lower than those observed in the OQ total scale scores based
classification results. Indeed, nearly 81 to 85% of NOT patients in all of the treatment conditions
in ITT analysis were classified as “no change” cases in the domains of outcome measured by the
IR and SR subscales. Even in efficacy analysis, approximately 76 % to 81% of NOT patients in
all treatment conditions were classified as “no changers.”
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Various possible interpretations of these results seem plausible. Such results may suggest
that the outcome related to one’s interpersonal relations and social role performance tend to be
more stable in terms of change than symptom distress. Another related view of these results may
suggest the challenging nature of improving clients’ relational concerns and social role
performance through psychotherapy, which in many cases is a time-limited enterprise. Yet,
another view may be offered in an acknowledgement of the magnitude of external and contextual
influences on patients’ relational experiences and social role performance. That is, in contrast to
symptom distress-related outcome, which may be more amiable to, treatment outcome related to
interpersonal relationships and social role performance may involve more external and
contextual influences that are beyond the reach of therapeutic effects of psychotherapy in
general. Thus, psychotherapy, at least the type of modality utilized in the studies reviewed in
this review (i.e., individual therapy), may be limited in its outcome enhancing influences on
interpersonal relationships and social role performance.
In the following sections, mega-analytic comparisons of the odds of deterioration and
clinically significant improvement between various treatment groups are presented. The
summaries of effect sizes, including 95% CI for each effect size are presented in Tables 20 and
21.
Feedback effect (Fb). When the odds of patient deterioration/reliable worsening at
termination for the NOT Fb group were compared against those of the NOT TAU group, ITT
analysis yielded the following odds ratios (OR) for the SD, IR, and SR subscales, respectively:
0.66 (p = 0.094), 0.93 (p = 0.807), and 0.64 (p = 0.192). In efficacy analysis, the OR for the SD,
IR, and SR subscales were 0.43 (p = 0.020), 0.67 (p = 0.313), and 0.53 (p = 0.179), respectively.
When the odds of patients achieving clinically significant improvement were compared between
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the NOT Fb group and NOT TAU, the OR from the ITT analysis for the SD, IR, and SR
subscales were 1.10 (p = 0.595), 1.45 (p = 0.240), and 2.16 (p = 0.006). In efficacy analysis, the
OR for the SD, IR, and SR subscales were 1.72 (p = 0.011), 2.25 (p = 0.018), and 2.86 (p <
0.001), respectively. These results suggest that provision of progress feedback to patients helped
prevent the occurrence of deterioration in symptom distress, especially for patients who stayed
long enough to reap the benefit of this treatment. Although the odds of deterioration seemed
lower for the NOT Fb group in other domains of outcome, the results did not reach statistical
significance. The results further suggest that patients in the NOT Fb group had two to three
times higher odds of achieving clinically significant improvement in social role performance
than those in NOT TAU. Similar odds of clinically significant improvement were observed in
the outcome related to interpersonal relations.
Patient/therapist feedback (P/T Fb) effect. When the odds of patient
deterioration/reliable worsening at termination for the NOT P/T Fb group were compared against
those of NOT Fb, the ITT analysis yielded the following odds ratios (OR) for the SD, IR, and SR
subscales, respectively: 1.11 (p = 0.718), 0.77 (p = 0.493), and 0.64 (p = 0.289). In efficacy
analysis, the OR for the SD, IR, and SR subscales were 1.40 (p = 0.369), 0.82 (p = 0.662), and
0.94 (p = 0.895), respectively. When the odds of patients achieving clinically significant
improvement were compared between the NOT Fb group and NOT TAU, the OR from the ITT
analysis for the SD, IR, and SR subscales were 1.34 (p = 0.172), 1.43 (p = 0.245), and 1.87 (p =
0.053), respectively. In efficacy analysis, the OR for the SD, IR, and SR subscales were, 1.28 (p
= 0.283), 1.53 (p = 0.183), 1.96 (p = 0.046) respectively. These results suggest that provision of
progress feedback to both patients and therapists in NOT cases had no significant incremental
benefit in reducing deterioration at the subscale level. The odds of clinically significant
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improvement among the NOT P/T Fb group were approximately two times higher for social role
performance related outcome. It is interesting to note that the odds ratios for deterioration were
higher in efficacy analysis than ITT analysis. A closer look at the differences in odds of patient
deterioration, however, do not indicate higher odds of deterioration among patients in the
efficacy sample than those in the ITT sample for the NOT P/T Fb group. The percentages of
deterioration were slightly lower among the efficacy group than the ITT; however, the degree of
reduction in the odds of deterioration among the NOT Fb group was greater than that of the NOT
P/T Fb, which led to increase in the ORs.
The odds of deterioration and clinically significant improvement were also compared
between the NOT P/T group and the NOT TAU group. In ITT analysis, when odds of patient
deterioration were compared between the two groups, odds ratios for the SD, IR, and SR
subscales were 0.84 (p = 0.496), 0.68 (p = 0.250), and 0.60 (p = 0.173), respectively. In efficacy
analysis, odds ratios for the SD, IR, and SR subscales were 0.73 (p = 0.255), 0.63 (p = 0.212),
and 0.62 (p = 0.231), respectively. When the odds of patients achieving clinically significant
change were compared between the NOT P/T Fb and NOT TAU groups, odds ratios for the SD,
IR, and SR subscales were 1.43 (p = 0.054), 2.38 (p = 0.004), and 2.21 (p = 0.006), respectively.
In efficacy analysis, the odds ratios for the respective subscales were 1.80 (p = 0.003), 3.12 (p =
0.001), and 2.79 (p < 0.001). These results suggest that patients in the NOT P/T Fb group as a
whole did not experience significant reduction in the odds of deterioration; however, the odds of
clinically significant improvement was higher in all subscales, more notably in the outcomes
related to interpersonal relations and social role performance.
Clinical support tools (CSTs) effects. The comparisons of odds of deterioration between
the CST Fb group and the NOT Fb group in ITT analysis yielded the following effect sizes
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(ORs) for the SD, IR, and SR subscales: 0.87 (p = 0.594), 0.65 (p = 0.225), and 0.51 (p = 0.055),
respectively. In efficacy analysis, the odds ratios for the respective subscales were 0.77 (p =
0.594), 0.60 (p = 0.317), and 0.42 (p = 0.129). The comparisons of the odds of patients
achieving clinically significant improvement between the CST Fb group and the NOT Fb group
yielded the following odds ratios for the SD, IR, and SR subscales: 1.32 (p = 0.110), 1.43 (p =
0.153), and 1.67 (p = 0.048), respectively. In efficacy analysis, the odds ratios for the respective
subscales were 1.69 (p = 0.013), 1.81 (p = 0.039), and 1.97 (p = 0.022). These results suggest
that CST’s incremental benefit in reducing the odds of the occurrence of deterioration in
outcomes measured by the OQ subscale did not reach statistical significance. The incremental
outcome enhancing benefit was found in the increased odds of patients achieving clinically
significant improvement in all subscales among the efficacy sample.
When the odds of deterioration were compared between the CST Fb group and NOT
TAU were compared in ITT analysis, odds ratios for the SD, IR, and SR subscales were 0.66 (p
= 0.059), 0.43 (p = 0.006), and 0.46 (p = 0.020), respectively. In efficacy analysis, the odds
ratios for the same comparisons for the respective subscales were 0.35 (p = 0.001), 0.32 (p =
0.008), and 0.27 (p = 0.010). Comparisons between the CST Fb and NOT TAU groups in the
odds of patients achieving clinically significant improvement yielded the following odds ratios
for the SD, IR, and SR subscales: 1.42 (p = 0.030), 2.49 (p < 0.001), and 2.18 (p = 0.002),
respectively. In efficacy analysis, the same group comparisons resulted in the following odds
ratios for the respective subscales: 2.52 (p < 0.001), 3.78 (p < 0.001), and 3.16 (p < 0.001).
These results suggest that patients in CST Fb group had significantly lower odds of
deterioration—approximately a half to a third—in all three domains of outcome measured by the
OQ subscales. The odds of patients in the CST Fb group achieving clinically significant
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improvement were significantly higher in all subscales, notably so on interpersonal relations and
social role performance subscales.
Discussion on Study 2
In this study, the effects of various progress feedback interventions were evaluated at the
OQ subscale level on various dimensions of treatment outcomes: differences in mean posttreatment scores across treatment groups, pre-treatment to post-treatment score change in each
treatment condition, differences in pre-post change scores across treatment groups, odds of
deterioration, and odds of achieving clinically significant improvement. The findings from these
analyses revealed the effects of feedback interventions on more specific aspects of treatment
outcome as measured by the OQ subscale scores, which were not available from the analyses
based on the OQ total scale scores alone. To summarize the findings from this study in
conjunction with the findings from the OQ total scale based analyses, the main findings for each
feedback treatment are now discussed in turn.
Progress feedback to not-on-track patients (NOT Fb). When comparing the posttreatment OQ subscale scores, the average not-on-track patient whose therapists received
progress feedback (NOT Fb) experienced superior outcome than 60% of NOT patients whose
therapists received no progress feedback (NOT TAU) on all subscales (effect sizes ranging from
g = -0.26 to g = -0.24). These results were comparable to the effect size for the same group
comparison on the OQ total scale. When the same comparisons were made between the NOT Fb
patients, who stayed in treatment long enough and completed at least a minimum number of the
OQ to measure the effects of the feedback intervention, and the NOT TAU, the results likewise
showed similarities between the effect sizes for the total scale (g = -0.53) and those for the
Symptom Distress (SD) and Social role performance (SR) subscales (g = -0.52 and -0.48,

72
respectively). These results suggest that the average patient in the NOT Fb group in the efficacy
sample experienced greater reduction of symptom distress and disturbances related to social role
performance than approximately 70% of NOT TAU patients.
When the amount of change in the OQ subscale scores from the pre-treatment to posttreatment were compared, the effect sizes of the NOT Fb group in comparison to the NOT TAU
group ranged from g = -0.28 for the SR subscale to g = -0.18 for the IR subscale. The degree of
pre-treatment to post-treatment change increased in all subscales among NOT Fb patients in the
efficacy sample, resulting in greater between-group difference in pre-post change (effect sizes
ranging from g = -0.47 for the SD subscale to g = -0.36 for the IR subscale). These effect sizes
were smaller than the effect size obtained from the difference in pre-post change on the total
scale scores between NOT Fb and NOT TAU (g = -0.60). These results suggest that while the
average patient in the NOT Fb experienced greater pre-post change on the total scale score than
approximately 73% of patients in the NOT TAU group, the average patient’s pre-post change on
the subscale scores were superior than approximately 64 to 68% of the NOT TAU patients.
The analyses of clinical significance indicated that, the NOT Fb group had 12%, 9%, and
6% of deterioration rate on the SD, IR, and SR subscales, respectively, in ITT analysis, while the
respective percentages reduced to 8%, 7%, and 5% in efficacy analysis. The rates of patients
achieving clinically significant improvement in the SD, IR, and SR subscale scores in the ITT
analyses were 31%, 10%, and 12%, respectively, while the respective percentages in the efficacy
analyses increased to 39%, 13%, and 13%. These results were contrasted to deterioration rates
among the NOT TAU in the SD, IR, and SR subscales (16%, 10%, and 8%, respectively) as well
as improvement in the respective subscales, 29%, 6%, and 7%. When odds of deterioration were
compared against those of the NOT TAU group, patients in the NOT Fb group had lower odds of
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deterioration in the SD and SR subscales, although the SD subscale reached statistical
significance in efficacy analysis. The odds of deterioration on the IR subscale for the NOT Fb
group were near identical with those for the NOT TAU group in ITT analysis, but improved in
the efficacy analysis. When the odds of clinically significant improvement were compared
across groups, the odds were highest on the SR subscale in both ITT and efficacy analyses,
favoring the NOT Fb group (OR = 2.2 and OR = 2.9, respectively). The SD subscale had the
lowest odds ratios; however, these results need to be understood in the context that the IR and SR
subscales generally had lower base rates of clinically significant achievement than the SD
subscale. Indeed, despite the higher odds ratios on the IR and SR subscales, the sheer percentage
of clinically significant improvement occurred in the SD subscale for all treatment groups
surpassed those found on the IR and SR subscales.
Progress feedback to both not-on-track patients and clinicians (NOT P/T Fb).
Provision of progress feedback to both patients and therapists was tested in previous feedback
studies to investigate its potential incremental benefits in preventing client deterioration and
enhancing outcome in comparison to provision of feedback to therapists alone. Overall, there
were only a few aspects of outcomes in which P/T Fb seemed to have had positive effects on
NOT patients. When comparing post-treatment OQ subscale scores of the NOT P/T Fb group
with those of NOT Fb group, the results showed small effect sizes favoring the NOT P/T Fb
group, but not at the statistically significant level. These results were consistent with the
findings from the meta-analysis of the OQ total scale scores (see Study 1 or Shimokawa,
Lambert, & Smart, 2010). The largest of the treatment effects (although still not statistically
significant) were found in the SR subscale. In terms of the amount of pre-treatment to posttreatment change scores, the NOT P/T Fb group showed very small effects on the SD and IR
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subscales. Small, but statistically significant effects were found on the SR subscale, favoring the
NOT P/T Fb group over the NOT Fb group in both ITT and efficacy analyses (g = -0.29 and g =
-0.24). When the odds of patient deterioration were compared to the NOT Fb group, the NOT
P/T Fb group had higher odds of deterioration on the SD subscale in both ITT and efficacy
analyses, OR = 1.11 and OR = 1.40, respectively, although these differences were not statistically
significant. These increased odds of deterioration were similar to the trend found on the OQ
total scale analyses. Such a trend was not found on the IR and SR subscales. The subscale
analyses were, thus, helpful in identifying what aspects of the outcome (i.e., symptom distress)
that contributed to the increased odds of deterioration observed in the total scale score analyses.
The reasons for potentially higher likelihood of deterioration in symptom distress are unknown at
this time. The odds of patients achieving clinically significant improvement were higher for the
NOT P/T Fb group than the NOT Fb group in all domains of outcome measured by the
subscales, although the results reached statistical significance only on the SR subscale. It is
interesting to note these significantly greater effects found on the SR subscale among the NOT
P/T Fb group. It appears that the potential “polarizing effect” of the P/T Fb among not-on-track
patients (Shimokawa, Lambert, & Smart, 2010) may have occurred most notably in patient
symptom distress in terms of deterioration and social role performance in terms of clinically
significant improvement.
Clinical support tools and progress feedback to not-on-track patients (CST Fb).
Potential incremental benefits of clinical support tools on patient outcome at the OQ subscale
level were evaluated against the outcome of provision of progress feedback alone (NOT Fb).
The post-test subscale score comparisons between the CST Fb and NOT Fb groups yielded small
effects in both ITT and efficacy analysis, with the SR subscale being the only subscale in which
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statistically significant effect sizes were observed in both ITT analysis, g = -0.20, and efficacy
analysis, g = -0.28. When the amount of pre-treatment to post-treatment change in subscales was
examined mega-analytically, the CST Fb group resulted in the greatest degree of change on all of
the subscales in the efficacy analysis, although the NOT P/T Fb group yielded a greater effect
size on the SR subscale in ITT analysis. Between-group comparisons of pre-post change scores
on the OQ subscales suggest that the CST Fb group was somewhat more helpful than the NOT
Fb group in patients experiencing positive change on all three dimensions of the outcome (g
= -0.23 on the SD subscale; g = -0.29 on the IR subscale; and g = -0.27 on the SR subscale).
These results indicate that the average patient in the CST Fb group, who met the minimum
criteria to be included in the efficacy analysis, had better outcome than approximately 59 to 62%
of patients in the NOT Fb group on the basis of pre-post changes in subscales. The results also
suggest that the average patient in the CST Fb group fared better than approximately 73% of
patients who did not receive any feedback treatments. While the SR subscale scores of the CST
Fb group resulted in an effect size similar to those of the NOT P/T Fb group, the IR subscale
resulted in better outcome favoring the CST Fb group. When the odds of deterioration were
compared with those of the NOT Fb group, the CST Fb group appeared to reduce the odds of
deterioration by 0.9 to 0.4 times, but not at the statistically significant level. In comparison to
the NOT Fb group, the odds of patients achieving clinically significant improvement on the SR
subscale in the ITT analysis and on all of the subscales in the efficacy analyses were significant.
These results suggest that the odds of CST Fb patients achieving clinically significant
improvement on dimensions measured by the OQ subscales are 1.7 to 2.0 times higher than those
in the Fb group. In comparison to the NOT TAU group, these odds increase to 2.2 to 3.8 times
higher. Based on the aforementioned results, the CST Fb appears to have incremental benefits in
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enhancing outcomes related to symptom distress, interpersonal relationships, and social role
performance. The incremental benefit of the CST Fb intervention on the IR subscale may
suggest the intervention effects that were unique to the nature of the CST Fb intervention. In
particular, the measures included as part of the Clinical Support Tools assessed the not-on-track
patients’ social support. Given the similarity between the construct of social support and the
interpersonal relationships, some of the greater effects found on the IR subscale scores among
patients in the CST Fb group may have been the result of the Clinical Support Tools being
utilized in the clinical work.
Limitations of study 2. All of the limitations discussed in study 1 applied to this study
because this study utilized the same methodologies as study 1 (except for the mega-analytic
approach used on the analyses of group differences in pre-post change scores in this study).
Some additional limitations should be noted that were unique to this study. Although the
accuracy of the degree of data match was deemed adequate in this study in favor of conserving
data, to the extent the discrepancy between the OQ scores in the original datasets and the merged
datasets occurred, the presence of error was likely, especially in a very small minority of cases
where the discrepancy was large. Conducting statistical analyses only on cases with reasonable
accuracy in the match may reduce the “noise” introduced by those observations with discrepant
scores in the match. Even then, however, the results of the analyses are expected to be similar,
given the small number of cases with such discrepantly matched scores.
Another limitation of this study and of this line of research was the exclusive use of OQ
total score in outcome monitoring and feedback provision. Although extensive examination of
OQ subscales was performed in this study, the original feedback studies did not utilize the
subscale information in provision of progress feedback. Thus, the treatment effects reflected at
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the subscale level were still effects based on the OQ total scale score system. As already
discussed earlier, subscale based information could provide unique clinical information that
could not be captured by the total scale score alone. One practical advantage of subscale-based
feedback system is that it requires no more burdens on patients other than filling out the OQ as
they normally do. Thus, the future development and implementation of the OQ subscale score
based progress feedback, in addition to the well-established total scale score based system may
further enhance the clinical utility of this quality assurance system.
Study 3: Multi-level Modeling of Change in Patient Outcome
Method
Participants and procedures. Given the emphasis of the psychotherapy quality
assurance system under study, only patients who were identified as signal alarm cases (not-ontrack or NOT; n = 1382) were analyzed in this study. To be consistent with the meta-analytic
and mega-analytic portion of this series of quantitative reviews, the data of NOT patients were
analyzed using the same inclusion criteria, thus obtaining the estimates for both intent-totreatment (ITT) sample and efficacy sample. It should be noted that these inclusion criteria pose
some important limitations in multilevel analyses. Specifically, in meta- and mega-analyses of
the ITT samples, the last observation carried forward method was used in cases where the posttest score was missing. In case of NOT patients who left treatment after the first warning event,
the OQ score at the time of warning was also treated as the post-treatment score. This procedure
was used to obtain a conservative estimate of the effects of treatment on patients. As long as this
estimate is accepted by the researcher as a reasonable estimate of the post-treatment score,
research questions regarding the amount of change may not pose a serious issue. In the case of
multilevel analyses, however, the research question frequently involves change, which occurs as
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a function of time. Thus, each data point connotes both change in terms of a measurement unit
and a temporal time associated with it. Because of this, if one treats a given score as a
substitution of another score at a different time point (e.g., an OQ score at the time of warning
signal that is also a last observation of a given patient as the patient’s post-treatment score), such
a procedure automatically produces a slope of zero for that patient. Because of this, the ITT
analyses with the inclusion of score substitution process in patients with missing scores may
introduce bias in the estimates, especially in the slope. Thus, another criterion was applied to
both ITT and efficacy analyses to examine the statistical models with no substitution of scores.
By applying this criterion, only the actual data points obtained through the courses of studies
were included. Patients without an OQ score after the first signal alarm event, for instance,
contributed only to the estimation of the intercept at the first warning event, but not to the slope.
Addition of this criterion doubled the number of analyses to be performed 11. Thus, for practical
reasons, not all of the results from the analyses based on alternative inclusion criteria are
reported.
Statistical analysis. In studies examining individual change, especially in studies
involving the use of multiple-time-point designs (such as the studies included in this study),
multi-level analyses are more appropriate than studying only the pre- and post-treatment data.
Multi-level analyses are called by various names, including the random-effects model, the
general mixed-linear model, and the hierarchical linear model (Raudenbush & Bryk, 2002).
Multilevel modeling of change allows modeling of patients within the individual as well as the

11

In addition to ITT and efficacy analysis, separate analyses were conducted with and without 355 cases that
belonged to patients who participated in studies more than once. All of the combinations of these analyses were
conducted separately with and without observations with substitution of scores as described. Given that repeated
participants comprised of about 5% of all participants (N = 6,151) and that results were comparable, this study
presents only the results based on repeated participants included because inclusion of repeated participants in
treatment is more reflective of typical clinical practice.
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between-individual and group levels. Thus, the use of multilevel analyses provides the
information that was not available in the traditional meta-analysis, which primarily examines the
differences in group sample means. In this study, the linear mixed models function of SPSS
Advanced Models 15.0 for Windows was used. Full maximum likelihood estimation method
was used.
Alternative models of change. To determine the appropriate level-1 sub-model of
change, empirical growth plots of NOT patients with person specific regression lines were
inspected. This initial inspection presented with a wide variety of individual change patterns. In
essence, by definition NOT patients deviated from the expected recovery curves defined by the
OQ algorithms that were based on the dose-response models of change. Although signal
warnings were operationally defined by the algorithms for predicting treatment failure as OQ
points of marked deviation (i.e., elevation or lack of expected reduction in OQ points) from
expected recovery pattern, such elevation occurred in various ways. For some patients, signal
warning appeared to have occurred as an outlier “peak” event, while for some individuals the
event of first warning seemed to mark the beginning of a phase with higher disturbance. The
timing and number of, and space between, warning events also varied across individuals, some
occurring close to each other whereas others occurring at what appeared to be separate phases of
worsening. For a majority of patients, the first signal warning seemed to have occurred after a
few sessions into treatment. For NOT patients who stayed in treatment for shorter periods of
time, the change in OQ scores appeared to be linear, especially those who did not return to
treatment after experiencing elevation in disturbance. For those who stayed in treatment longer,
the change appeared to occur more non-linearly than linearly, presenting multiple modes of

80
worsening and improving. Describing individual empirical growth plots in a systematic manner
seems daunting if not impossible as the patterns of change appeared quite diverse.
In the initial stage of model building, following the recommendations by Singer and
Willet (2003), the unconditional means model and unconditional growth models were fit on the
data of patients who were classified as not-on-track (NOT; n = 1382). These initial models were
used to obtain the “baseline” of within-person and between-person variability to assess the
incremental fit of, and the variance of change parameters explained by, more complex models.
Finding non-linear growth pattern at the leve-1 submodel of change that applies across
individuals can be a very tedious process (Singer & Willet, 2003). Various patterns of level-1
submodels of change, including the following were initially examined: linear model of change
from intake to termination, piecewise linear model of change (Gallop & Tasca, 2009) with an
added slope from the time of first signal warning feedback, log linear model of change from
intake to termination, linear models of change with discontinuity in slope at the first signal
warning, and a combination of linear slope and discontinuity in intercept and slope at the time of
first warning.
To fit the patterns of change in linear regression models, time was treated in several ways
at the initial stage of model building. First the session number without any transformation was
used. Based on the findings from dose-response research (e.g., Lutz, Lowry, Kopta, Einstein, &
Howard, 2001; Lutz, Martinovich, & Howard, 1999), natural logarithm of time (i.e., session
number + 1) was also used. However, this study’s exclusive focus on patients at risk of treatment
failure suggested that patterns of change among a minority subset of patients may not fit widely
recognized patterns of change reported in psychotherapy literature. For instance, by the
definition of the not-on-track (NOT) classification of patient treatment progress, it was deemed
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necessary that the level-1 submodel of change addressed the patterns of change before and after
the first signal warning event. Combinations of separate pre and post-warning slopes were
tested. Level-1 submodels with discontinuity in slope modeled the “shift” in linear slope after
the first warning signal. The piecewise model assumes the presence of separate slopes for before
and after a common time point where a presumed shift occurs. Although group mean
comparison of OQ total scales at pre-test, the time of signal warning, and termination were
different (e.g., Figure 2 of Harmon, et al., 2007), it was not clear if the pattern of change at the
individual level was represented by separate slopes for before and after the first signal event as in
the piecewise model. Although it was quite likely that some patients presented such a pattern,
having a worsening trajectory from the beginning of treatment to the first warning followed by a
change in the direction of recovery, fitting this model to all not on track patients presented some
questions at the theoretical level. Particularly, while a large body of psychotherapy research
findings demonstrate overall patterns of recovery among patients (whether it’s dose response or
good enough effect), is it reasonable to assume that not on track patients, as a group, for
whatever reasons followed a worsening pattern from the beginning of treatment until they were
identified as such? Undoubtedly some patients may enter treatment with already worsening
trajectory in symptoms and functioning; however, is it reasonable to assume that this would be
the norm for not-on-track patients as a group? Or, would the worsening be better construed as
deviation from an expected recovery trajectory? The latter fits better with the guiding rationale
for developing the OQ signal alarm system in the first place and seemed to fit the phenomenon
of worsening in treatment better for NOT patients as a group.
The model of deviation from the expected trajectory seemed to fit the notion of
discontinuity in intercept and slope due to fundamental shift in change process as discussed by
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Singer and Willett (2003, chapter 5). This model reflects an underlying change pattern with a
shifting point in disturbance level and different change trajectory after the first signal warning
event. These two competing models were empirically tested. Each of the various models of
change with varying level-1 submodels of change were initially tested without substantive
predictors at level-2, except for a predictor indicating the number of sessions attended by patients
as discussed in the next paragraph. This was conducted in order to select a model that seemed to
better reflect the pattern of recovery at the individual level.
An initial primary research question of this study was whether differences existed across
treatment groups in the rate of patient recovery. As discussed in the meta- and mega-analytic
portion of this quantitative review, however, patients in various feedback conditions experienced
superior outcome, but also stayed in treatment longer than the control group, especially after the
first warning event. This finding suggests that feedback interventions might have had a retention
effect, which in turn might have lead to improved outcome. If this potential retention effect
explained most of the variance contributing to improved outcome in terms of the amount of
change, differences in the rate of change would be unlikely to be found. Thus, the question in
this study was to investigate how much, if any, difference existed in individual patients’ rate of
change that were explained by feedback treatments. If the rate of change differed across
treatment groups, the amount of change found through the meta- and mega-analyses would be
explained by both the retention effect and differential rates of recovery.
Issues of taking into account varying treatment duration among patients. One
methodological issue regarding treating time needed to be addressed in this study. Because
patients left treatment after varying number of sessions at will, there was no arbitrary number of
sessions that could serve as a reference in estimating the “average slope.” Although a number of
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multilevel methods have been developed to handle “virtually every missing data problem”
(Duncan, Duncan, & Strycker, 2006, p.179), the nature of varied treatment lengths in
psychotherapy should not be construed as a missing data problem (Baldwin, Berkeljon, Atkins,
Olsen, & Nielsen., 2009). For example, when comparing the outcomes of clients who attended
five sessions of therapy with those who attended 10 sessions of therapy, it is inappropriate to
assume that the difference in session length (five sessions) is due to “missing sessions” because
the termination of therapy was considered a naturally occurring end point often negotiated
between therapists and patients.
As Baldwin and colleagues demonstrated differential rates of change as a function of the
number of sessions patients attended, in this study the total number of sessions attended by each
patient was tested as a level-2 predictor in each of the above submodels. Because of the
markedly positively skewed distribution of total number of sessions attended by NOT patients,
natural log transformation of number of sessions centered on the NOT patient mean was used to
assess whether the rate of change after the first signal warning differed as a function of the total
number of sessions patients attended. Centering of the number of sessions was performed
because this variable’s zero value was theoretically impossible (i.e., a patient attending zero
session of therapy) and because of the intuitive interpretation of centering this predictor to the
NOT sample mean (i.e., average number of sessions attended by NOT patients).
Based on the similar notion of heterogeneous recovery rates as a function of session
attendance, a level-2 predictor of the total number of sessions after the first warning event was
also tested. Initial testing of these level-2 predictors suggested a better model fit of stratification
based on the number of sessions attended after the first warning than stratification based on the
total number of session attendance.
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Separate multilevel analyses were also conducted for OQ total scale scores and subscale
scores for stratified bands of the number of sessions attended by NOT patients following the first
signal warning event marking the 25th, 50th, 75th, 85th, 95th percentiles. Through this method,
patients were classified into one of the following five groups based on the number of sessions
attended after the first warning event: 2 sessions or less (n = 390, 28.2%), 3 to 4 sessions (n =
289, 20.9%), 5 to 8 sessions (n = 341, 24.7%), 9 to 11 sessions (n = 146, 10.6%), and 12 to 18
sessions (n = 147, 10.6%). Patients who attended beyond 18 sessions (above 95th percentile, n =
69, 5%) were not tested because of the smaller number of samples, making the models
unreliable. Although a substantial number of patients attended only one or two sessions after the
first signal warning event, multilevel models were not fitted for this group because data points
per patient were too few. Because of the positively skewed distribution of session attendance,
natural log of session number following the first signal warning was used. The model with level2 predictors were estimated for each of the session bands.
Predictors. In level 2, variables that are commonly reported in this line of research as
non-significant (e.g., age, gender, and diagnoses of patients) were not tested. Level-2 predictors
included experimental conditions to which individuals were assigned, time variable (either linear
or log transformed time variable), and length of treatment (i.e., number of sessions attended).
Information such as the total number of session attended cannot be obtained prior to termination
of treatment. Thus, the models presented in this study are exploratory and explanatory rather
than predictive, that is, based on variables already known at the time of pre-treatment.
In the original feedback studies, with an exception of study 3, therapists served as the
blocking variable to randomly assign clients to treatment conditions to control for therapist
effects. Because of this design, experimental conditions essentially varied within therapists.
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Even in study 3, although random assignment was not implemented, each therapist was given
clients in both conditions based on the semester in which clients participated in treatment, thus
making the experimental conditions crossed with therapists.
Variables that differ across therapists were initially planned to be analyzed at level 3.
However, in the original feedback studies, datasets kept track of only the identification variable
of one primary therapist per patient. The counseling center in which most of the feedback
studies were conducted routinely assigned patients to different therapists after an intake sessions.
In multilevel analyses of therapist’s effects, each data point needed to be matched with the
treating therapist for that session. Thus, change of therapists presented cross-classification of
data. Such complex data structure cannot be handled with SPSS. Furthermore, very few, and no
consistent, therapist variables were recorded in the original studies, which would make it
difficult to study therapist effects. For these reasons therapist effects were not evaluated in this
study.
Results
Descriptive statistics. NOT patients attended an average of 10.06 sessions (SD = 7.03,
range = 2 – 60, Mdn = 8) and, after the first signal warning event, remained in treatment for an
average of 6.58 sessions (SD = 6.36, range = 1 – 55, Mdn = 5). The mean OQ total scale score at
intake was 80.16 (SD = 19.84, range = 18 – 149, Mdn = 79.00). The mean OQ score at the time
of first signal warning was 89.01 (SD = 15.66, range = 58, Mdn = 87). The average OQ score at
termination (the last recorded OQ for each patient) was 74.09 (SD = 22.55, range = 8 – 166, Mdn
= 74.00). These statistics, especially the proximity of means and medians of OQ scores at three
time points suggest that the distribution of OQ scores was normally distributed. For descriptive
purposes, and to evaluate the possibility that session attendance after the first signal event
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differed across treatment groups, n and percentage of the number of treatments NOT patients
attended after the first signal are presented in Table 22 for each treatment group.
Rate of change from intake to termination. As noted earlier, prior to testing the effects
of feedback interventions, models with various level-1 submodels of change and level-2 time
predictors were tested. These analyses were conducted to gain broader understanding about how
not-on-track patients change overtime. Patterns of change in patients were modeled for the
entire duration of treatment. Analyses were conducted for the ITT and efficacy samples and the
ITT sample without using substitution of scores, all pooled across treatment groups. To facilitate
integrated understanding between the OQ total scale scores and subscale scores, the results of the
total scale analyses and subscale analyses are presented and discussed in this study. The results
of comparing some of the models of change tested based on the OQ total scale scores are
presented in Table 23 (ITT sample), Table 24 (efficacy sample), Table 25 (ITT sample without
last observation carried forward), Table 26 (efficacy sample without last observation carried
forward). These models were based on linear time of change (i.e., session number and session
number after first warning event). Table 27 (ITT sample), Table 28 (efficacy sample), Table 29
(ITT sample without last observation carried forward), and Table 30 present results of models
based on natural log-transformation of time due to the possibility that the log linear pattern of
change as discussed in the dose-response effect literature might better capture the pattern of
change.
Model A in Tables 23 to 30 represent unconditional means model to partition the
variability in OQ scores within and across individuals. Interclass correlation coefficients of
0.301 in the ITT sample, 0.258 in the efficacy sample, 0.295 in the ITT sample without the use
of LOCF, and 0.240 in the efficacy sample without the use of LOCF indicate that approximately
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24% to 30% of variability in OQ total scores, without considering the rate of change, is
associated with between patients. Model B.1 in various tables represents the unconditional
growth models which provide the baseline for each patient’s variability around his or her true
linear change trajectory (rate of change) as well as between patient variability in the change
trajectory. Model C.1 stratified the number of sessions NOT patients attended by estimating the
effects of the total number of sessions patients attended in addition to the function of linear time.
Model D.1 included an additional slope parameter at the level-1 submodel of change, indicating
the added or altered rate of change after the first warning signal event in addition to the overall
linear rate of change. Model E.1 introduced another time-variant dichotomous predictor (labeled
“Signal” on the tables) at level-1 indicating whether or not a given data point belonged to before
or after the first signal warning event. This variable estimated the shift in intercept at the time of
first warning in comparison to the intake. As discussed earlier, Model E.1 was the theoretical
competitor to the piecewise model.
When the piecewise model and the discontinuous slope and intercept model (Model E.1)
were compared, Model E.1 indicated a significantly better fit, χ2(4) =719.2 to 1159.7 (depending
on the inclusion criteria used), p < 0.01, favoring the discontinuous slope and intercept model.
Model F.1 added a level-2 predictor (labeled #SessionPW) to Model E.1 to stratify the rate of
change by the number of sessions attended after the first onset of a signal warning.
Model B.2 was the unconditional growth model based on the natural log transformation
of session (time variable)—essentially a log transformed version of Model B.1. Comparison of
Model B.1 and Model B.2 showed that, regardless of inclusion criteria applied, Model B.1
showed superior model fit, -2 log likelihood differences of 317.9 to 428.1, favoring Model B.1.
These results indicate that when modeling the entire course of treatment for NOT patients,
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modeling the rate of change on linear time (non transformed session number) is superior to
natural log transformed time. Stratification of time as in Models C.1 and C.2 still favored a
linear model of change. Because of this, subsequent discontinuous slope and intercept terms
were added to an overall linear model of change. Model D.1 introduced a new linear slope from
the time of first signal. Model D.2 instead added a new log transformed linear slope from the
first signal warning. The comparison between Models D.1 and D.2 showed that the model fit
was better for Model D.2 by -2 log likelihood differences of 91.4 to 153, suggesting that after the
onset of first signal warning, patients pattern of change may be better captured by log
transformed time than the linear time. Addition of elevation in both the intercept and slope in
Models E.1 and E.2 similarly supported this conclusion. Models F.1 and F.2 stratified the rate of
change after the first signal warning. In model F.1 and F.2, inclusion of random effect terms for
both the linear time (session number) and the term indicating whether a given observation came
from before or after the first warning (“Signal”) did not achieve conversion. Removal of one or
the other reached model conversion. Although statistically significant fixed and random effects
existed with the linear time (“Session”), the random effects associated with this variable had a
relatively small variability across individuals, suggesting that the linear rate of change from
intake to termination had statistically significant variability among NOT patients, but this
variability was relatively small in comparison to the sum of all the between-patient variability.
Thus, then random effect term associated with the linear time was dropped. Furthermore, in
favor of parsimony, fixed effects that were non-significant or significantly unimportant were not
included in the model.
While it was possible that more complex non-linear patterns of change fitted the model
better, addition of quadratic or cubic terms after the first warning could not be performed
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because the computational demands exceeded the computer’s capability. Thus, in this study
Model F.2 was accepted as the best fitting model for the entire duration of treatment.
These results suggest that NOT patients as a group tend to have a slow rate of progress
prior to being recognized as at risk for treatment failure. The recovery after the first warning is
better captured by a log linear slope than a linear slope, suggesting that progress occur rapidly
shortly after the first warning event rather than following a linear trajectory. The results also
showed that patients who stay in treatment longer have slower rates of change, similar to the
findings reported by Baldwin, et al. (2009) who found differential rates of change when
modeling the entire course of treatment of a sample of a general counseling center patient
population. At this point, it is important to address the consequences of using the last
observation carried forward method in multilevel analyses of change. Comparison between
models with LOCF and those without appear to suggest that the use of LOCF method affected
the results to some degree, most notably the rates of change. Further analyses were thus
conducted on ITT and efficacy samples without the use of LOCF method, as these sets of
inclusion criteria were deemed most representative of the actually observed data.
Even though the aforementioned models of change provide an overview of how patients
change based on the OQ total scale scores, it was not clear prior to investigation whether the OQ
subscale scores followed the same trajectory. Similar procedures were followed for the OQ
subscales analyses; however, given the number of analyses involved, and for practical reasons,
only the final models (Models F.1 and F.2) are reported in Tables 31, 32, and 33, for SD, IR, and
SR subscales, respectively. Given the number of models and sets of samples modeled,
conducting model building to find the “best fitting model” for each subscale per each inclusion
criteria seemed impractical. Thus, the data was submitted to the same models developed for the
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OQ total scale score analyses to evaluate the fit within the parameters set by the models (with the
exception of Models F.1 and F.2 where the models converged with an inclusion of linear
trajectory across the entire course of treatment). The two models to which all subscale scores
were fitted had only one difference—either linear time or log transformed time was used after
the first signal warning, with all other parameters remaining the same across models. Model fit
was superior for the log transformed model, suggesting that, just as on the OQ total scale scores,
patients’ recovery patterns at the subscale level followed closer to the log transformed time than
the linear time.
Comparisons of rate of change across feedback treatment groups among NOT
patients.
OQ total scale. To address the main question of this study (i.e., whether or not
differences in the rate of recovery exist across feedback treatment groups), both linear and log
linear models were fitted from the time of first signal warning to termination of treatment. The
results of ITT multilevel analyses of patient change on the OQ total scale scores are presented in
Tables 34 and 35, comparing the results of modeling of change by feedback treatment conditions
based on non-transformed linear time (session after first episode of signal warning) and log
transformed time.
The results of the efficacy analyses are presented in Tables 36 and 37. The ITT analyses
suggest that when compared to NOT TAU patients with an average number of session attendance
after the first episode of signal warning, patients with the same number of sessions in CST Fb
and NOT Fb experience statistically significantly faster rate of recovery on the OQ total scores.
For the CST Fb group, this translates to -3.57 OQ points per session average rate of change on
the linear model of change and 10.56 OQ points per one log unit of session on average with
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initially rapid reduction of scores followed by a more gradual rate of change (i.e., 10.56 OQ
points reduction for the first 2.7 sessions and the same amount of reduction in the next 4.7
sessions span). For the NOT Fb group, the reduction in OQ points translates to 3.42 OQ points
on average per session after first warning and 10.52 OQ points per one log unit of number of
session on average after the first signal warning.
In separate analyses of rates of change grouped by differing number of sessions patients
attended, however, results did not reach statistical significance in most bands of treatment
lengths, except for the CST Fb patients among those who attended 12 to 18 sessions. In efficacy
analyses, the rate of change were more similarly significant for the CST Fb patients attending the
average number of sessions after first signal warning event, when compared to their NOT TAU
counterparts. Based on the linear model of change, this rate of change translates to 3.61 OQ
points on average per session. On the model based on log unit of time, this translates to about
11.56 OQ point reduction in the first 2.7 sessions and another 11.56 OQ points over the next 4.7
session span. In the separate analyses of rate of change based on varying session attendance, the
rate of change was significant for the CST Fb group only in the 12 to 18 session span after the
first signal warning event. However, statistically non-significant findings may have been due to
reduction of power resulted by conducting separate analyses on smaller subsets of patients
grouped by the number of session attendance. These combined results from both the ITT and
efficacy analyses suggest that CST Fb and NOT Fb present with similar rates of change on the
OQ total scale score that are significantly faster than the rate of recovery among those who
received no feedback intervention.
Symptom distress (SD) subscale. The results of ITT analyses of patient change on the
OQ Symptom Distress (SD) subscale score are presented in Tables 38 and 39, comparing the
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results of models based on linear time and natural log transformation of time. The results of
efficacy analyses are presented in Tables 40 and 41. As the difference of 164.8 in -2 log
likelihood with the same number of parameters, the model based on log transformed model fit
the data better. The linear model shrinks the variance in rate of change across individuals. The
results also show that patients with the average number of session attendance after the first signal
warning session in CST Fb group improve more rapidly in symptom reduction than those in
NOT TAU attending the same number of sessions in both models. The recovery rate of those in
NOT P/T Fb and NOT Fb are not expected to be significantly superior to those in TAU. The
results of analyses conducted on separate bands of number of sessions attended by patients
showed that the superior rate of change in symptom reduction for individuals in the CST Fb
group occurs most saliently among patients who attended 12 to 18 sessions after the first onset of
signal warning compared to those in the NOT TAU group (non-standardized regression
coefficient of -4.26 per 1 log unit of session, p = 0.006 in efficacy analysis and non-standardized
regression coefficient of -3.74, p = 0.01 in ITT analysis). Statistical difference in the rate of
change on the SD subscale scores was not observed in other bands of session lengths. This nonsignificant finding, however, may have been due to the lack of statistical power.
Interpersonal relations (IR) subscale. The results of analyses of Interpersonal Relations
(IR) subscale suggest that across all treatment groups, the rate of change after the first onset of
signal warning is quite slow (see Tables 42 and 43 for ITT analyses and Tables 44 and 45 for
efficacy analyses). However, when compared to NOT TAU patients attending the average
number of sessions, patients in CST Fb group attending the same number of sessions experience
statistically significant difference in the rate of change in ITT analysis when change was
modeled in natural log transformation of time or linear time. Under the linear time of change
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model, patients in NOT Fb may also experience statistically significant greater recovery rate in
the IR subscale scores. As with the SD subscale analyses, NOT patients who stay in treatment
longer are expected to have a slower rate of recovery as measured by the IR subscale scores
(1.24 OQ points per 1 log unit increase). Separate analyses of rate of change suggest that CST
Fb patients attending 9 to 11 sessions of treatment experience may experience a superior rate of
change than their NOT TAU counterparts attending the same number of sessions (nonstandardized regression coefficient of -0.98, p = 0.04). In efficacy analysis, the results were
equivalent to those found in the ITT analysis, except patients in CST Fb who attend 12 to 18
sessions may also experience a statistically greater rate of change in the IR subscale scores.
Social role performance (SR) subscale. The results of analyses of rates of change on the
SR subscale scores are presented in Tables 46 and 47 (ITT analyses) and Tables 48 and 49
(Efficacy analyses). The results suggest that addition of level-2 predictors (i.e., treatment group
assignment and number of sessions attended) improved overall model fit at a statistically
significant level in the -2 log likelihood (χ2 difference of 42.9, df = 10, p < 0.001 in the log linear
model) compared to unconditional growth model in efficacy analysis, other model fit indices
mixed results in terms of statistically significant improvement. Between-individual differences
in the rate of change, in particular, was quite small for both the linear and log linear models
(more notably in the linear model), suggesting that both models may not be capturing the rate of
change as they occur among patients. Another competing, and perhaps quite plausible,
explanation may be that recovery in social role performance and interpersonal relations is slower
compared to symptom reduction as reflected in the SD subscale scores. The results of ITT
analyses showed that the rate of change among patients in NOT P/T Fb group was statistically
significant at the .05 level. Statistically significant results were not found when the rate of
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change was tested in separate analyses with patients grouped by the number of sessions they
attended after first signal warning. No other significant findings were found in terms of
differences in the rate of change on the SR subscale scores.
Discussion on Study 3
This was the first attempt to evaluate the OQ-based quality assurance system using
multilevel analytic techniques. Initial investigation of the patterns of change suggested that NOT
patients varied considerably in their patterns of change. Yet, despite such variability, some
patterns of change fit better than others. The results of initial model fitting suggested that
patients who are identified as at risk of treatment failure have a slow linear recovery trajectory
that becomes disrupted at the time of first signal warning. At the time of first signal warning,
there is an elevation of about 11 to 12 OQ points on average, though there is between-patient
variability in the degree of elevation. After the point of first signal warning, patients’ pattern of
recovery is better captured by a non-linear (natural log of session number) trend with rapid initial
recovery, which gradually slows down as patients stay in treatment longer. This general pattern
of recovery was reflected in all subscales, though the rate of recovery was more gradual in the
Interpersonal Relations subscale and the Social Role performance subscale than that in the
Symptom Distress subscale.
At the subscale level, Patients in the CST Fb group appeared to have experienced a
higher rate of recovery in the dimensions of outcome measured by the SD and IR subscales than
those in TAU. The amount of effect as measured by the IR subscale was also shown to be
significantly greater than those in TAU according to the meta-and mega-analysis portion of this
study.
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The primary research question in this study was: Is there a difference in the rate of
change existed among treatment groups and control? The analyses of the OQ total scale score
found statistically significant difference between the CST Fb group and NOT TAU, favoring the
CST Fb group. It was unclear if this superior rate of change was present uniformly across
varying numbers of sessions attended after the first signal warning. As reported earlier, there
appeared to be between-group differences in the number of sessions patients attend after the first
signal warning based on treatment assignment. Considering the findings from the meta- and
mega-analyses demonstrating superior outcome experienced by patients in the CST Fb group, the
prolonged treatment participation, and statistically significant faster rates of recovery, the current
state of evidence regarding the outcome enhancing effects of CST Fb seem to suggest the
possible combination of direct treatment effects as well as the indirect effect mediated by
increased rate of patient retention in the treatment.
NOT Fb group and NOT P/T groups also showed statistically significant differences in
the rate of recovery in some of the multilevel analyses. Considering the findings from the metaand mega-analytic studies demonstrating the outcome enhancement associated with the NOT P/T
Fb and NOT Fb groups, non-significant findings in terms of the rates of change may also support
the notion of the retention effect that may mediate improvement in outcome. Future studies
explicitly testing such a hypothesis may help further our understanding about the mechanisms of
change. Although an explicit demonstration of this mediation effect was not tested in this study,
combinations of aforementioned evidence seem to support this relationship.
To the extent that retaining patients in treatment plays an important role in enhancing
treatment outcome among those who are predicted to experience negative outcome was
supported, this notion presents some important clinical considerations for mental health care
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systems and providers. The differences in the distribution of session attendance after the first
signal alarm event across treatment groups and the mean differences in session attendance after
the first signal alarm event suggest that, if patients are not identified as at risk of treatment failure
and this information is not provided to therapists, patients seem more likely to leave treatment
before experiencing improvement. Thus, implementation of routine monitoring of patient
outcome, especially with a system that is capable of predicting negative outcome, appears
important for at risk patients. Systems of care should seriously consider implementing such
systems. Another clinical implication appears to be the importance of allowing patients to
receive the care needed to achieve the desired improvement. The pooled dataset from the six
major studies showed that the average number of session attendance for NOT patients was twice
as many as that of all patients pooled together and that this had important positive consequences
for patients.
Although natural log transformed time fitted the data better than the linear time, there
was still a considerable amount of variation around the fitted trajectory both within and between
patients. Such variation appears reflective of the complex patterns in which patients change
through the course of therapy. In future studies, exploration of additional level-1 time varying
predictors may be helpful in capturing the dynamic nature of patient change throughout the
course of therapy.
Some limitations of this study should be noted. Although statistically significant findings
favoring feedback treatment groups on a combined dataset were found, the same findings were
not replicated in analyses where patients were grouped by the number of sessions attended after
the first signal warning. Given the decreased sample size, however, separate analyses of the rate
of change on the stratified samples of not-on-track patients may have been due to lack of
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statistical power. Due to practical limitations associated with conducting numerous analyses,
subscale score analyses were fitted to the statistical models that were fitted to the OQ total scale
scores, which excluded some predictors that did not contribute to increased model fit. It is
possible that building multilevel models of change “from scratch” for each of the subscales may
find those excluded predictors to behave in a different manner. Another criticism may be made
regarding the limited number of alternative models of change tested in this study. Although
complex polynomial models of change, such as the quadratic and cubic models could not be
tested on the entire duration of treatment when accounting for other change parameters (e.g.,
discontinuous intercept and slope) due to the technical limitations with the computer program
used in this study, statistical modeling of the rate of change from the first signal warning event to
termination could have included polynomial models of change. Thus, future examination of
alternative models of change may lead to the development of models that better account for the
change among the not-on-track patients.
Summary and Concluding Discussions
This meta-analytic and multi-level analytic review summarized the findings from the past
six major feedback studies published to date. Exhaustive statistical analyses were conducted to
obtain estimates of feedback effects in both the intent-to-treat and efficacy samples. These sets
of analyses provided estimated effects when feedback interventions are implemented as a policy
as well as when feedback interventions are evaluated among those who satisfied the least criteria
to have likely benefitted from the feedback interventions. The results yielded generally smaller
effects in the intent-to-treat analyses than in the efficacy analyses, however, both sets of analyses
showed clinically significant treatment effects of the feedback interventions among those
patients who were predicted to experience treatment failure. Such clinical benefits included
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greater degree of distress reduction, decreased odds of deterioration, increased odds of achieving
clinically significant improvement, and in some cases faster rates of recovery after first identified
as at-risk cases. These benefits were found at the overall treatment outcome as measured by the
OQ total scale scores as well as at more specific domains of the outcome as measured by the OQ
subscale scores (i.e., symptom distress, interpersonal relations, and social role performance).
This quantitative review also found the unique contributions the newer forms of feedback
intervention strategies (i.e., CST feedback and patient/therapist feedback) made to the patient
outcome in relation to providing patient progress feedback to the therapists alone. This review
also highlighted a retention effect in the newer feedback intervention, that is, feedback
interventions likely helped patients stay longer in treatment, which in turn contributed to
improved outcome among at risk patients. Limitations of this line of research were also
discussed in the discussion sections of respective studies. Despite the limitations already
discussed, however, the accumulating evidence appears substantial in favor of the routine use of
progress feedback and clinical problem-solving tools. When considering clinicians’ difficulty
with identifying patients at risk of treatment failure (Hannan et al 2005), the current state of
evidence seems sufficient to warrant routine use of these feedback interventions.
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Appendix A
Tables and Figure
Table 1
Characteristics of Clients from Studies Used in Meta-Analyses
Clients/therapistsa

Age

Females

Caucasians

Dosage

Intake OQ

NOTb

N

M (SD)

%

%

M (SD)

M (SD)

n (%)

Lambert, et
al. (2001)

609/36

22.23

70.0

87.4

4.68

69.23

66

(3.89)

(23.20)

(10.8)

Lambert, et
al. (2002)

1422/56

4.49

69.87

240

(3.39)

(22.58)

(16.9)

Whipple et
al. (2003)

1339/49

5.14

69.27

278

(4.80)

(23.37)

(20.8)

Hawkins, et
al. (2004)

306/5

6.06

83.23

101

(6.45)

(23.74)

(33.0)

Harmon, et
al. (2007)

1374/72

6.74

71.23

369

(6.44)

(22.61)

(26.9)

Slade, et al.
(2008)

1101/73

5.81

71.50

328

(5.67)

(22.07)

(29.8)

Study

(3.92)
22.37

66.7

85.0

(3.74)
23.01

63.5

86.0

(3.56)
30.51

63.1

94.1

(10.77)
22.68

61.0

83.0

(3.68)
24.25
(3.29)

57.5

82.7

Note. aNumbers of clients and therapists prior to applying any exclusion criteria. Thus, the numbers reported here do
not match with those reported in the original articles for studies that employed exclusion criteria i.e., Lambert et al.
(2002), Whipple et al. (2003), and Hawkins, et al. (2004). bNOT = Clients whose progress was identified by OQ-45
algorithms as being Not-On-Track.

107
Table 2
Meta-Analysis of Effects of Feedback Interventions on Mean Post-Test OQ-45 Total Scale Score

Comparison

k

n

ES

grp1/grp2

[95% CI]

Classic
failsafe N

Orwin’s
failsafe N

Trim and Fill
ES (studies
trimmed)

Intent to Treat Analyses
CST Fb vs. Fb

3

415 / 246

-0.16* [-0.33, -0.002]

0

0

-0.16 (0)

P/T Fb vs. Fb

3

222 / 188

-0.16 [-0.36, 0.03]

0

0

-0.16 (0)

Fb vs. TAU

4

269 / 318

-0.28** [-0.47, -0.10]

6

2

-0.28 (0)

CST Fb vs. TAUa

-

415 / 318

-0.44*** [-0.59, -0.30]

-

-

-

P/T Fb vs. TAUb

-

222 / 318

-0.36*** [-0.54, -0.19]

-

-

-

Efficacy Analyses
CST Fb vs. Fb

3

217 / 169

-0.19 [-0.43, 0.05]

0

1

-0.19 (0)

P/T Fb vs. Fb

3

177 / 147

-0.16 [-0.37, 0.06]

0

0

-0.11 (1)

Fb vs. TAU

4

136 / 318

-0.53*** [-0.78, -0.28]

20

8

-0.67 (2)

CST Fb vs. TAUa

-

217 / 318

-0.70*** [-0.88, -0.52]

-

-

-

P/T Fb vs. TAUb

-

177 / 318

-0.55*** [-0.73, -0.36]

-

-

-

Note. k = number of studies; n = total number of participants; ES = weighted effect size (Hedges’s g; random effect
model); CI = Confidence Interval; Classic fail-safe N = the number of null studies needed to bring the combined pvalue to above 0.05 (two-tail); Orwin’s fail-safe N = the number of studies (with null mean Hedges’s g) needed to
bring the combined effect size (fixed model) to above -0.2. Negative effect sizes indicate lower distress level.
Dashes in table indicate values are not applicable because given analysis was based on mega-analysis. aMegaanalysis using pooled CST Fb group versus pooled TAU group. bMega-analysis using pooled P/T Fb group versus
pooled TAU group.
*p < .05. **p < .01. ***p < .001.
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Table 3
Clinical Significance Classification of Not-On-Track Patients by Treatment Conditions
NOT
Clinical Significance

CST Fb

P/T Fb

OT
Fb

TAU

P/T Fb

OT Fb

TAU

Treatment Conditions (Intent-To-Treat Sample)
Worsened/Deteriorated

47
(11.3%)

35
(15.8%)

58
(13.6%)

64
(20.1%)

20
(2.1%)

45
(1.9%)

43
(3.0%)

No Change

212
(51.1%)

101
(45.5%)

237
(55.5%)

183
(57.5%)

507
(54.2%)

1485
(62.1%)

940
65.1%)

Improved/Recovered

156
(37.6%)

86
(38.7%)

132
(30.9%)

71
(22.3%)

408
(43.6%)

860
(36.0%)

461
(31.9%)

Treatment Conditions (Efficacy Sample)
Worsened/Deteriorated

12
(5.5%)

26
(14.7%)

24
(9.1%)

-

20
(2.6%)

40
(2.4%)

-

No Change

91
(41.9%)

71
(40.1%)

140
(53.2%)

-

349
(44.9%)

794
(48.1%)

-

Improved/Recovered

114
(52.5%)

80
(45.2%)

99
(37.6%)

-

408
(52.5%)

817
(49.5%)

-

Note. NOT = patients whose progress was identified by OQ algorithms as being not on track. OT = patients whose
progress was identified by OQ algorithms as being on track with expected recovery. CST Fb = NOT patients whose
therapists received clinical support tools feedback in addition to OQ progress feedback. P/T Fb = both patients and
therapists received patient OQ progress feedback. Fb = patients whose therapists received patient OQ progress
feedback. TAU = treatment as usual.
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Table 4
Meta-Analysis and Mega-Analysis of Effects of Feedback Interventions on Treatment Outcome:
Combined Odds Ratio of Reliable Worsening/Deterioration

Comparison

k

OR [95% CI]

Classic
failsafe N

Orwin’s
failsafe N

Trim and Fill ES
(studies trimmed)

Intent to Treat Analyses
CST Fb vs. Fb

3

0.76 [0.46, 1.26]

0

0

0.76 (0)

P/T Fb vs. Fb

3

1.35 [0.76, 2.41]

0

0

1.35 (0)

4

0.62* [0.40, 0.98]

3

1

0.70 (2)

CST Fb vs. TAU

-

0.51** [0.34, 0.76]

-

-

-

b

-

0.74 [0.47, 1.17]

-

-

-

Fb vs. TAU
a

P/T Fb vs. TAU

Efficacy Analyses
CST Fb vs. Fb

3

0.66 [0.29, 1.52]

0

1

0.83 (2)

P/T Fb vs. Fb

3

1.89 [0.90, 3.96]

0

1

2.95 (2)

Fb vs. TAU

4

0.44* [0.23, 0.85]

3

4

0.58 (2)

CST Fb vs. TAUa

-

0.23*** [0.12, 0.44]

-

-

-

P/T Fb vs. TAUb

-

0.68 [0.42, 1.13]

-

-

-

Note. k = number of studies; OR = Combined odds ratio (random effect model); CI = Confidence Interval; Classic
fail-safe N = the number of null studies needed to bring the combined p-value to above 0.05 (two-tail); Orwin’s failsafe N = the number of null studies (with odds ratio of 1.00) needed to bring the combined odds ratio (fixed model)
to above 0.66. Odds ratios smaller than 1.00 indicate lower odds of client deterioration among patients in the
treatment group, favoring the treatment group in comparison to a control group. Dashes in table indicate values are
not applicable because given analysis was based on mega-analysis.
a
Mega-analysis using pooled CST Fb group versus pooled TAU group.
b
Mega-analysis using pooled P/T Fb group versus pooled TAU group.
*p < .05. **p < .01. ***p < .001.
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Table 5
Meta-Analysis and Mega-Analysis of Effects of Feedback Interventions on Treatment Outcome:
Combined Odds Ratio of Clinically Significant Improvement

Comparison

k

OR [95% CI]

Classic
failsafe N

Orwin’s
failsafe N

Trim and Fill ES
(studies trimmed)

Intent to Treat Analyses
CST Fb vs. Fb

3

1.53* [1.08, 2.18]

2

1

1.40 (1)

P/T Fb vs. Fb

3

1.44 [0.95, 2.19]

0

0

1.44 (0)

4

1.70** [1.17, 2.46]

3

2

1.72 (1)

CST Fb vs. TAU

-

2.01*** [1.51, 2.92]

-

-

-

b

-

2.20*** [1.51, 3.21]

-

-

-

Fb vs. TAU
a

P/T Fb vs. TAU

Efficacy Analyses
CST Fb vs. Fb

3

1.83 [0.89, 3.76]

4

2

1.83 (0)

P/T Fb vs. Fb

3

1.38 [0.88, 2.18]

0

1

1.25 (2)

Fb vs. TAU

4

2.55*** [1.64, 3.98]

11

6

2.33 (1)

CST Fb vs. TAUa

-

3.85*** [2.65, 5.60]

-

-

-

P/T Fb vs. TAUb

-

2.97*** [1.93, 4.27]

-

-

-

Note. k = number of studies; OR = Combined odds ratio (random effect model); CI = Confidence Interval; Classic
fail-safe N = the number of null studies needed to bring the combined p-value to above 0.05 (two-tail); Orwin’s failsafe N = the number of null studies (with odds ratio of 1.00) needed to bring the combined odds ratio (fixed model)
to above 1.5. Odds ratios greater than 1.00 indicate higher odds of client improvement. Dashes in table indicate
values are not applicable because given analysis was based on mega-analysis.
a
Mega-analysis using pooled CST Fb group versus pooled TAU group.
b
Mega-analysis using pooled P/T Fb group versus pooled TAU group.
*p < .05. **p < .01. ***p < .001.
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Table 6
Meta-Analysis of Effects of Feedback Interventions on Pre-Post Change on OQ-45 Total Scale Score

Comparison

n

ES [95% CI]

Classic
failsafe N

Orwin’s
failsafe N

Trim and Fill ES
(studies trimmed)

Intent-to-treat analysis
CST Fb

415

-0.45*** [-0.59, -0.31]

53

4

-0.45 (0)

NOT P/T Fb

222

-0.49*** [-0.75, -0.22]

28

4

-0.49 (0)

NOT Fb

427

-0.25*** [-0.33, -0.16]

45

2

-0.23 (1)

NOT TAU

318

-0.04 [-0.23, 0.15]

0

0

-0.04 (0)

Efficacy analysis
CST Fb

217

-0.82*** [-0.98, -0.66]

75

10

-0.82 (0)

NOT P/T Fb

177

-0.68*** [-1.04, -0.32]

34

7

-0.68 (0)

NOT Fb

263

-0.42*** [-0.58, -0.26]

81

7

-0.33 (2)

Note. k = number of studies; n = number of participants; ES = weighted effect size (Hedges’s g; random effect
model); CI = Confidence Interval; Classic fail-safe N = the number of null studies needed to bring the combined pvalue to above 0.05 (two-tail); Orwin’s fail-safe N = the number of studies (with null mean Hedges’s g) needed to
bring the combined effect size (fixed model) to above -0.2. Negative effect sizes indicate lower distress level.
*p < .05. **p < .01. ***p < .001.
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Table 7
Meta-Analysis of Effects of Feedback Interventions on Mean Difference in OQ-45 Total Scale Pre-Post Change
Scores

Comparison

k

n

ES

grp1/grp2

[95% CI]

Classic
failsafe N

Orwin’s
failsafe N

Trim and Fill
ES (studies
trimmed)

Intent-to-treat analyses
CST Fb vs. Fb

3

415 / 246

-0.21* [-0.38, -0.04]

3

1

-0.21 (0)

P/T Fb vs. Fb

3

222 / 188

-0.17 [-0.37, 0.03]

0

0

-0.17 (0)

4

269 / 318

-0.28*** [-0.44, -0.11]

6

2

-0.26 (1)

CST Fb vs. TAU

-

415 / 318

-0.43*** [-0.58, -0.32]

-

-

-

b

-

222 / 318

-0.44*** [-0.62, -0.27]

-

-

-

Fb vs. TAU
a

P/T Fb vs. TAU

Efficacy analyses
CST Fb vs. Fb

3

217 / 169

-0.29 [-0.60, 0.02]

4

2

-0.19 (0)

P/T Fb vs. Fb

3

177 / 147

-0.15 [-0.37, 0.07]

0

0

-0.11 (1)

Fb vs. TAU

4

136 / 318

-0.60*** [-0.81, -0.40]

27

9

-0.65 (1)

CST Fb vs. TAUa

-

217 / 318

-0.78*** [-0.96, -0.60]

-

-

-

P/T Fb vs. TAUb

-

177 / 318

-0.56*** [-0.74, -0.37]

-

-

-

Note. k = number of studies; n = number of participants; ES = weighted effect size (Hedges’s g; random effect
model) ; CI = Confidence Interval; Classic fail-safe N = the number of null studies needed to bring the combined pvalue to above 0.05 (two-tail); Orwin’s fail-safe N = the number of studies (with null mean Hedges’s g) needed to
bring the combined effect size (fixed model) to above -0.2. Negative effect sizes indicate lower distress level.
a
Mega-analysis using pooled CST Fb group versus pooled TAU group.
b
Mega-analysis using pooled P/T Fb group versus pooled TAU group.
*p < .05. **p < .01. ***p < .001.
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Table 8
Meta-Analysis and Mega-Analysis of Effects of Feedback Interventions on Mean Number of Session Attendance

Comparison

k

n

ES

gr1/gr2

[95% CI]

Classic
failsafe N

Orwin’s
failsafe N

Trim and Fill ES
(studies trimmed)

Intent-to-treat analyses
CST Fb vs. Fb

3

415/ 246

0.41* [0.05, 0.76]

14

3

0.41 (0)

P/T Fb vs. Fb

3

222/ 188

0.12 [-0.11, 0.35]

0

0

0.12 (0)

Fb vs. TAU

4

269/ 318

0.27 [-0.16, 0.70]

4

0

0.42 (1)

CST Fb vs. TAUa

-

415/ 318

0.48*** [0.33, 0.63]

-

-

-

P/T Fb vs. TAUb

-

222/ 318

0.40*** [0.23, 0.58]

-

-

-

Note. k = number of studies; n = total number of participants; ES = weighted effect size (Hedges’s g; random effect
model) ; gr = group; CI = Confidence Interval; Classic fail-safe N = the number of null studies needed to bring the
combined p-value to above 0.05 (two-tail; based on fixed model); Orwin’s fail-safe N = the number of studies (with
null mean Hedges’s g) needed to bring the combined effect size (fixed model) to below 0.2. Positive effect sizes
indicate more number of session attendances among patients in the treatment group in comparison to the control
group. Dashes in table indicate values are not applicable because given analysis was based on mega-analysis.
a
Mega-analysis using pooled CST Fb group versus pooled TAU group.
b
Mega-analysis using pooled P/T Fb group versus pooled TAU group.
*p < .05. **p < .01. ***p < .001.
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Table 9
Comparison of Mean OQ Total Scores at Pre-Treatment, at the Time of Signal Warning, and Post-Treatment by
Treatment Conditions
Original Study Dataset
Treatment
Condition
CST Fb

Pre-Test

Warning

Post-Test

Pre-Test

Warning

Post-Test

79.8

88.2

70.5

79.4

87.8

70.8

(19.3)

(15.0)

(21.5)

(19.8)

(15.2)

(21.6)

n

415

415

415

412

409

412

M

81.4

89.4

72.0

81.0

88.8

72.6

(19.0)

(15.2)

(22.9)

(18.9)

(16.0)

(22.9)

n

222

222

222

221

218

221

M

79.8

88.9

74.2

79.4

88.9

74.1

(20.5)

(16.4)

(23.6)

(20.4)

(16.1)

(23.1)

n

427

427

427

423

418

423

M

80.3

90.3

80.0

80.4

90.3

79.7

(20.2)

(15.8)

(21.0)

(20.1)

(15.8)

(21.1)

n

318

318

318

312

309

312

M

69.1

54.8

68.8

54.6

(23.1)

(23.4)

(23.1)

(23.4)

n

934

934

915

915

M

67.7

56.1

67.6

55.9

(SD)

(23.3)

(22.9)

(23.2)

(22.7)

n

2387

2387

2346

2346

M

68.2

58.9

67.9

58.5

(SD)

(22.8)

(22.6)

(22.7)

(22.6)

n

1442

1442

1414

1414

M

70.8

89.1

60.6

70.6

88.8

60.4

(SD)

(23.0)

(15.7)

(24.0)

(22.9)

(15.8)

(24.0)

N

6145

1382

6145

6044

1354

6044

M
(SD)

NOT P/T Fb

(SD)
NOT Fb

(SD)
NOT TAU

(SD)
OT P/T Fb

(SD)
OT Fb

OT TAU

Total

Merged Dataset

Note. NOT = patients whose progress was identified by OQ algorithms as being not on track. OT = patients whose
progress was identified by OQ algorithms as being on track with expected recovery. CST Fb = NOT patients whose
therapists received clinical support tools feedback in addition to OQ progress feedback. P/T Fb = both patients and
therapists received patient OQ progress feedback. Fb = patients whose therapists received patient OQ progress
feedback. TAU = treatment as usual. The n for pre-treatment and post-treatment are matched because of the use of
the last observation carried forward method, where missing post-treatment scores were replaced by the last scores
recorded.
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Table 10
Correlations of Pre-treatment, Signal-warning, Post-treatment, and Pre-post Change Scores between the OQ Total
Scale and OQ Subscales
OQ Total Scale

SD scale

IR scale

SR scale

Pre-treatment score

.95

.75

.77

Score at signal warning*

.90

.60

.63

Post-treatment score

.96

.81

.81

Pre-post Change score

.94

.76

.75

Note. *Correlations for scores at signal warning were based on not-on-track patients only (n = 1068). All other
correlations were based on all patients with merged subscale scores (N = 6044). All correlations were significant at
p < 0.001.
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Table 11
Meta-Analysis of Effects of Feedback Interventions on Mean Post-Test OQ-45 Symptom Distress (SD) Subscale
Score

Feedback Condition

k

N

ES

grp1/grp2

[95% CI]

Classic
failsafe N

Orwin’s
failsafe N

Trim and Fill
ES (studies
trimmed)

Intent to Treat Analyses
CST Fb vs. Fb

3

412 / 244

-0.15 [-0.32, 0.01]

0

0

-0.15 (0)

P/T Fb vs. Fb

3

221 / 186

-0.11 [-0.30, 0.09]

0

0

-0.08 (1)

4

266 / 312

-0.26** [-0.42, -0.09]

5

2

-0.26 (0)

CST Fb vs. TAU

-

412 / 312

-0.33*** [-0.47, -0.18]

-

-

-

b

-

221 / 312

-0.24** [-0.41, -0.06]

-

-

-

Fb vs. TAU
a

P/T Fb vs. TAU

Efficacy Analyses
CST Fb vs. Fb

3

214 / 168

-0.18 [-0.38, 0.03]

0

0

-0.18 (0)

P/T Fb vs. Fb

3

176 / 147

-0.09 [-0.31, 0.13]

0

0

-0.09 (0)

Fb vs. TAU

4

135 / 312

-0.52*** [-0.73, -0.32]

18

7

-0.60 (2)

CST Fb vs. TAUa

-

214 / 312

-0.55*** [-0.73, -0.38]

-

-

-

P/T Fb vs. TAUb

-

176 / 312

-0.39*** [-0.57, -0.20]

-

-

-

Note. k = number of studies; N = total number of participants; ES = weighted effect size (Hedges’s g; random effect
model); CI = Confidence Interval; Classic fail-safe N = the number of null studies needed to bring the combined pvalue to above 0.05 (two-tail); Orwin’s fail-safe N = the number of studies (with null mean Hedges’s g) needed to
bring the combined effect size (fixed model) to above -0.2. Negative effect sizes indicate lower distress level.
a
Mega-analysis using pooled CST Fb group versus pooled TAU group.
b
Mega-analysis using pooled P/T Fb group versus pooled TAU group.
*p < .05. **p < .01. ***p < .001.
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Table 12
Meta-Analysis of Effects of Feedback Interventions on Mean Post-Test OQ-45 Interpersonal Relations (IR) Subscale
Score

Feedback Condition

k

N

ES

grp1/grp2

[95% CI]

Classic
failsafe N

Orwin’s
failsafe N

Trim and Fill
ES (studies
trimmed)

Intent to Treat Analyses
CST Fb vs. Fb

3

412 / 244

-0.08 [-0.24, 0.09]

0

0

-0.15 (0)

P/T Fb vs. Fb

3

221 / 186

-0.06 [-0.28, 0.15]

0

0

-0.06 (0)

4

266 / 312

-0.24* [-0.43, -0.05]

3

0

-0.37 (2)

CST Fb vs. TAU

-

412 / 312

-0.42*** [-0.57, -0.27]

-

-

-

b

-

221 / 312

-0.29** [-0.46, -0.12]

-

-

-

Fb vs. TAU
a

P/T Fb vs. TAU

Efficacy Analyses
CST Fb vs. Fb

3

214 / 168

-0.12 [-0.32, 0.08]

0

0

-0.12 (0)

P/T Fb vs. Fb

3

176 / 147

-0.12 [-0.34, 0.10]

0

0

-0.12 (0)

Fb vs. TAU

4

135 / 312

-0.37* [-0.67, -0.07]

9

5

-0.53 (2)

CST Fb vs. TAUa

-

214 / 312

-0.54*** [-0.71, -0.36]

-

-

-

P/T Fb vs. TAUb

-

176 / 312

-0.43*** [-0.61, -0.24]

-

-

-

Note. k = number of studies; N = total number of participants; ES = weighted effect size (Hedges’s g; random effect
model); CI = Confidence Interval; Classic fail-safe N = the number of null studies needed to bring the combined pvalue to above 0.05 (two-tail); Orwin’s fail-safe N = the number of studies (with null mean Hedges’s g) needed to
bring the combined effect size (fixed model) to above -0.2. Negative effect sizes indicate lower distress level.
a
Mega-analysis using pooled CST Fb group versus pooled TAU group.
b
Mega-analysis using pooled P/T Fb group versus pooled TAU group.
*p < .05. **p < .01. ***p < .001.
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Table 13
Meta-Analysis of Effects of Feedback Interventions on Mean Post-Test OQ-45 Social Role (SR) Subscale Score

Feedback Condition

k

N

ES

grp1/grp2

[95% CI]

Classic
failsafe N

Orwin’s
failsafe N

Trim and Fill
ES (studies
trimmed)

Intent to Treat Analyses
CST Fb vs. Fb

3

412 / 244

-0.20* [-0.36, -0.03]

2

0

-0.08 (2)

P/T Fb vs. Fb

3

221 / 186

-0.22 [-0.52, 0.07]

1

1

-0.22 (0)

Fb vs. TAU

4

266 / 312

-0.24** [-0.40, -0.07]

6

2

-0.35 (2)

-

412 / 312

-0.42*** [-0.57, -0.27]

-

-

-

-

221 / 312

-0.40*** [-0.57, -0.23]

-

-

-

CST Fb vs. TAUa
b

P/T Fb vs. TAU

Efficacy Analyses
CST Fb vs. Fb

3

214 / 168

-0.28** [-0.49, -0.08]

3

2

-0.36 (2)

P/T Fb vs. Fb

3

176 / 147

-0.24 [-0.61, 0.12]

1

1

-0.24 (0)

Fb vs. TAU

4

135 / 312

-0.48*** [-0.68, -0.21]

12

6

-0.58 (2)

CST Fb vs. TAUa

-

214 / 312

-0.54*** [-0.71, -0.36]

-

-

-

P/T Fb vs. TAUb

-

176 / 312

-0.56*** [-0.75, -0.37]

-

-

-

Note. k = number of studies; N = total number of participants; ES = weighted effect size (Hedges’s g; random effect
model); CI = Confidence Interval; Classic fail-safe N = the number of null studies needed to bring the combined pvalue to above 0.05 (two-tail); Orwin’s fail-safe N = the number of studies (with null mean Hedges’s g) needed to
bring the combined effect size (fixed model) to above -0.2. Negative effect sizes indicate lower distress level.
a
Mega-analysis using pooled CST Fb group versus pooled TAU group.
b
Mega-analysis using pooled P/T Fb group versus pooled TAU group.
*p < .05. **p < .01. ***p < .001.
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Table 14
Summary of Effects of Feedback Interventions on Mean Post-Test OQ-45 Subscale Scores

Feedback Condition

k

N

SD scale ES

IR scale ES

SR scale ES

grp1/grp2

[95% CI]

[95% CI]

[95% CI]

-0.15

-0.08

-0.20*

[-0.32, 0.01]

[-0.24, 0.09]

[-0.36, -0.03]

-0.11

-0.06

-0.22

[-0.30, 0.09]

[-0.28, 0.15]

[-0.52, 0.07]

-0.26**

-0.24*

-0.24**

[-0.42, -0.09]

[-0.43, -0.05]

[-0.40, -0.07]

-0.33***

-0.42***

-0.42***

[-0.47, -0.18]

[-0.57, -0.27]

[-0.57, -0.27]

-0.24**

-0.29**

-0.40***

[-0.41, -0.06]

[-0.46, -0.12]

[-0.57, -0.23]

-0.18

-0.12

-0.28**

[-0.38, 0.03]

[-0.32, 0.08]

[-0.49, -0.08]

-0.09

-0.12

-0.24

[-0.31, 0.13]

[-0.34, 0.10]

[-0.61, 0.12]

-0.52***

-0.37*

-0.48***

[-0.73, -0.32]

[-0.67, -0.07]

[-0.68, -0.21]

-0.55***

-0.54***

-0.54***

[-0.73, -0.38]

[-0.71, -0.36]

[-0.71, -0.36]

-0.39***

-0.43***

-0.56***

[-0.57, -0.20]

[-0.61, -0.24]

[-0.75, -0.37]

Intent-to-treat analyses
CST Fb vs. Fb

P/T Fb vs. Fb

Fb vs. TAU

CST Fb vs. TAU

P/T Fb vs. TAU

3

3

4

-

-

412 / 244

221 / 186

266 / 312

412 / 312

221 / 312

Efficacy Analyses
CST Fb vs. Fb

P/T Fb vs. Fb

Fb vs. TAU
CST Fb vs. TAUa
P/T Fb vs. TAUb

3

3

4

-

-

214 / 168

176 / 147

135 / 312

214 / 312

176 / 312

Note. k = number of studies; N = total number of participants; ES = weighted effect size (Hedges’s g; random effect
model); CI = Confidence Interval; Negative effect sizes indicate lower distress level.
a
Mega-analysis using pooled CST Fb group versus pooled TAU group.
b
Mega-analysis using pooled P/T Fb group versus pooled TAU group.
*p < .05. **p < .01. ***p < .001.

120
Table 15
Mega-Analysis of Effects of Feedback Interventions on Pre-Post Change on OQ-45 Subscale Scores

Comparison

N

SD scale ES

IR scale ES

SR scale ES

[95% CI]

[95% CI]

[95% CI]

-0.43***

-0.23***

-0.29***

[-0.53, -0.33]

[-0.33, -0.13]

[-0.40, -0.17]

-0.42***

-0.16*

-0.37***

[-0.56, -0.27]

[-0.30, -0.02]

[-0.51, -0.23]

-0.30***

-0.06

-0.13**

[-0.39, -0.21]

[-0.15, 0.03]

[-0.23, -0.03]

-0.14*

0.12*

0.09

[-0.25, -0.02]

[0.02, 0.22]

[-0.03, 0.21]

-0.76***

-0.46***

[-0.91, -0.60]

[-0.61, -0.32]

-0.54***
[-0.70, -0.38]

-0.56***

-0.28**

-0.50***

[-0.74, -0.37]

[-0.44, -0.11]

[-0.68, -0.32]

-0.49***

-0.17**

-0.25***

[-0.61, -0.37]

[-0.29, -0.06]

[-0.39, -0.12]

-

-

-

Intent-to-treat analyses
CST Fb

NOT P/T Fb

NOT Fb

NOT TAU

412

221

423

312

Efficacy analysis
CST Fb

NOT P/T Fb

NOT Fb

NOT TAU

214

176

262

312

Note. k = number of studies; N = total number of participants; ES = pre-post change effect size (Hedges’s g); CI =
Confidence Interval; Negative effect sizes indicate lower distress level.
*p < .05. **p < .01. ***p < .001.
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Table 16
Mega-Analysis of Effects of Feedback Interventions on Mean Difference in OQ Subscale Pre-Post Change Scores

Comparison

N

SD scale ES

IR scale ES

SR scale ES

grp1/grp2

[95% CI]

[95% CI]

[95% CI]

-0.13

-0.12

-0.18*

[-0.29, 0.03]

[-0.28, 0.04]

[-0.34, -0.02]

-0.10

-0.07

-0.29**

[-0.29, 0.10]

[-0.26, 0.13]

[-0.48, -0.09]

-0.20*

-0.18*

-0.28***

[-0.37, -0.04]

[-0.35, -0.02]

[-0.44, -0.11]

-0.30***

-0.36***

-0.34***

[-0.45, -0.15]

[-0.51, -0.21]

[-0.49, -0.19]

-0.27**

-0.29***

-0.44***

[-0.44, -0.10]

[-0.47, -0.12]

[-0.62, -0.27]

-0.23*

-0.29**

-0.27**

[-0.44, -0.03]

[-0.49, -0.09]

[-0.47, -0.07]

-0.08

-0.13

-0.24*

[-0.29, 0.14]

[-0.35, 0.09]

[-0.46, -0.03]

-0.47***

-0.36***

-0.41***

[-0.68, -0.27]

[-0.56, -0.15]

[-0.61, -0.20]

-0.60***

-0.60***

-0.57***

[-0.78, -0.42]

[-0.78, -0.42]

[-0.74, -0.39]

-0.39***

-0.41***

-0.53***

[-0.57, -0.20]

[-0.60, -0.22]

[-0.71, -0.34]

Intent-to-treat analyses
CST Fb vs. Fb

P/T Fb vs. Fb

Fb vs. TAU

CST Fb vs. TAU

P/T Fb vs. TAU

412 / 244

221 / 186

266 / 312

412 / 312

221 / 312

Efficacy Analyses
CST Fb vs. Fb

P/T Fb vs. Fb

Fb vs. TAU

CST Fb vs. TAU

P/T Fb vs. TAU

214 / 168

176 / 147

135 / 312

214 / 312

176 / 312

Note. k = number of studies; N = total number of participants; ES = weighted effect size (Hedges’s g; random effect
model); CI = Confidence Interval; Negative effect sizes indicate lower distress level.
*p < .05. **p < .01. ***p < .001.
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Table 17
OQ Symptom Distress (SD) Subscale Score-Based Clinical Significance Classification of Patients by Treatment
Conditions
NOT
Clinical Significance

CST Fb

P/T Fb

OT
Fb

TAU

P/T Fb

OT Fb

TAU

Intent-To-Treat Sample
Worsened/Deteriorated

No Change

Improved/Recovered

45

30

51

49

22

41

33

(10.9%)

(13.6%)

(12.1%)

(15.7%)

(2.4%)

(1.7%)

(2.3%)

215

109

242

172

521

1449

936

(52.2%)

(49.3%)

(57.2%)

(55.1%)

(56.9%)

(61.7%)

(66.2%)

152

82

130

91

372

857

445

(36.9%)

(37.1%)

(30.7%)

(29.2%)

(40.7%)

(36.5%)

(31.5%)

22

33

(2.8%)

(2.0%)

379

817

(49.0%)

(49.7%)

372

794

(48.1%)

(48.3%)

Efficacy Sample
Worsened/Deteriorated

No Change

Improved/Recovered

13

21

22

(6.1%)

(11.9%)

(8.4%)

92

80

139

(43.0%)

(45.5%)

(53.1%)

109

75

101

(50.9%)

(42.6%)

(38.5%)

-

-

-

-

-

-

Note. NOT = patients whose progress was identified by OQ algorithms as being not on track. OT = patients whose
progress was identified by OQ algorithms as being on track with expected recovery. CST Fb = NOT patients whose
therapists received clinical support tools feedback in addition to OQ progress feedback. P/T Fb = both patients and
therapists received patient OQ progress feedback. Fb = patients whose therapists received patient OQ progress
feedback. TAU = treatment as usual. The n for pre-treatment and post-treatment are matched because of the use of
the last observation carried forward method, where missing post-treatment scores were replaced by the last scores
recorded.
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Table 18
OQ Interpersonal Relations (IR) Subscale Score-Based Clinical Significance Classification of Patients by Treatment
Conditions
NOT
Clinical Significance

CST Fb

P/T Fb

OT
Fb

TAU

P/T Fb

OT Fb

TAU

Intent-To-Treat Sample
Worsened/Deteriorated

No Change

Improved/Recovered

18

15

36

30

4

30

26

(4.4%)

(6.8%)

(8.5%)

(9.6%)

(0.4%)

(1.3%)

(1.8%)

334

175

347

262

764

2035

1249

(81.1%)

(79.2%)

(82.0%)

(84.0%)

(83.6%)

(86.8%)

(88.3%)

60

31

40

20

146

280

139

(14.6%)

(14.0%)

(9.5%)

(6.4%)

(16.0%)

(11.9%)

(9.8%)

4

26

(0.5%)

(1.6%)

(Efficacy Sample
Worsened/Deteriorated

No Change

Improved/Recovered

7

11

18

(3.3%)

(6.3%)

(6.9%)

163

134

211

(76.2%)

(76.1%)

(80.5%)

44

31

33

(20.6%)

(17.6%)

(12.6%)

-

-

-

623

-

1351

(80.6%)

(82.2%
)

146

267

(18.9%)

(16.3%)

-

-

Note. NOT = patients whose progress was identified by OQ algorithms as being not on track. OT = patients whose
progress was identified by OQ algorithms as being on track with expected recovery. CST Fb = NOT patients whose
therapists received clinical support tools feedback in addition to OQ progress feedback. P/T Fb = both patients and
therapists received patient OQ progress feedback. Fb = patients whose therapists received patient OQ progress
feedback. TAU = treatment as usual. The n for pre-treatment and post-treatment are matched because of the use of
the last observation carried forward method, where missing post-treatment scores were replaced by the last scores
recorded.
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Table 19
OQ Social Role (SR) Subscale Score-Based Clinical Significance Classification of Patients by Treatment Conditions
NOT
Clinical Significance

CST Fb

P/T Fb

OT
Fb

TAU

P/T Fb

OT Fb

TAU

10
(1.1%)

26
(1.1%)

25
(1.8%)

774
(84.6%)

2062
(87.9%)

1270
(89.8%)

131
(14.3%)

259
(11.0%)

119
(8.4%)

Intent-to-treat sample
Worsened/Deteriorated

No Change

Improved/Recovered

18

15

36

30

(4.4%)

(6.8%)

(8.5%)

(9.6%)

334

175

347

262

(81.1%)

(79.2%)

(82.0%)

(84.0%)

60

31

40

20

(14.6%)

(14.0%)

(9.5%)

(6.4%)

Efficacy sample
Worsened/Deteriorated

5
(2.3%)

9
(5.1%)

14
(5.3%)

-

No Change

166
(77.6%)

135
(76.7%)

213
(81.3%)

-

Improved/Recovered

43
(20.1%)

32
(18.2%)

35
(13.4%)

-

10

25

(1.3%)

(1.5%)

632

1375

(81.8%)

(83.6%)

131

244

(16.9%)

(14.8%)

-

-

-

Note. NOT = patients whose progress was identified by OQ algorithms as being not on track. OT = patients whose
progress was identified by OQ algorithms as being on track with expected recovery. CST Fb = NOT patients whose
therapists received clinical support tools feedback in addition to OQ progress feedback. P/T Fb = both patients and
therapists received patient OQ progress feedback. Fb = patients whose therapists received patient OQ progress
feedback. TAU = treatment as usual. The n for pre-treatment and post-treatment are matched because of the use of
the last observation carried forward method, where missing post-treatment scores were replaced by the last scores
recorded.
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Table 20
Mega-Analysis of Effects of Feedback Interventions on Reducing Deterioration at Termination in Not-on-Track
(NOT) Patients Based on OQ Subscale Scores

Comparison

SD scale

IR scale

SR scale

OR [95% CI]

OR [95% CI]

OR [95% CI]

Intent-to-treat analyses
CST Fb vs. Fb

0.87 [0.53, 1.43]

0.65 [0.33, 1.30]

0.51 [0.25, 1.01]

P/T Fb vs. Fb

1.11 [0.62, 1.99]

0.77 [0.37, 1.61]

0.64 [0.28, 1.45]

Fb vs. TAU

0.66 [0.40, 1.07]

0.93 [0.53, 1.64]

0.64 [0.32, 1.25]

CST Fb vs. TAU

0.66 [0.43, 1.02]

0.43** [0.23, 0.79]

0.46* [0.24, 0.88]

P/T Fb vs. TAU

0.84 [0.52, 1.38]

0.68 [0.36, 1.30]

0.62 [0.28, 1.36]

Efficacy analyses
CST Fb vs. Fb

0.77 [0.35, 1.71]

0.60 [0.22, 1.64]

0.42 [0.14, 1.29]

P/T Fb vs. Fb

1.40 [0.67, 2.90]

0.82 [0.35, 1.96]

0.94 [0.35, 2.49]

0.43* [0.21, 0.88]

0.67 [0.31, 1.46]

0.53 [0.21, 1.33]

0.35** [0.18, 0.66]

0.32** [0.14, 0.74]

0.27** [0.10, 0.73]

0.73 [0.42, 1.26]

0.63 [0.31, 1.28]

0.62 [0.28, 1.36]

Fb vs. TAU
CST Fb vs. TAU
P/T Fb vs. TAU

Note. OR = odds ratio; CI = Confidence Interval; Odds ratios smaller than 1.00 indicate lower odds of client
deterioration among patients in the treatment group, favoring the treatment group in comparison to the control
group. CST Fb = NOT patients whose therapists received clinical support tools feedback in addition to OQ progress
feedback. P/T Fb = both patients and therapists received patient OQ progress feedback. Fb = patients whose
therapists received patient OQ progress feedback. TAU = treatment as usual.
*p < .05. **p < .01. ***p < .001.
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Table 21
Mega-Analysis of Effects of Feedback Interventions on Enhancing Clinically Significant Improvement in Not-onTrack (NOT) Patients at Termination based on OQ Subscale Scores

Comparison

SD scale

IR scale

SR scale

OR [95% CI]

OR [95% CI]

OR [95% CI]

Intent-to-treat analyses
CST Fb vs. Fb

1.32 [0.94, 1.85]

1.43 [0.88, 2.33]

1.67* [1.00, 2.78]

P/T Fb vs. Fb

1.34 [0.88, 2.02]

1.43 [0.78, 2.63]

1.87 [0.99, 3.51]

Fb vs. TAU

1.10 [0.77, 1.57]

1.45 [0.78, 2.68]

2.16** [1.25, 3.72]

CST Fb vs. TAU

1.42* [1.04, 1.95]

2.49*** [1.47, 4.23]

2.18** [1.32, 3.62]

P/T Fb vs. TAU

1.43 [0.99, 2.07]

2.38** [1.32, 4.30]

2.21** [1.26, 3.87]

Efficacy analyses
CST Fb vs. Fb

1.69* [1.12, 2.54]

1.81* [1.03, 3.19]

1.97* [1.10, 3.53]

P/T Fb vs. Fb

1.28 [0.82, 2.00]

1.53 [0.82, 2.87]

1.96* [1.01, 3.77]

1.72* [0.13, 2.62]

2.25* [1.15, 4.40]

2.86*** [1.56, 5.24]

CST Fb vs. TAU

2.52*** [1.75, 3.62]

3.78*** [2.16, 6.62]

3.16*** [1.84, 5.42]

P/T Fb vs. TAU

1.80** [1.23, 2.65]

3.12*** [1.72, 5.67]

2.79*** 1.58, 4.95]

Fb vs. TAU

Note. OR = odds ratio; CI = Confidence Interval; Odds ratios greater than 1.00 indicate higher odds of client
improvement among patients in the treatment group, favoring the treatment group in comparison to the control
group. CST Fb = NOT patients whose therapists received clinical support tools feedback in addition to OQ progress
feedback. P/T Fb = both patients and therapists received patient OQ progress feedback. Fb = patients whose
therapists received patient OQ progress feedback. TAU = treatment as usual.
*p < .05. **p < .01. ***p < .001.
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Table 22
Number of Sessions Attended by Not-On-Track Patients after the First Signal Warning Event
Treatment group among NOT patients
# of sessions after
first worsening

CST Fb

P/T Feedback

Feedback

No feedback
(TAU)

1 – 2 sessions

92 (22.2%)

52 (23.4%)

135 (31.6%)

111 (34.9%)

3 – 4 sessions

84 (20.2%)

41 (18.5%)

93 (21.8%)

71 (22.3%)

5 – 8 sessions

101 (24.3%)

55 (24.8%)

101 (23.7%)

84 (26.4%)

9 – 11 sessions

53 (12.8%)

24 (10.8%)

42 (9.8%)

27 (8.5%)

12 – 18 sessions

51 (12.3%)

33 (14.9%)

43 (10.1%)

20 (6.3%)

> 19 sessions

34 (8.2%)

17 (7.7%)

13 (3.0%)

5 (1.6%)

Note. NOT = patients whose progress was identified by OQ algorithms as being not on track. CST Fb = NOT
patients whose therapists received clinical support tools feedback in addition to OQ progress feedback. P/T Fb =
both patients and therapists received patient OQ progress feedback. Fb = patients whose therapists received patient
OQ progress feedback. TAU = treatment as usual.
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Table 23
Comparison of Linear Models of Change on ITT Sample

Model Aa

Parameter

Model
B.1b

Model
C.1c

Model
D.1d

Model
E.1e

Model
F.1f

79.06***
(0.52)

78.67***
(0.53)

78.70***
(0.52)

10.72***
(0.38)

11.77***
(0.39)

0.68***
(0.09)

-1.41***
(0.09)

-1.42***
(0.09)

-2.17***
(0.14)

-0.97***
(0.13)

-0.17***
(0.14)

Fixed effects
Initial
Status

Intercept

78.25***
(0.45)

81.04***
(0.51)

#Sessionsg

80.29***
(0.53)
-2.84***
(0.79)

Signalh
Rate of
change

Session

-0.62***
(0.06)

-0.55***
(0.07)

SessionPWi
Session
×#Sessions

-0.19
(0.12)
2.36***
(0.17)

SessionPW
×#SessionsPWj
Random effects
Level 1

Within-person

177.38***
(2.32)

139.25***
(1.94)

139.05***
(1.93)

132.52***
(1.88)

115.53***
(1.70)

115.48***
(1.69)

Level 2

Initial status

256.69***
(10.78)

303.56***
(22.48)

298.48***
(13.32)

307.23***
(14.12)

318.93***
(14.30)

318.89***
(14.30)

2.72***
(0.22)

2.78***
(0.23)

1.38***
(0.28)

1.33***
(0.22)

1.31***
0.21)

4.18***
(0.73)

5.33***
(0.76)

3.68***
(0.63)

53.85***
(6.88)

55.68***
(6.90)

Session
SesssionPW
Signal
-2 log likelihood

108580.6

107032.0

107007.2

106658.7

105604.1

105430.6

AIC

108586.6

107044.0

107023.2

106678.7

105634.1

105462.6

BIC

108609.0

107088.8

107083.0

106753.5

105746.3

105582.3

Note. Standard errors are in parenthesis. a = unconditional means model; b = Unconditional linear growth model; c =
Stratified linear growth model; d = Discontinuous slope model; e = Discontinuous intercept and slope model; f =
Stratified discontinuous intercept and slope model; g = natural log transformation of number of sessions attended by
not-on-track patients centered on sample mean; h = intercept at the time of first signal warning, noting the elevation
of intercept in OQ points; i = rate of change after the first warning signal event; j = natural log transformation of
number of sessions attended after first signal warning by not-on-track patients centered on sample mean
** p < .01, *** p < .001.
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Table 24
Comparison of Alternative Linear Models of Change (Efficacy sample)

Model Aa

Parameter

Model
B.1b

Model
C.1c

Model
D.1d

Model
E.1e

Model
F.1f

80.92***
(0.58)

80.92***
(0.58)

78.27***
(0.59)

10.13***
(0.45)

11.22***
(0.46)

0.52***
(0.11)

-1.50***
(0.10)

-1.50***
(0.10)

-2.03***
(0.15)

-0.75***
(0.14)

-1.68***
(0.16)

Fixed effects
Initial
Status

Intercept

77.58***
(0.52)

82.53***
(0.66)

#Sessionsg

82.19***
(0.66)
-0.57
(1.11)

Signalh
Rate of
change

Session

-0.79 ***
(0.07)

-0.85***
(0.08)

SessionPWi
Session
×#Sessions

0.29*
(0.14)
2.41***
(0.18)

SessionPW
×#SessionsPWj
Random effects
Level 1

Within-person

183.63***
(2.70)

141.99***
(2.21)

142.20***
(2.22)

135.36***
(2.15)

120.57***
(1.98)

120.22***
(1.96)

Level 2

Initial status

244.21***
(12.18)

282.95***
(15.03)

278.78***
(14.85)

296.17***
(16.32)

305.76***
(16.48)

305.92***
(16.50)

2.54***
(0.23)

2.48***
(0.22)

1.64***
(0.35)

1.42***
(0.25)

1.37***
(0.24)

3.54***
(0.74)

4.29***
(0.72)

3.11***
(0.61)

50.52***
(7.85)

52.06***
(7.87)

Session
SesssionPW
Signal
-2 log likelihood

84875.7

83517.4

83508.6

83254.0

82574.1

82416.4

AIC

84881.7

83529.4

83524.6

83274.0

82604.1

82448.4

BIC

84903.4

83572.8

83582.4

83346.4

82712.6

82564.1

Note. Standard errors are in parenthesis. a = unconditional means model; b = Unconditional linear growth model; c =
Stratified linear growth model; d = Discontinuous slope model; e = Discontinuous intercept and slope model; f =
Stratified discontinuous intercept and slope model; g = natural log transformation of number of sessions attended by
not-on-track patients centered on sample mean; h = intercept at the time of first signal warning, noting the elevation
of intercept in OQ points; i = rate of change after the first warning signal event; j = natural log transformation of
number of sessions attended after first signal warning by not-on-track patients centered on sample mean
** p < .01, *** p < .001.
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Table 25
Comparison of Alternative Linear Models of Change (ITT Sample without Last Observation Carried Forward
Method)

Model Aa

Parameter
Initial
Status

Intercept

77.96***
(0.45)

#Sessionsg

Model
Model
C.1c
B.1b
Fixed effects
81.05***
80.57***
(0.50)
(0.52)
-2.99***
(0.79)

Model
D.1d

Model
E.1e

Model
F.1f

79.18***
(0.52)

78.69***
(0.52)

78.69***
(0.52)

0.49***
(0.09)
-2.05***
(0.14)

10.37***
(0.38)
-1.43***
(0.09)
-0.99 ***
(0.13)

11.40***
(0.38)
-1.42***
(0.09)
-1.96***
(0.14)

Signalh
Rate of
change

Session

-0.73 ***
(0.06)

-0.74***
(0.07)

SessionPWi
Session
×#Sessions
SessionPW
×#SessionsPWj
Level 1

Within-person

Level 2

Initial status

0.19
(0.12)
2.83***
(0.18)
179.05***
(2.37)
253.94***
(10.77)

Session

Random effects
140.89*** 141.06***
(1.98)
(1.98)
298.99*** 293.74***
(13.41)
(16.39)
2.55***
2.51***
(0.21)
(0.21)

SesssionPW

134.01***
(1.92)
304.60***
(14.11)
1.16***
(0.25)
4.10***
(0.71)

Signal
-2 log likelihood
AIC
BIC

106201.7
106207.7
106230.1

104672.4
104684.4
104729.2

104658.2
104674.2
104733.9

104320.2
104340.2
104414.8

118.42***
(1.76)
316.80***
(14.33)
1.32***
(0.22)
5.26***
(0.77)
44.29***
(6.62)
103392.5
103422.5
103534.3

117.68***
(1.74)
316.78***
(14.33)
1.28***
(0.22)
3.75***
(0.64)
44.82***
(6.56)
103158.9
103190.9
103310.2

Note. Standard errors are in parenthesis. a = unconditional means model; b = Unconditional linear growth model; c =
Stratified linear growth model; d = Discontinuous slope model; e = Discontinuous intercept and slope model; f =
Stratified discontinuous intercept and slope model; g = natural log transformation of number of sessions attended by
not-on-track patients centered on sample mean; h = intercept at the time of first signal warning, noting the elevation
of intercept in OQ points; i = rate of change after the first warning signal event; j = natural log transformation of
number of sessions attended after first signal warning by not-on-track patients centered on sample mean
** p < .01, *** p < .001.
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Table 26
Comparison of Alternative Linear Models of Change (Efficacy Sample without Last Observation Carried Forward
Method)

Model Aa

Parameter
Initial
Status

Intercept

77.42***
(0.52)

#Sessionsg

Model
Model
C.1c
B.1b
Fixed effects
81.30***
81.47***
(0.58)
(0.58)
-2.78**
(0.79)

Model
D.1d

Model
E.1e

Model
F.1f

79.29**
(0.61)

78.86***
(0.61)

78.85***
(0.61)

0.42**
(0.11)
-1.96**
(0.15)

9.93***
(0.44)
-1.51***
(0.10)
-0.76 ***
(0.14)

11.02***
(0.45)
-1.50***
(0.11)
-1.78***
(0.16)

Signalh
Rate of
change

Session

-0.84 ***
(0.07)

-0.97***
(0.08)

SessionPWi
Session
×#Sessions
SessionPW
×#SessionsPWj
Level 1

Within-person

Level 2

Initial status

0.50***
(0.14)
2.59***
(0.19)
184.12***
(2.72)
242.11***
(12.14)

Session

Random effects
142.63*** 142.89***
(2.23)
(2.23)
279.18*** 275.11***
(14.91)
(14.73)
2.43***
2.32***
(0.22)
(0.21)

SesssionPW

135.96***
(2.17)
292.71***
(16.22)
1.45***
(0.33)
3.50***
(0.73)

Signal
-2 log likelihood
AIC
BIC

84031.0
84040.0
84061.7

82684.1
82696.1
82739.4

82669.1
82685.1
82742.9

82428.3
82448.3
82520.6

121.45***
(2.00)
303.76***
(16.47)
1.40***
(0.25)
4.28***
(0.72)
44.95***
(7.63)
81793.6
81823.6
81931.9

121.20***
(1.99)
303.84***
(16.46)
1.33***
(0.24)
3.17***
(0.61)
45.44**
(7.60)
81615.5
81647.5
81763.1

Note. Standard errors are in parenthesis. a = unconditional means model; b = Unconditional linear growth model; c =
Stratified linear growth model; d = Discontinuous slope model; e = Discontinuous intercept and slope model; f =
Stratified discontinuous intercept and slope model; g = natural log transformation of number of sessions attended by
not-on-track patients centered on sample mean; h = intercept at the time of first signal warning, noting the elevation
of intercept in OQ points; i = rate of change after the first warning signal event; j = natural log transformation of
number of sessions attended after first signal warning by not-on-track patients centered on sample mean
** p < .01, *** p < .001.
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Table 27
Comparison of Alternative Linear Models of Change Based on Natural Log Transformed Time (ITT Sample)

Model Aa

Parameter
Initial
Status

Intercept

78.25***
(0.45)

#Sessionsg

Model
Model
B.2b
C.2c
Fixed effects
81.79***
81.09***
(0.56)
(0.59)
-0.82
(0.89)

Model
D.2d

Model
E.2e

Model
F.2f

80.74***
(0.50)

77.56***
(0.50)

77.61***
(0.50)

0.09
(0.07)

11.03***
(0.34)
-.20***
(0.04)

11.42***
(0.35)
-0.24***
(0.05)

-3.97***
(0.41)

-7.96***
(0.37)

-8.19***
(0.36)

Signalh
Rate of
change

Session
LgSession

-2.27***
(0.26)

-2.05***
(0.26)

LgSessionPWi
LgSession
×#Sessions
LgSessionPW
×#SessionsPWj
Level 1

Within-person

Level 2

Initial status

-2.62***
(0.42)
2.42***
(0.45)
177.38***
(2.32)
256.69***
(10.78)

Random effects
146.70*** 146.18***
(2.02)
(2.01)
348.31*** 347.67***
(16.72)
(16.69)

130.88***
(1.85)
305.11***
(13.38)

Signal
Session

118.12***
(1.71)
293.33***
(12.98)
33.26***
(5.87)

63.18***
(4.75)
105419.8
105441.8
105524.1

57.47***
(4.53)
105393.0
105518.8
105506.8

1.10***
(0.18)

LgSession

47.25***
(3.26)

47.08***
(3.21)

LgSesssionPW
-2 log likelihood
AIC
BIC

117.99***
(1.71)
293.89***
(13.00)
32.15***
(5.82)

108580.6
108586.6
108609.0

107460.1
107472.1
107516.9

107388.3
107404.3
107464.1

77.93***
(7.71)
106567.3
106587.3
106662.1

Note. Standard errors are in parenthesis. a = unconditional means model; b = Unconditional linear growth model; c =
Stratified linear growth model; d = Discontinuous slope model, using linear time throughout the course of treatment
and natural log of time after the first signal warning; e = Discontinuous intercept and slope model; f = Stratified
discontinuous intercept and slope model; g = natural log transformation of number of sessions attended by not-ontrack patients centered on NOT sample mean; h = elevation in intercept at the time of first signal warning; i = rate of
change after the first warning signal event; j = natural log transformation of number of sessions attended after first
signal warning by not-on-track (NOT) patients centered on NOT sample mean. ** p < .01, *** p < .001.
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Table 28
Comparison of Alternative Linear Models of Change Based on Natural Log Transformed Time (Efficacy Sample)

Model Aa

Parameter
Initial
Status

Intercept

77.58***
(0.52)

#Sessionsg

Model
Model
B.2b
C.2c
Fixed effects
82.53***
82.19***
(0.66)
(0.66)
-0.57
(1.11)

Model
D.2d

Model
E.2e

Model
F.2f

80.92***
(0.58)

77.66***
(0.58)

77.74***
(0.58)

0.06
(0.08)

10.73***
(0.41)
-0.19***
(0.05)

11.23***
(0.42)
-0.25***
(0.05)

-4.47***
(0.47)

-8.10***
(0.41)

-8.72***
(0.41)

Signalh
Rate of
change

Session
LgSession

-3.15 ***
(0.29)

-2.85***
(0.30)

LgSessionPWi
Session
×#Sessions
SessionPW
×#SessionsPWj
Level 1

Within-person

Level 2

Initial status

-1.70**
(0.53)
3.50***
(0.54)
183.63***
(2.70)
244.21***
(12.18)

Random effects
149.63*** 149.42***
(2.32)
(2.31)
329.24*** 328.82***
(18.88)
(18.87)

133.24***
(2.11)
285.19***
(14.96)

Signal
Session

122.38***
(1.98)
278.46***
(14.83)
34.18***
(7.00)

57.38***
(4.90)
82376.7
82398.7
82478.2

50.84***
(1.54)
82336.5
82360.5
82447.3

1.11***
(0.21)

LgSession

47.62***
(3.72)

47.85***
(3.72)

LgSesssionPW
-2 log likelihood
AIC
BIC

122.33***
(1.98)
279.20***
(14.85)
32.51***
(6.93)

84875.7
84881.7
84903.4

83842.9
83854.9
83898.3

83823.5
83839.5
83897.3

76.39***
(8.50)
83139.3
83159.3
83231.7

Note. Standard errors are in parenthesis. a = unconditional means model; b = Unconditional linear growth model; c =
Stratified linear growth model; d = Discontinuous slope model, using linear time throughout the course of treatment
and natural log of time after the first signal warning; e = Discontinuous intercept and slope model; f = Stratified
discontinuous intercept and slope model; g = natural log transformation of number of sessions attended by not-ontrack patients centered on NOT sample mean; h = elevation in intercept at the time of first signal warning; i = rate of
change after the first warning signal event; j = natural log transformation of number of sessions attended after first
signal warning by not-on-track (NOT) patients centered on NOT sample mean. ** p < .01, *** p < .001.
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Table 29
Comparison of Alternative Linear Models of Change Based on Natural Log Transformed Time (ITT Sample without
Last Observation Carried Forward Method)

Model Aa

Parameter
Initial
Status

Intercept

77.96***
(0.45)

#Sessionsg

Model
Model
B.2b
C.2c
Fixed effects
82.09***
81.44***
(0.57)
(0.59)
-1.17
(0.90)

Model
D.2d

Model
E.2e

Model
F.2f

80.57***
(0.50)

77.52***
(0.50)

77.61***
(0.50)

0.12
(0.07)

10.71***
(0.34)
-0.18***
(0.04)

11.32***
(0.35)
-0.26***
(0.05)

-4.86***
(0.43)

-8.43***
(0.38)

-9.18***
(0.37)

Signalh
Rate of
change

Session
LgSession

-2.79***
(0.26)

-2.53***
(0.26)

LgSessionPWi
Session
×#Sessions
SessionPW
×#SessionsPWj
Level 1

Within-person

Level 2

Initial status

-1.74***
(0.44)
5.20***
(0.51)
179.05***
(2.37)
253.94***
(10.77)

Random effects
148.46*** 148.07***
(2.07)
(2.06)
364.57*** 345.81***
(16.89)
(16.87)

131.40***
(1.87)
301.79***
(13.33)

Signal
Session

119.86***
(1.75)
291.05***
(12.96)
26.07***
(5.67)

66.50***
(5.10)
103147.1
103169.1
103251.2

56.88***
(4.55)
103047.6
103071.6
103161.1

2.84***
(0.59)

LgSession

46.04***
(3.29)

46.64***
(3.30)

LgSesssionPW
-2 log likelihood
AIC
BIC

120.15***
(1.76)
292.09***
(13.00)
24.84***
(5.63)

106201.7
106207.7
106230.1

105082.2
105094.2
105138.9

105046.4
105062.4
105122.1

82.76***
(8.19)
104167.2
104187.2
104261.8

Note. Standard errors are in parenthesis. a = unconditional means model; b = Unconditional linear growth model; c =
Stratified linear growth model; d = Discontinuous slope model, using linear time throughout the course of treatment
and natural log of time after the first signal warning; e = Discontinuous intercept and slope model; f = Stratified
discontinuous intercept and slope model; g = natural log transformation of number of sessions attended by not-ontrack patients centered on NOT sample mean; h = elevation in intercept at the time of first signal warning; i = rate of
change after the first warning signal event; j = natural log transformation of number of sessions attended after first
signal warning by not-on-track (NOT) patients centered on NOT sample mean. ** p < .01, *** p < .001.
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Table 30
Comparison of Alternative Linear Models of Change Based on Natural Log Transformed Time (Efficacy Sample
without Last Observation Carried Forward Method)

Model Aa

Parameter
Initial
Status

Intercept

77.43***
(0.52)

#Sessionsg

Model
Model
B.2b
C.2c
Fixed effects
82.68**
82.41***
(0.66)
(0.66)
-0.85
(1.11)

Model
D.2d

Model
E.2e

Model
F.2f

80.84***
(0.58)

77.62***
(0.58)

77.73***
(0.58)

0.07
(0.08)

10.56***
(0.41)
-0.18***
(0.05)

11.16***
(0.41)
-0.26***
(0.05)

-4.83***
(0.47)

-8.30***
(0.41)

-9.26***
(0.41)

Signalh
Rate of
change

Session
Intercept

-3.41***
(0.30)

-3.17***
(0.31)

SessionPWi
Session
×#Sessions
SessionPW
×#SessionsPWj
Level 1

Within-person

Level 2

Initial status

-1.08***
(0.54)
4.88***
(0.56)
184.12***
(2.37)
242.11***
(12.14)

Random effects
150.38*** 150.23***
(2.33)
(2.33)
326.37*** 325.75***
(18.88)
(18.86)

133.36***
(2.12)
281.75***
(14.83)

Signal
Session

123.10***
(1.99)
276.61***
(14.77)
28.92***
(6.79)

58.66***
(5.04)
81572.8
81594.8
51674.3

50.97***
(4.56)
81500.9
81524.9
81611.6

1.08***
(0.21)

LgSession

46.09***
(3.67)

46.64***
(3.68)

LgSesssionPW
-2 log likelihood
AIC
BIC

123.28***
(2.00)
277.57***
(14.81)
27.88***
(6.75)

84034.0
84040.0
84061.7

83002.0
83014.0
83057.4

82992.2
83008.2
83066.0

78.60***
(8.68)
82289.2
82309.2
82381.5

Note. Standard errors are in parenthesis. a = unconditional means model; b = Unconditional linear growth model; c =
Stratified linear growth model; d = Discontinuous slope model, using linear time throughout the course of treatment
and natural log of time after the first signal warning; e = Discontinuous intercept and slope model; f = Stratified
discontinuous intercept and slope model; g = natural log transformation of number of sessions attended by not-ontrack patients centered on NOT sample mean; h = elevation in intercept at the time of first signal warning; i = rate of
change after the first warning signal event; j = natural log transformation of number of sessions attended after first
signal warning by not-on-track (NOT) patients centered on NOT sample mean. ** p < .01, *** p < .001.
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Table 31
Comparison of Discontinuous Intercept and Slope Models (Symptom Distress Subscale)
Model F.1a

Parameter

Model F.2b

Fixed effects
Initial Status
Intercept

46.83*** (0.35)

46.32*** (0.34)

Signalc

6.93*** (0.26)

7.02*** (0.25)

-1.03*** (0.07)

-0.41*** (0.05)

Rate of change
Sessiond
SessionPWe

-1.04*** (0.10)
f

-4.97*** (0.27)

LgSessionPW

SessionPW × #SessionsPW

1.71*** (0.11)

3.56*** (0.33)

Random effects
Level 1
Within-person

49.06*** (0.74)

46.95*** (0.72)

Initial status

142.61*** (6.47)

138.37*** (6.16)

Signal

21.70*** (3.06)

21.17*** (3.06)

Session

0.67***

(0.12)

0.76*** (0.12)

SessionPW

1.53***

(0.29)

Level 2

LgSesssionPW

27.56*** (3.26)

-2 log likelihood

90424.7

90006.8

AIC

90456.7

90038.8

BIC

90575.7

90157.8

Note: Standard errors are in parenthesis. a = stratified discontinuous intercept and slope model, using linear time
from intake to termination and another linear time from the first warning signal event to termination; b = stratified
discontinuous intercept and slope model, using linear time from intake to termination and an additional slope from
the time of first signal warning to termination; a = natural log transformation of the number of post-warning sessions
(session-1) centered on NOT patient mean; b = rate of change as a function of session number after the first signal
warning event; c = time variant indicating if a given observation occurred before or after the first signal warning; d =
session number; session number after the first warning; natural log transformation of session numbers after the first
signal warning event. ** p < .01, *** p < .001.
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Table 32
Comparison of Discontinuous Intercept and Slope Models (Interpersonal Relations Subscale)
Parameter

Model F.1a

Model F.2b

Fixed effects
Initial Status
Intercept

16.75*** (0.15)

16.63*** (0.15)

2.74*** (0.12)

2.87*** (0.12)

Sessiond

-0.26*** (0.03)

-0.12*** (0.03)

SessionPWe

-0.40*** (0.05)

Signal

c

Rate of change

LgSessionPWf
SessionPW × #SessionsPW

-1.62*** (0.12)
0.54*** (0.05)

1.23*** (0.14)

Random effects
Level 1
Within-person

10.12*** (0.15)

9.66*** (0.15)

Initial status

26.93*** (1.25)

26.12*** (1.18)

Signal

3.59*** (0.67)

5.04*** (0.66)

Session

0.16*** (0.04)

0.15*** (0.03)

SessionPW

0.37*** (0.07)

Level 2

LgSesssionPW

6.28*** (0.71)

-2 log likelihood

70389.4

70117.6

AIC

70421.4

70149.6

BIC

70540.4

70268.7

Note: Standard errors are in parenthesis. a = stratified discontinuous intercept and slope model, using linear time
from intake to termination and another linear time from the first warning signal event to termination; b = stratified
discontinuous intercept and slope model, using linear time from intake to termination and an additional slope from
the time of first signal warning to termination; a = natural log transformation of the number of post-warning sessions
(session-1) centered on NOT patient mean; b = rate of change as a function of session number after the first signal
warning event; c = time variant indicating if a given observation occurred before or after the first signal warning; d =
session number; session number after the first warning; natural log transformation of session numbers after the first
signal warning event. ** p < .01, *** p < .001.
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Table 33
Comparison of Discontinuous Intercept and Slope Models (Social role performance Subscale)
Model F.1a

Parameter

Model F.2b

Fixed effects
Initial Status
Intercept

14.94*** (0.11)

14.87*** (0.11)

Signalc

1.94*** (0.10)

2.20*** (0.09)

-0.17*** (0.03)

-0.08*** (0.02)

Rate of change
Sessiond
SessionPWe

-0.39*** (0.04)
f

-1.52*** (0.10)

LgSessionPW

SessionPW × #SessionsPW

0.41*** (0.03)

0.76*** (0.11)

Random effects
Level 1
Within-person

7.29*** (0.11)

7.05*** (0.11)

Initial status

12.64*** (0.63)

12.32*** (0.60)

Signal

2.21*** (0.40)

2.22*** (0.40)

Session

0.07*** (0.02)

0.08*** (0.01)

SessionPW

0.24*** (0.04)

Level 2

LgSesssionPW

3.30*** (0.45)

-2 log likelihood

65392.7

65145.2

AIC

65424.7

65177.2

BIC

65543.7

65296.2

Note: Standard errors are in parenthesis. a = stratified discontinuous intercept and slope model, using linear time
from intake to termination and another linear time from the first warning signal event to termination; b = stratified
discontinuous intercept and slope model, using linear time from intake to termination and an additional slope from
the time of first signal warning to termination; a = natural log transformation of the number of post-warning sessions
(session-1) centered on NOT patient mean; b = rate of change as a function of session number after the first signal
warning event; c = time variant indicating if a given observation occurred before or after the first signal warning; d =
session number; session number after the first warning; natural log transformation of session numbers after the first
signal warning event. ** p < .01, *** p < .001.

139
Table 34
Multilevel Analyses of Rate of Change in OQ Total Scale Scores after First Signal Warning by Feedback Treatment
Conditions Based on Linear Time (ITT Analysis)
Parameter

Model G

Model H.1

Model I.1

84.62** (0.44)

86.67** (0.96)

Fixed effects
Initial Status
Intercept (TAU)

79.43** (0.46)

CST Fb

-1.64

(1.23)

P/T Fb

-2.30

(1.42)

-1.06

(1.22)

Fb
#SessionsPW-1

a

-1.90** (0.62)

Rate of changeb
Intercept (TAU)

-2.26** (0.10)

-2.90** (0.23)

SessionPW (CST Fb)

-0.67* (0.27)

SessionPW (P/T Fb)

-0.52 (0.31)

SessionPW (Fb)

-0.55* (0.28)

#SessionsPW-1

2.86** (0.18)
Random effects

Level 1
Within-person

191.50** (3.20)

135.17** (2.44)

133.78** (2.40)

237.17** (11.05)

203.70** (10.25)

201.56** (10.06)

4.92**

3.33** (0.36)

Level 2
Initial status
Rate of change after warning

(0.50)

-2 log likelihood

71345.9

69682.7

69423.6

AIC

71351.9

69694.7

69451.6

BIC

71373.0

69737.0

69550.3

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of session number after the first signal warning event.
* < .05, ** < .01
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Table 35
Multilevel Analyses of Rate of Change in OQ Total Scale Scores after First Signal Warning by Feedback Treatment
Conditions Based on Log Transformation of Time (ITT Analysis)
Parameter

Model G

Model H.2

Model I.2

87.79** (0.45)

89.03** (0.98)

Fixed effects
Initial Status
Intercept (TAU)

79.43** (0.46)

CST Fb

-1.23 (1.27)

P/T Fb

-1.25 (1.47)

Fb
#SessionsPW-1

a

-0.61

(1.25)

-0.64

(.63)

Rate of change (log)b
Intercept (TAU)

-9.00** (0.33)

-8.61** (0.74)

SessionPW (CST Fb)

-1.95* (0.92)

SessionPW (P/T Fb)

-2.07

SessionPW (Fb)

-1.91* (0.94)

#SessionsPW-1

5.19** (0.54)

(1.05)

Random effects
Level 1
Within-person

191.50** (3.20)

132.06** (2.37)

131.85** (2.36)

237.17** (11.05)

189.85** (10.71)

189.52** (10.67)

58.55** (4.85)

50.88** (4.42)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

71345.9

69333.9

69239.7

AIC

71351.9

69345.9

69267.7

BIC

71373.0

69388.2

69366.4

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of natural log of session number after the first signal warning event.
* < .05, ** < .01
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Table 36
Multilevel Analyses of Rate of Change in OQ Total Scale Scores after First Signal Warning by Feedback Treatment
Conditions Based on Linear Time (Efficacy Analysis)
Parameter

Model G

Model H.1

Model I.1

84.06** (0.51)

86.99** (0.98)

Fixed effects
Initial Status
Intercept (TAU)

78.19** (0.54)

CST Fb

-1.80

P/T Fb

-3.64* (1.53)

Fb
#SessionsPW-1

2.18
a

(1.51)

(1.38)

-1.26 (0.83)

Rate of changeb
Intercept (TAU)

-2.14** (0.10)

-2.82** (0.22)

SessionPW (CST Fb)

-0.79** (0.27)

SessionPW (P/T Fb)

-0.44

(0.29)

SessionPW (Fb)

-0.49

(0.28)

#SessionsPW-1

2.66** (0.19)
Random effects

Level 1
Within-person

192.48** (3.48)

136.84** (2.67)

135.77** (2.63)

236.39** (12.67)

197.06** (11.61)

195.56** (11.41)

4.23**

2.83**

Level 2
Initial status
Rate of change after warning

(0.47)

-2 log likelihood

59275.0

57875.1

57672.0

AIC

59281.0

57887.1

57700.0

BIC

59301.5

57928.3

57796.1

(0.34)

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of session number after the first signal warning event.
* < .05, ** < .01
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Table 37
Multilevel Analyses of Rate of Change in OQ Total Scale Scores after First Signal Warning by Feedback Treatment
Conditions Based on Log Transformed Time (Efficacy Analysis)
Parameter

Model G

Model H.2

Model I.2

87.80** (0.53)

89.28** (1.00)

Fixed effects
Initial Status
Intercept (TAU)

78.19** (0.54)

CST Fb

-0.39

(1.55)

P/T Fb

-2.32

(1.59)

-1.42

(1.42)

-0.22

(0.85)

Fb
#SessionsPW-1

a

Rate of change (log)b
Intercept (TAU)

-8.90** (0.34)

-8.56** (0.72)

SessionPW (CST Fb)

-3.00** (0.98)

SessionPW (P/T Fb)

-1.83

(1.04)

SessionPW (Fb)

-1.74

(0.97)

#SessionsPW-1

4.83** (0.61)
Random effects

Level 1
Within-person

192.48** (3.48)

133.59** (2.58)

133.59** (2.57)

236.39** (12.67)

180.80** (12.15)

179.85** (12.08)

51.78** (4.79)

45.01

Level 2
Initial status
Rate of change after warning
-2 log likelihood

59275.0

57565.8

57495.1

AIC

59281.0

57577.8

57523.1

BIC

59301.5

57619.0

57619.2

(4.38)

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of natural log of session number after the first signal warning event.
* < .05, ** < .01
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Table 38
Results of Analysis of Rate of Change on OQ Symptom Distress (SD) Subscale Scores after First Signal Warning by
Feedback Treatment Conditions Based on Linear Time (ITT analysis)
Parameter

Model G

Model H.1

Model I.1

49.82** (0.31)

50.72** (0.67)

Fixed effects
Initial Status
Intercept (TAU)

46.71** (0.31)

CST Fb

-0.47

(0.85)

P/T Fb

-0.88

(0.99)

-0.05

(0.85)

-0.78

(0.43

Fb
#SessionsPW-1

a

Rate of changeb
Intercept (TAU)

-1.31** (0.07)

-1.74** (0.15)

SessionPW (CST Fb)

-0.41* (0.17)

SessionPW (P/T Fb)

-0.29

SessionPW (Fb)

-0.38* (0.18)

#SessionsPW-1

1.70** (0.11)

(0.19)

Random effects
Level 1
Within-person

78.00** (1.32)

55.73** (1.01)

55.25** (1.00)

109.20** (5.03)

100.04** (4.88)

99.96** (4.84)

1.84** (0.19)

1.26** (0.14)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

62408.4

60882.8

60659.0

AIC

62414.4

60894.8

60687.0

BIC

62435.5

60937.0

60785.3

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of session number after the first signal warning event.
* < .05, ** < .01
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Table 39
Results of Analysis of Rate of Change on OQ Symptom Distress (SD) Subscale Scores after First Signal Warning by
Feedback Treatment Conditions Based on Log Transformed Time (ITT analysis)
Parameter

Model G

Model H.2

Model I.2

51.80** (0.32)

52.24** (0.69)

Fixed effects
Initial Status
Intercept (TAU)

46.71** (0.31)

CST Fb

-0.27 (0.86)

P/T Fb

-0.23 (1.02)

Fb
a

#SessionsPW-1

0.23

(0.88)

0.06

(0.88)

Rate of change (log)b
Intercept (TAU)

-5.51** (0.21)

-5.32** (0.48)

SessionPW (CST Fb)

-1.10

(0.60)

SessionPW (P/T Fb)

-1.13

(0.68)

SessionPW (Fb)

-1.26* (0.61)

#SessionsPW-1

3.04** (0.35)
Variance components

Level 1
Within-person

78.00** (1.32)

54.22** (0.99)

54.14** (0.98)

109.20** (5.03)

97.63** (5.20)

97.90** (5.20)

23.81** (1.99)

21.11** (1.84)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

62408.4

60575.1

50494.6

AIC

62414.4

60587.1

60522.6

BIC

62435.5

60629.3

60620.9

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of natural log of session number after the first signal warning event.
* < .05, ** < .01
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Table 40
Results of Analysis of Rate of Change on OQ Symptom Distress (SD) Subscale Scores after First Signal Warning by
Feedback Treatment Conditions Based on Linear Time (Efficacy analysis)
Parameter

Model G

Model H.1

Model I.1

49.46** (0.36)

50.95** (0.68)

Fixed effects
Initial Status
Intercept (TAU)

45.88** (0.37)

CST Fb

-0.76

(1.06)

P/T Fb

-1.78

(1.07)

-0.77

(0.96)

-0.34

(0.58)

Fb
#SessionsPW-1

a

Rate of changeb
Intercept (TAU)

-1.31** (0.07)

-1.71*** (0.14)

SessionPW (CST Fb)

-0.49** (0.17)

SessionPW (P/T Fb)

-0.24

SessionPW (Fb)

-0.36* (0.18)

#SessionsPW-1

1.60** (0.12)

(0.19)

Random effects
Level 1
Within-person

78.50** (1.43)

56.16** (2.44)

55.81** (1.20)

109.43** (5.80)

98.36** (5.60)

98.44** (5.56)

1.64** (0.19)

1.11** (0.14)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

51721.4

50418.8

50241.6

AIC

51727.4

50430.8

50269.6

BIC

51747.9

50471.9

50365.3

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of session number after the first signal warning event.
* < .05, ** < .01
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Table 41
Results of Analysis of Rate of Change on OQ Symptom Distress (SD) Subscale Scores after First Signal Warning by
Feedback Treatment Conditions Based on Log Transformation of Time (Efficacy analysis)
Parameter

Model G

Model H.2

Model I.2

51.81** (0.37)

52.42** (0.71)

Fixed effects
Initial Status
Intercept (TAU)

45.88** (0.37)

CST Fb

0.24

P/T Fb

-0.97 (1.12)

Fb
#SessionsPW-1

(1.10)

-0.28 (1.00)
a

-0.40 (0.60)

Rate of change (log)b
Intercept (TAU)

-5.52** (0.23)

-5.30** (0.48)

SessionPW (CST Fb)

-1.78** (0.64)

SessionPW (P/T Fb)

-0.98

(0.68)

SessionPW (Fb)

-1.21

(0.63)

#SessionsPW-1

2.85** (0.40)
Variance components

Level 1
Within-person

78.50** (1.43)

54.49** (1.07)

54.49** (1.07)

109.43** (5.80)

95.96** (6.01)

95.86** (6.00)

21.96** (2.02)

19.51** (1.88)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

51721.4

50137.4

50076.8

AIC

51727.4

50149.4

50104.8

BIC

51747.9

50190.4

50200.5

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of natural log of session number after the first signal warning event.
* < .05, ** < .01
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Table 42
Results of Analysis of Rate of Change on OQ Interpersonal Relations (IR) Subscale Scores after First Signal
Warning by Feedback Treatment Conditions Based on Linear Time (ITT analysis)
Parameter

Model G

Model H.1

Model I.1

18.47** (0.14)

19.17** (0.31)

Fixed effects
Initial Status
Intercept (TAU)

17.53** (0.14)

CST Fb

-0.67

(0.40)

P/T Fb

-0.62

(0.46)

-0.57

(0.40)

-0.28

(0.20)

Fb
#SessionsPW-1

a

Rate of changeb
Intercept (TAU)

-0.41** (0.03)

-0.52** (0.06)

SessionPW (CST Fb)

-0.22* (0.07)

SessionPW (P/T Fb)

-0.16* (0.08)

SessionPW (Fb)

-0.14

#SessionsPW-1

0.59** (0.05)

(0.08)

Random effects
Level 1
Within-person

14.35** (0.24)

11.23** (0.20)

11.16** (0.20)

22.40** (1.02)

22.17** (1.07)

20.04** (1.05)

0.28** (0.03)

0.22** (0.03)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

48472.1

47528.0

47372.5

AIC

48478.1

47540.0

47400.5

BIC

48499.2

47582.2

47498.8

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of session number after the first signal warning event.
* < .05, ** < .01
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Table 43
Results of Analysis of Rate of Change on OQ Interpersonal Relations (IR) Subscale Scores after First Signal
Warning by Feedback Treatment Conditions Based on Log Transformation of Time (ITT analysis)
Parameter

Model G

Model H.2

Model I.2

51.80** (0.32)

52.24** (0.69)

Fixed effects
Initial Status
Intercept (TAU)

46.71** (0.31)

CST Fb

-0.27 (0.86)

P/T Fb

-0.23 (1.02)

Fb
a

#SessionsPW-1

0.23

(0.88)

0.06

(0.88)

Rate of change (log)b
Intercept (TAU)

-5.51** (0.21)

-5.32** (0.48)

SessionPW (CST Fb)

-1.10

(0.60)

SessionPW (P/T Fb)

-1.13

(0.68)

SessionPW (Fb)

-1.26* (0.61)

#SessionsPW-1

3.04** (0.35)
Variance components

Level 1
Within-person

78.00** (1.32)

54.22** (0.99)

54.14** (0.98)

109.20** (5.03)

97.63** (5.20)

97.90** (5.20)

23.81** (1.99)

21.11** (1.84)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

62408.4

60575.1

50494.6

AIC

62414.4

60587.1

60522.6

BIC

62435.5

60629.3

60620.9

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of natural log of session number after the first signal warning event.
* < .05, ** < .01
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Table 44
Results of Analysis of Rate of Change on OQ Interpersonal Relations (IR) Subscale Scores after First Signal
Warning by Feedback Treatment Conditions Based on Linear Time (Efficacy Analysis)
Parameter

Model G

Model H.1

Model I.1

18.47** (0.17)

19.27** (0.32)

Fixed effects
Initial Status
Intercept (TAU)

17.37** (0.17)

CST Fb

-0.58

P/T Fb

-1.06*

Fb
#SessionsPW-1

a

(0.50)
(0.51)

-0.71

(0.46)

-0.18

(0.28)

Rate of changeb
Intercept (TAU)

-0.39** (0.03)

-0.50** (0.06)

SessionPW (CST Fb)

-0.25** (0.08)

SessionPW (P/T Fb)

-0.14 (0.08)

SessionPW (Fb)

-0.14

#SessionsPW-1

0.53** (0.05)

(0.08)

Random effects
Level 1
Within-person

14.63** (0.27)

11.50** (0.23)

11.48** (0.23)

23.52** (1.23)

22.14** (1.29)

22.99** (1.27)

0.25** (0.03)

0.20** (0.03)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

40253.9

39464.8

39348.0

AIC

40259.9

39476.8

39376.0

BIC

40280.4

39517.8

39471.8

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of session number after the first signal warning event.
* < .05, ** < .01
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Table 45
Results of Analysis of Rate of Change on OQ Interpersonal Relations (IR) Subscale Scores after First Signal
Warning by Feedback Treatment Conditions Based on Log Transformation of Time (Efficacy Analysis).
Parameter

Model G

Model H.2

Model I.2

19.18** (0.18)

19.64** (0.34)

Fixed effects
Initial Status
Intercept (TAU)

17.37** (0.17)

CST Fb

-0.13 (0.53)

P/T Fb

-0.84 (0.54)

Fb
#SessionsPW-1

a

-0.52

(0.49)

-0.52

(0.49)

Rate of change (log)b
Intercept (TAU)

-1.69** (0.10)

-1.53** (0.21)

SessionPW (CST Fb)

-0.94** (0.29)

SessionPW (P/T Fb)

-0.43

(0.30)

SessionPW (Fb)

-0.43

(0.28)

#SessionsPW-1

1.08** (0.18)
Random effects

Level 1
Within-person

14.63** (0.27)

11.27** (0.22)

11.28** (0.22)

23.52** (1.23)

23.82** (1.43)

23.68** (1.42)

4.09** (0.39)

3.72** (0.37)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

40253.9

39299.7

39248.6

AIC

40259.9

39311.7

39276.6

BIC

40280.4

39352.7

39372.4

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of natural log of session number after the first signal warning event.
* < .05, ** < .01
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Table 46
Results of Analysis of Linear Rate of Change on OQ Social role performance (SR) Subscale Scores after First Signal
Warning by Feedback Treatment Conditions Based on Linear Time (ITT analysis)
Parameter

Model G

Model H.1

Model I.1

16.13** (0.10)

16.68** (0.21)

Fixed effects
Initial Status
Intercept (TAU)

15.21** (0.10)

CST Fb

-0.56* (0.27)

P/T Fb

-0.68* (0.32)

Fb
#SessionsPW-1

-0.53
a

(0.27)

-0.70** (0.14)

Rate of changeb
Intercept (TAU)

-0.37** (0.02)

-0.52** (0.05)

SessionPW (CST Fb)

-0.08

(0.06)

SessionPW (P/T Fb)

-0.08

(0.08)

SessionPW (Fb)

-0.06

(0.08)

#SessionsPW-1

0.43** (0.04)
Random effects

Level 1
Within-person

9.82** (0.17)

7.84** (0.14)

7.80** (0.14)

9.84** (0.48)

9.57** (0.51)

9.08** (0.50)

0.14** (0.02)

0.11** (0.01)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

44842.0

43864.4

43693.2

AIC

44848.0

43876.4

43721.2

BIC

44869.1

43918.6

43819.5

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of session number after the first signal warning event.
* < .05, ** < .01
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Table 47
Results of Analysis of Log Linear Rate of Change on OQ Social role performance (SR) Subscale Scores after First
Signal Warning by Feedback Treatment Conditions Based on Log Transformation of Time (ITT analysis)
Parameter

Model G

Model H.2

Model I.2

16.74** (0.10)

17.10** (0.23)

Fixed effects
Initial Status
Intercept (TAU)

15.21** (0.10)

CST Fb

-0.50 (0.29)

P/T Fb

-0.40 (0.34)

Fb
#SessionsPW-1

-0.44
a

(0.29)

-0.46** (0.14)

Rate of change (log)b
Intercept (TAU)

-1.58** (0.07)

-1.55** (0.16)

SessionPW (CST Fb)

-0.17

(0.20)

SessionPW (P/T Fb)

-0.46* (0.23)

SessionPW (Fb)

-0.26

#SessionsPW-1

0.78** (0.12)

(0.21)

Random effects
Level 1
Within-person

9.82** (0.17)

7.69** (0.14)

7.69** (0.14)

9.84** (0.48)

9.46** (0.60)

9.20** (0.60)

2.17** (0.21)

1.97** (0.20)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

44842.0

43638.1

43580.5

AIC

44848.0

43650.1

43608.5

BIC

44869.1

43692.2

43706.8

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of natural log of session number after the first signal warning event.
* < .05, ** < .01
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Table 48
Results of Analysis of Rate of Change on OQ Social role performance (SR) Subscale Scores after First Signal
Warning by Feedback Treatment Conditions Based on Linear Time (Efficacy Analysis)
Parameter

Model G

Model H.1

Model I.1

15.99** (0.11)

16.71** (0.22)

Fixed effects
Initial Status
Intercept (TAU)

14.96** (0.11)

CST Fb

-0.71* (0.33)

P/T Fb

-0.76* (0.34)

Fb
#SessionsPW-1

-0.62* (0.31)
a

-0.70* (0.14)

Rate of changeb
Intercept (TAU)

-0.34** (0.02)

-0.51** (0.05)

SessionPW (CST Fb)

-0.06

(0.06)

SessionPW (P/T Fb)

-0.07

(0.06)

SessionPW (Fb)

-0.04

(0.06)

#SessionsPW-1

0.41** (0.04)
Random effects

Level 1
Within-person

9.84** (0.18)

7.94** (0.16)

7.90** (0.15)

9.66** (0.54)

9.37** (0.59)

8.85** (0.56)

0.12** (0.02)

0.09** (0.01)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

37120.9

36324.2

36189.8

AIC

37126.9

36336.2

36217.8

BIC

37127.4

36377.2

36313.6

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of session number after the first signal warning event.
* < .05, ** < .01
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Table 49
Results of Analysis of Rate of Change on OQ Total Scale Scores after First Signal Warning by Feedback Treatment
Conditions Based on Log Transformation of Time (Efficacy Analysis)
Parameter

Model G

Model H.2

Model I.2

16.7** (0.12)

17.12** (0.23)

Fixed effects
Initial Status
Intercept (TAU)

14.96** (0.11)

CST Fb

-0.52 (0.36)

P/T Fb

-0.41 (0.37)

Fb
#SessionsPW-1

-0.48
a

(0.37)

-0.46** (0.33)

Rate of change (log)b
Intercept (TAU)

-1.56** (0.07)

-1.54** (0.16)

SessionPW (CST Fb)

-0.29 (0.21)

SessionPW (P/T Fb)

-0.44 (0.23)

SessionPW (Fb)

-0.22

#SessionsPW-1

0.72** (0.13)

(0.21)

Random effects
Level 1
Within-person

9.84** (0.18)

7.78** (0.15)

7.78** (0.15)

9.66** (0.54)

9.33** (0.66)

9.05** (0.65)

1.93** (0.22)

1.74** (0.21)

Level 2
Initial status
Rate of change after warning
-2 log likelihood

37120.9

36135.3

36092.4

AIC

37126.9

36147.3

36120.4

BIC

37127.4

36188.3

36216.2

Note: a = natural log transformation of the number of post-warning sessions (session-1) centered on NOT patient
mean; b = rate of change as a function of natural log of session number after the first signal warning event.
* < .05, ** < .01
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Deterioration occurred in total
scale and:
SD scale only
n = 105 (43%)
Deterioration occurred in:

Total scale
deterioration
n = 309

Both SD & IR
n = 30 (12%)

Total scale only
n = 66 (21%)

Both SD & SR
n = 33 (14%)

Both total scale
& subscale
n = 243 (79%)

IR scale only
n = 24 (10%)
Both IR & SR
n = 4 (2%)
SR scale only
n = 24 (10%)
All subscales
n = 23 (10%)

No change in all subscales
n = 3046 (85%)

Total scale no
change
n = 3578

Deterioration in subscale
n = 166 (5%)

Deterioration in SD (n = 67; 40%); IR
(n = 59; 36%); SR (n = 46; 28%)

Improvement in subscale
n = 337 (9%)

Improvement in SD (n = 265; 79%);
IR (n = 46; 14%); SR (n = 47; 14%)

Both det. & imp. in
subscale
n = 29 (1%)

Improvement occurred in total
scale and:

Improvement occurred in:

Total scale
improvement
n = 2157

Total scale only
n = 207 (10%)
Both total scale &
subscale
n = 1950 (90%)

SD scale only
n = 941 (49%)
Both SD & IR
n = 335 (17%)
Both SD & SR
n = 305 (16%)
IR scale only
n = 57 (3%)
Both IR & SR
n = 5 (<1%)
SR scale only
n = 40 (2%)
All subscales
n = 267 (14%)

Figure 1.
Breakdown of clinical significance match between the total scale and subscales.
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Appendix B
Calculation of Effect Sizes and Standard Errors
Effect Sizes: Post Treatment Score Comparison
Hedge’s standardized mean difference (g) for mean post-test OQ scores and mean session
attendance comparisons is calculated as the following (Comprehensive Meta-Analysis Version 2;
Hedges, 1981):
1. Calculate standardized difference in means (d) by dividing the raw score difference in means
by pooled standard deviation of two samples (M1 – M2) in comparison: d = (M1 – M2)/spooled
where spooled is calculated by using the following formula:
𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 = �

(𝑛𝑛 1 − 1)× 𝑠𝑠12 +(𝑛𝑛 2 −1)×𝑠𝑠22
(𝑛𝑛 1 + 𝑛𝑛 2 − 2)

.

(1)

where n1 and n2 represent the sample sizes of samples 1 and 2, and s1 and s2 represent the
standard deviations of samples 1 and 2.
2. Compute correction factor J for correcting bias: J = 1 – [3/(4df – 1)], where df is given by
df =n1 + n2 − 2 .

(2)

3. Compute Hedge’s standardized mean difference (g) by multiplying d by a correction factor
(J): 𝑔𝑔 = 𝑑𝑑 × 𝐽𝐽.

(3)

Standard Errors

1. Obtain standard error for standard difference in means (d):
𝑆𝑆𝑆𝑆 (𝑑𝑑 ) = �

1

𝑛𝑛 1

+

1

𝑛𝑛 2

+ 2(𝑛𝑛

𝑑𝑑 2

1 +𝑛𝑛 2 )

.

(4)

2. Correct for bias by multiplying standard error of standardized mean difference by a
correction factor J:
𝑆𝑆𝑆𝑆 (𝑔𝑔) = 𝑆𝑆𝑆𝑆(𝑑𝑑 ) × 𝐽𝐽 .

(5)
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Effect Sizes: Pre-Post Change Score per Group
1. Obtain independent standardized mean difference between pre-treatment and post-treatment
(dpre-post) by:

𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 =

(

(𝑀𝑀𝑝𝑝𝑝𝑝𝑝𝑝 − 𝑀𝑀𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 )
𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

�2 (1− 𝑟𝑟 𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 )

)

(6)

where (Mpre – Mpost) represents the difference in the mean pre-treatment scores and the mean
post-treatment scores, rpre-post represents the correlation coefficient between the pre-treatment
and post-treatment scores, and spre-post is obtained by
2 + 𝑠𝑠 2
𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 = �𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 − 2 × 𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 × 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝 × 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

(7)

2. Calculate a correction factor J by following equation (2) and apply this correction factor to
dpre-post as obtained by equation (6):
𝑔𝑔𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 = 𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 × 𝐽𝐽 .

(8)

Standard Errors for Pre-Post Change Effect Size
1. Obtain standard error for independent standardized mean difference between pre-treatment
and post-treatment by:
𝑆𝑆𝑆𝑆𝑑𝑑 𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 =

𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
√𝑛𝑛

(9)

2. Correct for bias by applying a correction factor J:
𝑆𝑆𝑆𝑆𝑔𝑔𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 = 𝑆𝑆𝑆𝑆𝑑𝑑 𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 × 𝐽𝐽 .

(10)

Effect Sizes: Pre-Post Change Score Comparison
Effect size for difference in pre-post change scores between two groups is obtained in the
similar manner as for the standard mean difference in post-treatment scores as described
above. In place of formula (1), the following formulae are used.
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Calculate standardized difference in mean change scores (𝑑𝑑𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 ) by dividing the raw score
difference in mean change scores (𝑀𝑀𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 1 − 𝑀𝑀𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 2 ) by pooled standard deviation of
two samples in comparison:

𝑑𝑑𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 = (𝑀𝑀𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 1 − 𝑀𝑀𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 2 )/𝑠𝑠𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 _𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

(11)

where 𝑠𝑠𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 _𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 is given by
𝑠𝑠𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 _𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 = �

2
2
(𝑛𝑛 1 −1)× 𝑠𝑠𝑐𝑐ℎ
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 1 + (𝑛𝑛 2 − 1)× 𝑠𝑠𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 2
(𝑛𝑛 1 + 𝑛𝑛 2 − 2)

and 𝑠𝑠𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 1 and 𝑠𝑠𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 2 are given by

2
2
𝑠𝑠𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 1 = �𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝
1 + 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 1 − 2 × 𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 × 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝 1 × 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 1

(12)

(13)

and

2
2
𝑠𝑠𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 2 = �𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝
2 + 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 2 − 2 × 𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 × 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝 2 × 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 2 .

(14)

In equations (13) and (14), 𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝 −𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 is the weighted mean correlation coefficient between

pre-treatment and post-treatment scores of sample 1 and sample 2. 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝 1 and 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝 2 represent

the pre-treatment standard deviations of samples 1 and 2, and 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 1 and 𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 2 represent the
post-treatment standard deviations of samples 1 and 2.
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Appendix C
Assignment of Random Weight
Random weight and the main effect are calculated as the following (Hedges & Vevea, 1998;
Comprehensive Meta-Analysis, Version 2):
A random weight (w) assigned to each individual study (i) is defined as:
wi =

1
vi∗

(15)

where vi∗ represents the sum of within-study variance study (i) and the between-studies variance
( τ 2 ):
vi∗= vi + τ 2 .

(16)

The mean effect size ( g ) is calculated as:
k

g=

∑w g
i =1
k

i

i

.

∑w
i =1

(17)

i

The variance of the mean effect is defined as the reciprocal of sum of the individual study
weights. Thus, the standard error (SE) of the mean effect is the square root of the sampling
variance:

SE ( g ) =

1
k

∑w
i =1

i

.

(18)
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Appendix D
Detailed Results of Meta-analyses and Forest Plots

Table 1

ITT Analysis of Post-Treatment OQ Score Comparisons (*Fb vs. TAU)
Study name

Statistics for each study
Hedges's
g

Lambert et al., 2001
Lambert et al., 2002
Whipple et al., 2003
Hawkins et al., 2004

-0.38
-0.42
-0.22
0.08
-0.28

Standard
error
0.25
0.13
0.14
0.25
0.09

Hedges's g and 95% CI

p-Value
0.124
0.001
0.106
0.743
0.003
-1.00 -0.50
Favors Fb

*Fb = Feedback group; TAU = Treatment as usual

0.00

0.50

Favors TAU

1.00
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Table 2

Efficacy Analysis of Post-Treatment OQ Score Comparisons (*Fb vs. TAU)
Study name

Statistics for each study
Hedges's
g

Lambert et al., 2001
Lambert et al., 2002
Whipple et al., 2003
Hawkins et al., 2004

-0.32
-0.78
-0.57
-0.18
-0.53

Standard
error
0.28
0.17
0.18
0.28
0.13

Hedges's g and 95% CI

p-Value
0.242
0.000
0.001
0.523
0.000
-1.00 -0.50
Favors Fb

*Fb = Feedback group; TAU = Treatment as usual

0.00

0.50

Favors TAU

1.00
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Table 3

ITT Analysis of Post-Treatment OQ Score Comparisons (*P/T Fb vs. Fb)
Study name

Statistics for each study
Hedges's
g

Hawkins et al., 2004
Harmon et al., 2007
Slade et al, 2008

-0.44
-0.09
-0.12
-0.16

Standard
error
0.24
0.15
0.16
0.10

Hedges's g and 95% CI

p-Value
0.071
0.526
0.430
0.099
-1.00 -0.50
Favors P/T Fb

*P/T Fb = Patient and therapist feedback group; Fb = Feedback group

0.00

0.50
Favors Fb

1.00
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Table 4

Efficacy Analysis of Post-Treatment OQ Score Comparisons (*P/T Fb vs. Fb)
Study name

Statistics for each study
Hedges's
g

Hawkins et al., 2004
Harmon et al., 2007
Slade et al, 2008

-0.39
-0.06
-0.17
-0.16

Standard
error
0.29
0.17
0.17
0.11

Hedges's g and 95% CI

p-Value
0.177
0.734
0.322
0.163
-1.00 -0.50
Favors P/T Fb

*P/T Fb = Patient and therapist feedback group; Fb = Feedback group

0.00

0.50
Favors Fb

1.00
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Table 5

ITT Analysis of Post-Treatment OQ Score Comparisons (*CST Fb vs. Fb)
Study name

Statistics for each study
Hedges's
g

Whipple et al., 2003
Harmon et al., 2007
Slade et al, 2008

-0.15
-0.23
-0.11
-0.16

Standard
error
0.17
0.13
0.14
0.08

Hedges's g and 95% CI

p-Value
0.368
0.094
0.415
0.048
-1.00 -0.50
Favors CST Fb

*CST Fb = Clinical Support Tools feedback group; Fb = Feedback group

0.00

0.50
Favors Fb

1.00
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Table 6

Efficacy Analysis of Post-Treatment OQ Score Comparisons (*CST Fb vs. Fb)
Study name

Statistics for each study
Hedges's
g

Whipple et al., 2003
Harmon et al., 2007
Slade et al, 2008

0.11
-0.32
-0.26
-0.19

Standard
error
0.22
0.17
0.16
0.12

Hedges's g and 95% CI

p-Value
0.606
0.053
0.110
0.113
-1.00 -0.50
Favors CST Fb

*CST Fb = Clinical Support Tools feedback group; Fb = Feedback group

0.00

0.50
Favors Fb

1.00
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Table 7

ITT Analysis of Odds of Clinically Significant Worsening (*Fb vs. TAU)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Lambert et al., 2001
Lambert et al., 2002
Whipple et al., 2003
Hawkins et al., 2004

0.21
0.72
0.67
0.33
0.62

0.04
0.39
0.32
0.03
0.40

1.09
1.36
1.42
3.40
0.98

0.063
0.315
0.294
0.354
0.040
0.01

0.1
Favors Fb

*Fb = Feedback group; TAU = Treatment as usual

1

10
Favors TAU

100
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Table 8

Efficacy Analysis of Odds of Clinically Significant Worsening (*Fb vs. TAU)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Lambert et al., 2001
Lambert et al., 2002
Whipple et al., 2003
Hawkins et al., 2004

0.34
0.60
0.21
0.51
0.44

0.06
0.25
0.05
0.05
0.23

1.84
1.41
0.94
5.26
0.85

0.212
0.238
0.041
0.571
0.015
0.01

0.1
Favors Fb

*Fb = Feedback group; TAU = Treatment as usual

1

10
Favors TAU

100
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Table 9

ITT Analysis of Odds of Clinically Significant Improvement (*Fb vs. TAU)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Lambert et al., 2001
Lambert et al., 2002
Whipple et al., 2003
Hawkins et al., 2004

1.44
2.17
1.46
1.47
1.70

0.45
1.19
0.81
0.52
1.17

4.65
3.97
2.64
4.17
2.46

0.539
0.012
0.212
0.473
0.005
0.01

0.1

Favors TAU
*Fb = Feedback group; TAU = Treatment as usual

1

10
Favors Fb

100
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Table 10

Efficacy Analysis of Odds of Clinically Significant Improvement (*Fb vs. TAU)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Lambert et al., 2001
Lambert et al., 2002
Whipple et al., 2003
Hawkins et al., 2004

1.23
2.67
2.97
2.69
2.55

0.32
1.29
1.44
0.85
1.64

4.67
5.53
6.11
8.54
3.98

0.766
0.008
0.003
0.093
0.000
0.01

0.1

Favors TAU
*Fb = Feedback group; TAU = Treatment as usual

1

10
Favors Fb

100
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Table 11

ITT Analysis of Odds of Clinically Significant Worsening (*P/T Fb vs. Fb)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Hawkins et al., 2004 1.57
Harmon et al., 2007 1.74
Slade et al, 2008
1.00
1.35

0.14 18.15
0.77
3.95
0.42
2.38
0.76
2.41

0.719
0.184
1.000
0.306
0.01

0.1

Favors P/T Fb

*P/T Fb = Patient and therapist feedback group; Fb = Feedback group

1

10
Favors Fb

100
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Table 12

Efficacy Analysis of Odds of Clinically Significant Worsening (*P/T Fb vs. Fb)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Hawkins et al., 2004 0.68
Harmon et al., 2007 2.95
Slade et al, 2008
1.35
1.89

0.04 11.53
1.02
8.54
0.44
4.13
0.90
3.96

0.788
0.047
0.594
0.094
0.01

0.1

Favors P/T Fb

*P/T Fb = Patient and therapist feedback group; Fb = Feedback group

1

10
Favors Fb

100
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Table 13

ITT Analysis of Odds of Clinically Significant Improvement (*P/T Fb vs. Fb)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Hawkins et al., 2004 1.94
Harmon et al., 2007 1.43
Slade et al, 2008
1.26
1.44

0.74
0.76
0.65
0.95

5.10
2.70
2.47
2.19

0.179
0.274
0.495
0.086
0.1 0.2

0.5 1

Favors Fb

*P/T Fb = Patient and therapist feedback group; Fb = Feedback group

2

5 10

Favors P/T Fb
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Table 14

Efficacy Analysis of Odds of Clinically Significant Improvement (*P/T Fb vs. Fb)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Hawkins et al., 2004 1.55
Harmon et al., 2007 1.46
Slade et al, 2008
1.25
1.38

0.48
0.72
0.63
0.88

4.99
2.96
2.50
2.18

0.459
0.291
0.521
0.164
0.1 0.2

0.5 1

Favors Fb

*P/T Fb = Patient and therapist feedback group; Fb = Feedback group

2

5 10

Favors P/T Fb
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Table 15

ITT Analysis of Odds of Clinically Significant Worsening (*CST Fb vs. Fb)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Whipple et al., 2003
Harmon et al., 2007
Slade et al, 2008

0.59
1.04
0.64
0.76

0.20
0.48
0.29
0.46

1.76
2.29
1.41
1.26

0.342
0.916
0.266
0.288
0.1 0.2

0.5 1

Favors CST Fb

*CST Fb = Clinical Support Tools feedback group; Fb = Feedback group

2

5 10

Favors Fb
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Table 16

Efficacy Analysis of Odds of Clinically Significant Worsening (*CST Fb vs. Fb)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Whipple et al., 2003
Harmon et al., 2007
Slade et al, 2008

0.53
0.83
0.54
0.66

0.05
0.25
0.15
0.29

6.05
2.74
2.00
1.52

0.606
0.756
0.356
0.329
0.1 0.2

0.5 1

Favors CST Fb

*CST Fb = Clinical Support Tools feedback group; Fb = Feedback group

2

5 10

Favors Fb
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Table 17

ITT Analysis of Odds of Clinically Significant Improvement (*CST Fb vs. Fb)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Whipple et al., 2003
Harmon et al., 2007
Slade et al, 2008

1.97
1.22
1.60
1.53

1.00
0.68
0.90
1.08

3.87
2.18
2.85
2.18

0.050
0.497
0.107
0.016
0.1 0.2

0.5 1

Favors Fb

*CST Fb = Clinical Support Tools feedback group; Fb = Feedback group

2

5 10

Favors CST Fb
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Table 18

Efficacy Analysis of Odds of Clinically Significant Improvement (*CST Fb vs. Fb)
Study name

Statistics for each study

Odds ratio and 95% CI

Odds Lower Upper
ratio limit
limit p-Value
Whipple et al., 2003
Harmon et al., 2007
Slade et al, 2008

1.17
1.35
3.61
1.83

0.49
0.68
1.85
0.89

2.79
2.65
7.06
3.76

0.729
0.392
0.000
0.098
0.1 0.2

0.5 1

Favors Fb

*CST Fb = Clinical Support Tools feedback group; Fb = Feedback group

2

5 10

Favors CST Fb
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Table 19

ITT Analysis of Mean Session Attendance (* Fb vs. TAU)
Study name

Statistics for each study
Hedges's
g

Lambert et al., 2001
Lambert et al., 2002
Whipple et al., 2003
Hawkins et al., 2004

1.09
0.25
-0.10
-0.04
0.27

Standard
error
0.26
0.13
0.14
0.25
0.22

Hedges's g and 95% CI

p-Value
0.000
0.052
0.459
0.865
0.217
-2.00 -1.00
More session for TAU

*Fb = Feedback group; TAU = Treatment as usual

0.00

1.00

More session for Fb

2.00
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Table 20

ITT Analysis of Mean Session Attendance (*P/T Fb vs. Fb)
Study name

Statistics for each study
Hedges's
g

Hawkins et al., 2004
Harmon et al., 2007
Slade et al, 2008

-0.22
0.17
0.23
0.12

Standard
error
0.24
0.15
0.16
0.12

Hedges's g and 95% CI

p-Value
0.356
0.244
0.145
0.311
-1.00 -0.50

0.00

0.50

1.00

More session for Fb More session for P/T Fb

*P/T Fb = Patient and therapist feedback group; Fb = Feedback group
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Table 21

ITT Analysis of Mean Session Attendance (*CST Fb vs. Fb)
Study name

Statistics for each study
Hedges's
g

Whipple et al., 2003
Harmon et al., 2007
Slade et al, 2008

0.82
0.22
0.23
0.40

Standard
error
0.17
0.13
0.14
0.18

Hedges's g and 95% CI

p-Value
0.000
0.106
0.093
0.024
-1.00 -0.50

0.00

0.50

1.00

More session for Fb More session for CST

*CST Fb = Clinical Support Tools feedback group; Fb = Feedback group

